



Deposition of:  
**Jaqueline Moline , M.D., MSc, FACP,  
FACOEM**

*February 26, 2020*

In the Matter of:  
**Zimmerman, Linda Vs. Autozone Inc.,  
Et Al.**

Veritext Legal Solutions

800.808.4958 | calendar-atl@veritext.com | 770.343.9696

Page 1

1 SUPERIOR COURT OF THE STATE OF CALIFORNIA  
2 FOR THE COUNTY OF LOS ANGELES  
3 Coordinated Proceeding JCCP NO. 4674  
4 Special title (Rule 3.550) Case No. BC720153

5 LAOSD ASBESTOS CASES

6 LINDA ZIMMERMAN,  
7 Plaintiff,  
8 vs.  
9 AUTOZONE, INC., et al.,  
10 Defendants.

11 Telephonic Deposition of JACQUELINE MOLINE, MD,  
12 MSc, FACP, FACOEM,  
13 Taken by Meghan B. Senter,  
14 Before Jennifer D. Hamon,  
15 Certified Court Reporter,

16 On Wednesday, February 26, 2020,  
17 Beginning at 10:06 a.m. and ending at 1:42 p.m.

18  
19  
20  
21  
22  
23  
24  
25

|   |        |  |
|---|--------|--|
|   | Page 2 | Page 4   |
| 1 APPEARANCES OF COUNSEL                          |        | 1 INDEX TO PROCEEDINGS                               |
| 2 For the Plaintiff:                              |        | 2 EXAMINATION INDEX                                  |
| 3 LEAH KAGAN                                      |        | 3 JACQUELINE MOLINE, MD, MSc, FACP, FACOEM           |
| (Via Telephone)                                   |        | 4 Examination by Ms. Senter 5                        |
| 4 Simon Greenstone Panatier Bartlett PC           |        | Examination by Ms. Romano 61                         |
| Suite 540   |        | 5 Examination by Mr. Polchinski 107                  |
| 5 3780 Kilroy Airport Way                         |        | Examination by Ms. Anderson-Thompson 130             |
| Long Beach, CA 90806                              |        | 6 Re-Examination by Ms. Senter 131                   |
| 6 562.590.3400                                    |        | Re-Examination by Ms. Romano 133                     |
| lkagan@sgpblaw.com                                |        | 7 Examination by Ms. Kagan 135                       |
| 7   |        | 8 Certificate Page 142                               |
| 8 For the Defendant Chanel:                       |        | 9  |
| 9 MEGHAN B. SENTER                                |        | 10 EXHIBIT INDEX                                     |
| (Via Telephone)                                   |        | 11 Exhibits  |
| 10 MG+M   |        | 12 Exhibit 1 J&J Defendants' Notice of Deposition 6  |
| One Canal Place, Suite 3000                       |        | of Plaintiff's Expert Witness Dr.                    |
| 11 365 Canal Street                               |        | 13 Jacqueline Moline and Requests for                |
| New Orleans, LA 70130                             |        | Production of Documents                              |
| 12 504.555.2879                                   |        | 14 Exhibit 2 Depositions and Testimony 2015-2019, 6  |
| msenter@mgmlaw.com                                |        | 15 Revised 12/19/2019                                |
| 13  |        | 16 Exhibit 3 Curriculum Vitae 6                      |
| 14 For the Defendants Johnson & Johnson and       |        | 17 Exhibit 4 Reference List - Linda Zimmerman 6      |
| Johnson & Johnson Consumer Inc.:                  |        | 18 Exhibit 5 Handwritten notes 6                     |
| 15 JULIA ROMANO                                   |        | 19 Exhibit 6 Wind Rose Plot 18                       |
| (Via Telephone)                                   |        | 20   |
| King & Spalding                                   |        | 21 (Original Exhibits 1 through 6 have been attached |
| 17 Suite 1600                                     |        | to the original transcript.)                         |
| 633 West Fifth Street                             |        | 22   |
| 18 Los Angeles, CA 90071                          |        | 23   |
| 213.443.4365                                      |        | (End of Index)                                       |
| 19 jromano@kslaw.com                              |        | 24   |
| 20  |        | 25   |
| 21  |        |  |
| 22  |        |  |
| 23  |        |  |
| 24  |        |  |
| 25 (Continued on next page)                       |        |  |
|   | Page 3 | Page 5   |
| 1 For the Defendants Ralphs Grocery Company and   |        | 1 February 26, 2020                                  |
| Thrifty Payless Inc. dba Rite Aid Pharmacy:       |        | 2 10:06 a.m.   |
| 2 GABRIELLE ANDERSON-THOMPSON                     |        | 3 (Pursuant to OCGA 15-14-37 (a) and (b) a           |
| (Via Telephone)                                   |        | 4 written disclosure statement was submitted         |
| Barnes & Thornburg LLP                            |        | 5 by the court reporter to all counsel present       |
| 4 Suite 300                                       |        | 6 at the deposition and is attached hereto.)         |
| 5 2029 Cnetury Park East                          |        | 7 JACQUELINE MOLINE, MD, MSc, FACP, FACOEM,          |
| 5 Los Angeles, CA 90067                           |        | 8 being first duly sworn, was examined and           |
| 310.284.3884                                      |        | 9 testified as follows:                              |
| 6 gathompson@btlaw.com                            |        | 10 EXAMINATION                                       |
| 7   |        | 11 BY MS. SENTER:                                    |
| For the Defendant Whittaker Clark & Daniels Inc.: |        | 12 Q Good morning, Dr. Moline. This is               |
| 8 REBECCA BELLOW                                  |        | 13 Meghan Senter. We met via telephone just a few    |
| (Via Telephone)                                   |        | 14 moments ago. I think I'm going to be starting us  |
| Berkes Crane Robinson & Seal                      |        | 15 off today, and I want to cover just a little bit  |
| 10 Suite 1500                                     |        | 16 of background. All right?                         |
| 515 South Figueroa                                |        | 17 A Okay.   |
| 11 Los Angeles, CA 90071                          |        | 18 Q I promise I'm going to try not to be            |
| 213.955.1150                                      |        | 19 redundant. I know you've done this a few times.   |
| 12 rbelow@berslaw.com                             |        | 20 I'm not going to try and run you through          |
| 13  |        | 21 everything. But it's fair for me to kind of       |
| For the Defendants Revlon and Macy's:             |        | 22 dispense with the usual admonitions? You're       |
| 14 PETER D. POLCHINSKI                            |        | 23 familiar with the process?                        |
| (Via Telephone)                                   |        | 24 A Yes.  |
| Hawkins Parnell & Young LLP                       |        | 25 - - -   |
| 16 8th Floor                                      |        |  |
| 600 Lexington Avenue                              |        |  |
| 17 New York, NY 10022                             |        |  |
| 212.897.9655                                      |        |  |
| 18 ppolchinski@hpylaw.com                         |        |  |
| 19  |        |  |
| 20  |        |  |
| 21  |        |  |
| 22  |        |  |
| 23  |        |  |
| 24  |        |  |
| 25  |        |  |

|   |        |   |        |
|---|--------|---|--------|
| <p>1 (Whereupon documents were identified as<br/>2 Exhibit 1, Exhibit 2, Exhibit 3, Exhibit 4,<br/>3 and Exhibit 5.)<br/>4 Q At the outset, I'd like to just go<br/>5 ahead and mark a number of exhibits I'd like to<br/>6 discuss for the record. The first is going to be<br/>7 the Notice of Deposition. We'll mark that as<br/>8 Exhibit 1.<br/>9 The second thing I'd like to mark is<br/>10 your list of prior testimony. We'll mark that as<br/>11 Exhibit 2. Your CV we'll go ahead and mark as<br/>12 Exhibit 3. And your reliance list we'll mark as<br/>13 Exhibit 4. And because we're going to be<br/>14 discussing them later on, we'll go ahead and mark<br/>15 your notes as Exhibit 5.<br/>16 MS. KAGAN: Counsel, I just want to<br/>17 note for the record that we did submit objections<br/>18 to the notice and that we did provide an updated<br/>19 Madigan report that is not on the reliance list.<br/>20 MS. SENTER: Okay. Thanks, Leah.<br/>21 MS. KAGAN: No problem.<br/>22 BY MS. SENTER:<br/>23 Q Dr. Moline, when were you first<br/>24 retained in this matter?<br/>25 A I'm not sure of the exact date. It</p> | Page 6 | <p>1 to form your opinions?<br/>2 MS. KAGAN: I'm going to object. If<br/>3 you have reviewed her reference and reliance<br/>4 list, it has specific documents identified in the<br/>5 Zimmerman section.<br/>6 BY MS. SENTER:<br/>7 Q Dr. Moline?<br/>8 A There have been a number of materials<br/>9 that are related on the reliance list. Some of<br/>10 them are more general, and then some of them are<br/>11 more specific, including testing of Jean Nate and<br/>12 testing of some of the -- Dr. Longo's testing,<br/>13 Dr. Gordon's report, looking at some Unarco<br/>14 materials, looking at some Chanel testing, if I<br/>15 didn't mention that. And the rest are enumerated<br/>16 on my report -- I mean on my reliance list.<br/>17 Q Okay. So I know your reliance list in<br/>18 this case is 43 pages long, so I'm just trying to<br/>19 get a complete sense of what you reviewed<br/>20 specifically in preparation for this case beyond<br/>21 all 43 pages.<br/>22 MS. KAGAN: Counsel, there's a<br/>23 specific Zimmerman section on the reliance list<br/>24 that identifies specific case-specific documents<br/>25 besides the things Dr. Moline has just enumerated</p> | Page 8 |
| <p>1 was some point in the -- in the fall. It was --<br/>2 hold on. Around September-ish.<br/>3 Q Around September of 2019?<br/>4 A That's when I first became aware of<br/>5 it, yes. Correct.<br/>6 Q And how were you retained? By letter?<br/>7 By phone call? Email?<br/>8 A I think that it would be by phone<br/>9 call. I honestly don't recall. It definitely<br/>10 was not by letter.<br/>11 Q Do you know when it was that you first<br/>12 started reviewing materials specifically for this<br/>13 case?<br/>14 A Well, I know it was before the<br/>15 declaration was submitted in mid-October, so it<br/>16 was at some point in October, I think early<br/>17 October. And then I went back and did some<br/>18 refinement of my notes and was given things like<br/>19 the -- looked at the sister's deposition somewhat<br/>20 later.<br/>21 Q And I know we have your notes. We<br/>22 marked them as Exhibit 5. Outside of the<br/>23 materials listed in your notes, which are various<br/>24 depositions and some medical records, what all<br/>25 have you reviewed specific to this case in order</p>                 | Page 7 | <p>1 for you.<br/>2 BY MS. SENTER:<br/>3 Q That's beginning on page 25; is that<br/>4 right, Doctor?<br/>5 A I don't know if I have that reliance<br/>6 list in -- I didn't bring a copy of that with me<br/>7 into the room today, so I can't tell you what<br/>8 page it's on.<br/>9 Q That's fair. What do you have with<br/>10 you in the room today?<br/>11 A I have a copy of my notes. I actually<br/>12 have the testing binders of the testing results<br/>13 from Dr. Compton, Dr. Longo and his declaration,<br/>14 some Jean Nate testing, Mr. Martin's death<br/>15 certificate, some Unarco documents, a copy of my<br/>16 declaration, and -- yeah. That's it.<br/>17 Q Okay. Thank you. About how many<br/>18 hours have you spent in preparation for this<br/>19 case?<br/>20 A About 15.<br/>21 Q Are you able to break down how you've<br/>22 spent those 15 hours?<br/>23 A Reading and writing my notes. So I<br/>24 can't tell you -- I don't parse it out on -- I<br/>25 don't know how I would do that. I don't say for</p>   | Page 9 |

|  |         |   |         |
|--|---------|---|---------|
| <p>1 hour 1 through hour 7.2, I reviewed the medical<br/>2 records, and then from 7.2 to 16.9, I reviewed<br/>3 the depositions. That's not how I work.<br/>4 Q With that many lawyers on the phone<br/>5 today, do you wish you could --<br/>6 A I'm sure they do, but I don't bill in<br/>7 ten-minute increments.<br/>8 Q Included in that 15 hours is there any<br/>9 time spent in preparation for today's deposition?<br/>10 A I spent about half an hour in<br/>11 preparation. I had a conversation with<br/>12 Ms. Kagan, which was brief in part due to the<br/>13 fact that Ms. Kagan couldn't speak. And that was<br/>14 not included.<br/>15 Q Have you issued any invoices in this<br/>16 case?<br/>17 A Not yet.<br/>18 Q What's your current rate?<br/>19 A It's \$600 an hour.<br/>20 Q Do you anticipate, other than this<br/>21 deposition, doing any additional work on this<br/>22 matter prior to trial?<br/>23 MS. KAGAN: Counsel, I will note for<br/>24 the record that we have not yet received the<br/>25 final materials from Dr. Roggli as to digestion</p>   | Page 10 | <p>1 to answer. So could you refine that a bit?<br/>2 BY MS. SENTER:<br/>3 Q You said that you were asked to review<br/>4 the documents and to identify, first, whether or<br/>5 not Ms. Zimmerman had an asbestos-related<br/>6 disease; is that right?<br/>7 A Correct. So I would offer that she<br/>8 does in fact have an asbestos-related disease.<br/>9 Q Do you have an opinion as to what type<br/>10 of asbestos-related disease Ms. Zimmerman has?<br/>11 A I do.<br/>12 Q What is that?<br/>13 A She has malignant mesothelioma.<br/>14 Q And then the second portion of your<br/>15 scope of work that was provided was to provide an<br/>16 opinion as to the cause of that asbestos-related<br/>17 disease; is that correct?<br/>18 MS. KAGAN: Mischaracterizes the scope<br/>19 of the work, parts of it. The scope of<br/>20 Dr. Moline's opinions are disclosed in the 2034<br/>21 designation, in her notes, and reliance materials<br/>22 and reference list.<br/>23 THE WITNESS: So I was asked if in<br/>24 fact she -- I felt she did have an<br/>25 asbestos-related disease. And just to be clear,</p>   | Page 12 |
| <p>1 or anything else that he might use and the<br/>2 evidence that he might offer. So to the extent<br/>3 that those materials are received and provided to<br/>4 Dr. Moline, she may review those.<br/>5 MS. SENTER: Understood.<br/>6 THE WITNESS: I don't anticipate doing<br/>7 additional work unless something becomes<br/>8 available for me to review or -- Ms. Zimmerman is<br/>9 still alive, so if additional medical records<br/>10 become available, I would review those prior to<br/>11 trial. But I don't have those now.<br/>12 BY MS. SENTER:<br/>13 Q When you were contacted and retained<br/>14 in this matter, what were you asked to do? What<br/>15 was your scope of work?<br/>16 A I was asked to review the documents<br/>17 and identify whether I felt Ms. Zimmerman had an<br/>18 asbestos-related disease and what exposures might<br/>19 contribute.<br/>20 Q In line with that scope of work, what<br/>21 opinions do you intend to offer at trial?<br/>22 MS. KAGAN: Overbroad.<br/>23 THE WITNESS: I mean, I'm asked<br/>24 questions at trial, so this is a question that,<br/>25 the way it's worded, is very challenging for me</p> | Page 11 | <p>1 I wasn't asked specifically in this case. This<br/>2 is just an ongoing understanding I have with<br/>3 Ms. Kagan and her firm to identify where she<br/>4 might have had exposure to asbestos which I went<br/>5 through and is incorporated in my notes.<br/>6 BY MS. SENTER:<br/>7 Q So in your notes, you've identified on<br/>8 multiple pages from your review of multiple<br/>9 depositions, correct, where you believe that<br/>10 Ms. Zimmerman may have had exposure to asbestos?<br/>11 MS. KAGAN: Mischaracterizes.<br/>12 THE WITNESS: My notes state what the<br/>13 review of the deposition said from Ms. Zimmerman<br/>14 and her family members' sworn testimony. So this<br/>15 is a description of what transpired. It's not --<br/>16 I believe it's what they said in the deposition<br/>17 transcript.<br/>18 BY MS. SENTER:<br/>19 Q What possible sources of exposure did<br/>20 you identify through your review of the<br/>21 materials?<br/>22 A She had exposure to cosmetic talc from<br/>23 a number of different manufacturers. She had a<br/>24 potential exposure from her stepfather. And<br/>25 there was a potential exposure from her two sons</p> | Page 13 |

|   |  |
|---|--|
| <p style="text-align: right;">Page 14</p> <p>1 who worked at a gas station where friction<br/>2 materials were used.</p> <p>3 Q Do you have a copy of your notes with<br/>4 you? I believe you said you did. I just want to<br/>5 be sure.</p> <p>6 A I do.</p> <p>7 Q Let's go ahead and look at those.</p> <p>8 They've been marked as Exhibit 5. Aside from<br/>9 what you've written on these papers, do you have<br/>10 any handwritten notes or highlighting on the<br/>11 actual depositions themselves?</p> <p>12 A No.</p> <p>13 Q If you could turn to page three, it<br/>14 looks like -- I'm sorry -- page two, it looks<br/>15 like you've noted from Ms. Zimmerman's deposition<br/>16 that she considered Chanel to be a special treat?</p> <p>17 You have that in quotations. Is that correct?</p> <p>18 A Yes.</p> <p>19 Q And then it looks like on page ten you<br/>20 ran some calculations; is that right?</p> <p>21 A I wouldn't call them calculations. I<br/>22 would call them -- well, I guess they are<br/>23 calculations. It was just basically taking how<br/>24 many times she said she used it by how many<br/>25 years.</p>                  | <p style="text-align: right;">Page 16</p> <p>1 THE WITNESS: That's correct.</p> <p>2 BY MS. SENTER:</p> <p>3 Q I wanted to ask about some of the<br/>4 other materials that we were provided. And I'm<br/>5 not sure if you have them in front of you. I<br/>6 know you reviewed some of the Unarco documents.<br/>7 But in the materials provided to us, there was a<br/>8 document called a wind rose document.</p> <p>9 A I'm sorry. A -- oh, a wind rose?</p> <p>10 Yes.</p> <p>11 Q What is that?</p> <p>12 A That's a document -- hold on. Let me<br/>13 get to it. It's wind directional plots based on<br/>14 prevailing wind patterns that was accumulated by<br/>15 the Illinois State Climatologic Office for<br/>16 October 7th, 2004.</p> <p>17 Q Where did you get this document?</p> <p>18 A It was provided to me by Plaintiff's<br/>19 counsel.</p> <p>20 Q Did you ask for it?</p> <p>21 A I didn't know such a thing existed,<br/>22 but I asked about prevailing winds and location<br/>23 of the plant to the family home.</p> <p>24 Q Have you ever relied on a document<br/>25 like this before?</p>  |
| <p style="text-align: right;">Page 15</p> <p>1 Q Okay. And then from that information<br/>2 you have determined, based on your review of the<br/>3 depositions, approximately how many containers of<br/>4 each type of talcum powder products that she<br/>5 would have used? Is that fair?</p> <p>6 A The container description comes<br/>7 straight from her deposition. That's correct.</p> <p>8 Q So as we're going through this, I'm<br/>9 looking at the comparison of the calculations<br/>10 that you ran. And if you look at Chanel, it<br/>11 looks like the Chanel entry has the fewest number<br/>12 of containers. Is that fair?</p> <p>13 A Yes.</p> <p>14 Q And then I also note that you included<br/>15 the Unarco. That was in relation to her<br/>16 stepfather; is that right?</p> <p>17 A Correct.</p> <p>18 MS. KAGAN: Foundation.</p> <p>19 BY MS. SENTER:</p> <p>20 Q The Unarco calculation that you ran,<br/>21 you came to the conclusion -- I think it says<br/>22 that there were approximately 2,607 possible<br/>23 interactions with Ms. Zimmerman's stepfather<br/>24 after work; is that right?</p> <p>25 MS. KAGAN: Mischaracterizes.</p> | <p style="text-align: right;">Page 17</p> <p>1 A You know, I'm sure I have at some<br/>2 point. I've certainly looked at prevailing wind<br/>3 patterns in some of my nonlitigation work, like<br/>4 World Trade Center related work when the wind<br/>5 patterns and the wind flows were mapped post<br/>6 9-11.</p> <p>7 So I don't know -- I don't think I've<br/>8 ever seen one quite as pretty as this one, but I<br/>9 have seen prevailing wind patterns before.</p> <p>10 Q It says on there that it's from<br/>11 Station 14842. Do you see that?</p> <p>12 A Yes.</p> <p>13 Q Do you know where that station is?</p> <p>14 A It looks like it says the Greater<br/>15 Peoria Airport in Peoria, Illinois.</p> <p>16 Q And I apologize. I'm not trying to<br/>17 sound rude. But are you versed in climatology to<br/>18 be able to read this plot?</p> <p>19 MS. KAGAN: Objection. Argument.</p> <p>20 THE WITNESS: I can read a plot. It's<br/>21 basically describing the average wind speeds in<br/>22 different colors and the direction of the wind.<br/>23 That's my understanding of it. And that was the<br/>24 only way I was looking at this.</p> <p>25 I would not be qualified to develop</p> |

|  |  |
|--|--|
| <p style="text-align: right;">Page 18</p> <p>1 such a map, but I can look at a map and see where<br/>2 the biggest spokes out of the radius are or of<br/>3 the center are.</p> <p>4 BY MS. SENTER:</p> <p>5 Q Do you know what the input parameters<br/>6 were to create the plot?</p> <p>7 A I do not. I assume that they are wind<br/>8 speeds that were garnered in some fashion.</p> <p>9 Q Do you have any information about how<br/>10 that wind speed was collected?</p> <p>11 A I do not. I've been around enough to<br/>12 know that there are windsocks that they collect<br/>13 wind speed in, but I do not have any specific<br/>14 information regarding how the data for this<br/>15 particular plot was collected.</p> <p>16 MS. SENTER: Let's go ahead and mark<br/>17 this as Exhibit 6 since we talked about it a bit.<br/>18 (Whereupon a document was identified<br/>19 as Exhibit 6.)</p> <p>20 BY MS. SENTER:</p> <p>21 Q How did the wind rose document help to<br/>22 form your opinions in this case?</p> <p>23 A Well, I'm often asked questions if<br/>24 there happens to be an asbestos plant to ask<br/>25 questions related to the relative distance and</p> | <p style="text-align: right;">Page 20</p> <p>1 and say -- based on how it's described here.<br/>2 But it doesn't specifically say what<br/>3 the wind pattern was in 1977. It's just the data<br/>4 from 1977 would have been included as a data<br/>5 point to be averaged in with the other years.</p> <p>6 Q So based on your understanding of the<br/>7 document, there could be certain years where the<br/>8 prevailing wind pattern was not necessarily away<br/>9 from the home, and that would be included in the<br/>10 average?</p> <p>11 MS. KAGAN: Mischaracterizes. Also<br/>12 speculation.</p> <p>13 THE WITNESS: I mean, if that were the<br/>14 case, then that would cause some skewing of the<br/>15 average, and that would cause a blip in the<br/>16 average that would be reflected in the plot. I<br/>17 mean, if there was a huge wind shift in one<br/>18 particular year, I would expect that there would<br/>19 be some skewing of the data.</p> <p>20 BY MS. SENTER:</p> <p>21 Q So, for instance, if we're looking at<br/>22 this document, I think what you're saying is you<br/>23 see this biggest point that kind of extends out<br/>24 and goes due south; is that right?</p> <p>25 MS. KAGAN: Mischaracterizes.</p> |
| <p style="text-align: right;">Page 19</p> <p>1 the wind patterns related to where the home is<br/>2 and the plant.</p> <p>3 And this particular wind rose showed<br/>4 that the prevailing winds appeared to be in the<br/>5 opposite direction from where the home was<br/>6 relative to the Unarco plant.</p> <p>7 Q And just so we're clear, the wind rose<br/>8 document, that talks about prevailing winds over<br/>9 decades; right?</p> <p>10 A It is -- yes.</p> <p>11 Q Is it your understanding that that<br/>12 would be an average of the speeds over decades?</p> <p>13 A Correct.</p> <p>14 Q But it doesn't take into account any<br/>15 smaller time frame; is that right?</p> <p>16 MS. KAGAN: Vague as to "smaller time<br/>17 frame."</p> <p>18 BY MS. SENTER:</p> <p>19 Q For instance -- I can rephrase that.<br/>20 If you were asking about a particular<br/>21 year, that doesn't take a particular year into<br/>22 account, does it?</p> <p>23 A Not to enumerate that particular year.<br/>24 But all the data from that year would be included<br/>25 and averaged into -- you wouldn't take out 1977</p>  | <p style="text-align: right;">Page 21</p> <p>1 THE WITNESS: That the wind comes from<br/>2 the -- I mean, it's -- correct. It's coming from<br/>3 the south, blowing from the south.</p> <p>4 BY MS. SENTER:</p> <p>5 Q So the biggest spike is wind blowing<br/>6 from the south?</p> <p>7 A Right. It says that. It says,<br/>8 "Direction (blowing from)," in Orientation,<br/>9 blowing from the south.</p> <p>10 Q But then also if you look, there are<br/>11 other peaks that show wind blowing from the<br/>12 northwest or west-northwest?</p> <p>13 A Well, I mean, there are other data<br/>14 points. There -- yes. But they're not as --<br/>15 they're not as high as the one from south to<br/>16 north.</p> <p>17 Q So based on this plot, it does show<br/>18 wind blowing from essentially every direction.<br/>19 It's just that the largest data point was blowing<br/>20 from the south. Is that fair?</p> <p>21 MS. KAGAN: Mischaracterizes.</p> <p>22 THE WITNESS: It shows that wind<br/>23 patterns have been at varying levels, but the<br/>24 prevailing wind -- or the most frequent direction<br/>25 of the wind is from the south to the north.</p>  |

|  |         |  |
|--|---------|--|
| 1 BY MS. SENTER:<br>2 Q I also noted in the materials that<br>3 were produced to us there were multiple local<br>4 newspaper articles. Did you review those?<br>5 A Can you be more specific?<br>6 Q Yes. There were multiple articles<br>7 from the Pantagraph Sun?<br>8 A And what's the content, please?<br>9 Q Did you --<br>10 A I mean, I don't have -- they were<br>11 sent -- some of them were sent to me<br>12 electronically in a list. So are you talking<br>13 about the ones where Linda was in college and her<br>14 being active in college?<br>15 Q I'm asking if you had reviewed them,<br>16 and the follow-up would be how they informed your<br>17 opinion. Because they're just listed in the<br>18 reliance materials as Pantagraph newspaper<br>19 articles.<br>20 A Oh, it was just showing that she was<br>21 really active. She was spending a lot of time at<br>22 school, not at home. I can probably venture a<br>23 guess that I am the only person on the phone who<br>24 has actually been to Illinois State University,<br>25 so I thought that was kind of cool because that's  | Page 22 | 1 for just a moment, you mentioned earlier when we<br>2 were talking about potential exposures the<br>3 potential exposures from Ms. Zimmerman's two sons<br>4 who worked at a gas station and did mechanic<br>5 work; is that right?<br>6 A Correct.<br>7 Q And I believe that starts on page<br>8 three with the deposition of Stephen Zimmerman?<br>9 A Correct.<br>10 Q I note in the margin -- and I<br>11 apologize. I'm just really bad with handwriting,<br>12 my own included. But the writing as to Bendix,<br>13 it says Bendix on the top. It's an indented<br>14 section.<br>15 A That's not the margin. That's<br>16 actually within the body the way I take notes,<br>17 but, yes, it says Bendix. It was -- I'm taking<br>18 these notes as I'm reading. So he discussed the<br>19 brand Bendix as the brand he recalled seeing.<br>20 Q What you've written under there,<br>21 "brake - cleaned," can you just read that section<br>22 under Bendix for me?<br>23 A It says, "brakes - cleaned everything.<br>24 Scruffed up with sandpaper. Delivered brakes<br>25 around 24 times. Assisted mechanic with brakes  |
| 1 actually a place that I've spent many hours.<br>2 And she just had things like, you<br>3 know, her wedding announcement, honors she got.<br>4 But she was active in college.<br>5 Q Beyond showing her activities,<br>6 college, her wedding announcement, do the<br>7 newspaper articles otherwise inform your opinions<br>8 in this case?<br>9 A They corroborated her deposition<br>10 transcript and her sister's deposition transcript<br>11 that she did not spend a lot of time at home when<br>12 she was in college. That's the extent to which<br>13 they really inform my opinion.<br>14 Q So you're still relying on the<br>15 deposition testimony. You just believe that the<br>16 newspaper articles kind of bolster that. Is that<br>17 what I'm understanding?<br>18 A I'm going to rely on the sworn<br>19 testimony. The fact that there are documents<br>20 that were in the same time period that supplement<br>21 or that corroborate what she said is always<br>22 something that is helpful when someone is<br>23 recalling events that occurred, you know,<br>24 60 years before.<br>25 Q If we could turn back to your notes | Page 23 | 1 around twice a month. Clutch, gaskets, every<br>2 several months." And the Q means every, and C<br>3 means with, just in medical shorthand.<br>4 Q And then, additionally, to the left of<br>5 that, it says, "home - 20 car event/brakes." Is<br>6 that right?<br>7 A Right.<br>8 Q Did you do similar calculations as you<br>9 did with the talcum powder products and the<br>10 Unarco exposure for potential brake exposures?<br>11 A I did not.<br>12 Q Was there a reason why?<br>13 A In part because, during the time<br>14 period that they were working, it was unclear if<br>15 they were even using asbestos brakes because, at<br>16 that point in time, both nonasbestos and asbestos<br>17 brakes were available. Neither Mr. Zimmerman or<br>18 Mr. Zimmerman knew what was actually being used.<br>19 They just knew they were brakes. So I thought<br>20 that was too speculative and also was --<br>21 That was the main reason. It was also<br>22 not -- the numbers would not have been as high<br>23 just in terms of the amount of time that they did<br>24 that. But that was the main reason. It was just<br>25 too speculative. I wasn't even sure that they |

|  |  |
|--|--|
| Page 26<br>1 were using asbestos products.<br>2 Q Do you have an understanding of when<br>3 asbestos-free brakes were first placed on the<br>4 market?<br>5 A Well, if you talk to the brake<br>6 manufacturers, they'll give varying dates that<br>7 some were available I believe in the '70s. I<br>8 think there was a move towards nonasbestos brakes<br>9 certainly in the mid-'80s.<br>10 And the Zimmerman boys were working at<br>11 the gas station starting -- I think the older one<br>12 started in 1986, so that would have been during<br>13 the transition period. So it's unclear what type<br>14 of brakes they actually worked with. He didn't<br>15 work with brakes per se. He might have helped<br>16 the mechanics on occasion, but he wasn't the<br>17 primary brake replacer.<br>18 Q You noted that they cleaned everything<br>19 with compressed air and that they scuffed up the<br>20 brakes with sandpaper?<br>21 A Correct.<br>22 Q So assuming that some of the brakes<br>23 that they used were in fact asbestos-containing,<br>24 would you count this as a potential exposure for<br>25 Ms. Zimmerman? | Page 28<br>1 cases; correct?<br>2 A Yes.<br>3 Q Were you just simply not asked to do<br>4 one in this case?<br>5 A I was not specifically asked to do one<br>6 in this case.<br>7 Q And just to be clear, you said that<br>8 you're not planning on doing any additional work<br>9 before the trial aside from if there are<br>10 additional materials that come up that you need<br>11 to review. You're not planning on doing a dose<br>12 estimate for use at trial. Is that fair?<br>13 MS. KAGAN: Mischaracterizes.<br>14 THE WITNESS: That's correct.<br>15 BY MS. SENTER:<br>16 Q I'm sorry. What was the answer?<br>17 A I wasn't planning on doing a dose<br>18 estimate based on the numbers, correct.<br>19 Q Thank you. I'm looking at your<br>20 case-specific materials that you reviewed and<br>21 rely on, and I note there's a number of testing<br>22 reports that you're relying on, including<br>23 Dr. Compton and Dr. Longo.<br>24 I just want to make sure. You haven't<br>25 reviewed any testing of any Chanel products |
| Page 27<br>1 A Well, that activity would have been an<br>2 exposure for the children. The exposure<br>3 Ms. Zimmerman would have had would have been from<br>4 laundering her children's clothes. So it is a<br>5 potential exposure.<br>6 Q And would you also consider<br>7 Ms. Zimmerman's stepfather's work at Unarco a<br>8 potential exposure?<br>9 A Yes.<br>10 Q I want to ask just a little bit about<br>11 the specific work that you've done. I know that<br>12 we discussed your calculations on the number of<br>13 containers or exposures that you kind of<br>14 extrapolated out of the deposition testimony.<br>15 What I haven't seen on the calculation<br>16 page are any dose estimates. Have you done a<br>17 dose estimate for Ms. Zimmerman in this case?<br>18 A No.<br>19 MS. KAGAN: Vague as to "dose<br>20 estimate."<br>21 THE WITNESS: The only calculations<br>22 I've done are on that page, and it was simply the<br>23 number of times she used the various products.<br>24 BY MS. SENTER:<br>25 Q You've done dose estimates in past  | Page 29<br>1 specifically from Ms. Zimmerman; is that correct?<br>2 MS. KAGAN: You mean Ms. Zimmerman's<br>3 own containers?<br>4 MS. SENTER: Correct.<br>5 THE WITNESS: I don't recall that she<br>6 had any to be tested. I have not seen any<br>7 testing specific to Ms. Zimmerman with respect to<br>8 Chanel.<br>9 BY MS. SENTER:<br>10 Q I've looked through some of your past<br>11 testimony to kind of eliminate some of my<br>12 questions, but I wanted to confirm as well: On<br>13 these tests that are bulk samples, you would need<br>14 somebody to convert the bulk sample results to a<br>15 fiber per cc value in order to determine whether<br>16 a specific product would result in<br>17 above-background exposure; is that right?<br>18 MS. KAGAN: Mischaracterizes.<br>19 Foundation. Argument.<br>20 THE WITNESS: A bulk sample by<br>21 definition is going to be upon a percentage by<br>22 weight or per gram, and it would need to be<br>23 converted to a volumetric exposure for fiber per<br>24 cc.<br>25 - - - |

|  |   |
|--|---|
| 1 BY MS. SENTER:<br>2 Q That was a yes?<br>3 MS. KAGAN: Mischaracterizes. Asked<br>4 and answered.<br>5 THE WITNESS: I gave you a more<br>6 thorough -- you need a conversion because -- and<br>7 a bulk sample gives you one point of information.<br>8 Then you would need to have a sense of testing<br>9 for what becomes airborne.<br>10 We do know from the published<br>11 literature that a very small percentage by weight<br>12 can lead to millions or billions of fibers. So<br>13 you would need to have some type of volumetric<br>14 measurement. You can't just convert what's a<br>15 bulk sample to an air sample.<br>16 BY MS. SENTER:<br>17 Q Just to be sure that you and I are on<br>18 the same page, if you had a result that showed<br>19 that a sample that was tested was 0.00016 percent<br>20 asbestos by weight, you wouldn't be able to tell<br>21 me just from that result whether or not that<br>22 would result in an above-background exposure?<br>23 MS. KAGAN: Argument. Foundation.<br>24 THE WITNESS: I would need additional<br>25 information, and that -- so weight percent is not   | Page 30<br>1 product that was sampled would result in an<br>2 exposure above background. Is that true?<br>3 MS. KAGAN: Argument.<br>4 THE WITNESS: If you're asking me for<br>5 a particular number, I don't know how you're able<br>6 to do that. I mean, it's been well described by<br>7 some of the authors I mentioned, you know, Rohl<br>8 and Mattenkrott, in terms of the percentage of<br>9 bulk samples leading to millions or billions of<br>10 fibers in the air.<br>11 I would not be able to give you an<br>12 actual quantification. I would have to rely on<br>13 others to do that.<br>14 BY MS. SENTER:<br>15 Q Dr. Moline, you're not a microscopist;<br>16 is that correct?<br>17 A I am not a microscopist.<br>18 Q And you're not a material scientist?<br>19 A Correct.<br>20 Q So in terms of methodology employed by<br>21 various experts, would you defer to experts in<br>22 those fields as to whether the methodology<br>23 employed was proper?<br>24 MS. KAGAN: Vague as to "proper" and<br>25 vague as to "experts in those fields."   |
| Page 31<br>1 the accurate way of measuring what becomes<br>2 airborne, so I would not be able to do that.<br>3 That's not something that I have done.<br>4 But my understanding is it's been<br>5 described as an underestimation, if you just look<br>6 at the bulk sample percentage, to what becomes<br>7 airborne because the individual fibers weigh so<br>8 little that even a small percentage by weight can<br>9 translate into a very large percentage.<br>10 This has been described in the medical<br>11 literature by Rohl in the '70s or by Mattenkrott<br>12 or the EPA. I believe also the FDA recently made<br>13 a comment about that in their January statement.<br>14 So sorry to give such a long-winded<br>15 answer to that. But bulk samples are not -- even<br>16 if it sounds like a very small percentage, are<br>17 not indicative of what can be a potential<br>18 airborne exposure.<br>19 BY MS. SENTER:<br>20 Q And I understand your testimony that<br>21 you don't think it's indicative of what could<br>22 become airborne. My question to you was more<br>23 limited. It was just that, given those bulk<br>24 sample results, you could not look at the bulk<br>25 sample results and testify whether use of that | Page 31<br>Page 33<br>1 THE WITNESS: I'm sorry. I don't<br>2 understand what you mean by methodology. The<br>3 methodology of what?<br>4 BY MS. SENTER:<br>5 Q In terms of the testing that you're<br>6 relying on, the various bulk samples and testing<br>7 of specific products, if there's any question as<br>8 to the validity of the methodology used on those<br>9 samples, would you defer to the experts in<br>10 microscopy and material science as to whether or<br>11 not the methodology employed was valid or proper?<br>12 MS. KAGAN: Vague as to "valid or<br>13 proper" and vague as to "those experts."<br>14 THE WITNESS: I would not comment on<br>15 whether someone -- on the methodology apart from<br>16 saying whether they described it as something<br>17 that is standard and reported. But I would not<br>18 comment on the specifics of how one went about<br>19 doing that and how it is described.<br>20 BY MS. SENTER:<br>21 Q I think I saw from a past deposition<br>22 that when you are considering your background<br>23 levels you sometimes take into account the<br>24 geographic region in which an individual was<br>25 living. Is that correct? |

|   |         |   |         |
|---|---------|---|---------|
| <p>1 MS. KAGAN: Vague. Foundation.<br/>2 THE WITNESS: I'm not sure which<br/>3 testimony you're referring to. I think -- the<br/>4 EPA's most recent background levels do not<br/>5 differentiate based on region. They just give a<br/>6 general number.<br/>7 I -- so I don't know how -- I don't<br/>8 know what you're referring to so I can comment on<br/>9 what you're specifically referring to. In the<br/>10 past, there have been differentiation between<br/>11 rural and urban, but not with more recent<br/>12 calculations.<br/>13 BY MS. SENTER:<br/>14 Q What number do you use for background?<br/>15 A 0.00001 fibers per cc.<br/>16 Q And is it fair for me to assume that<br/>17 that's across the board you use that?<br/>18 MS. KAGAN: Vague as to "across the<br/>19 board."<br/>20 THE WITNESS: If you're referring to<br/>21 that's what the US description has been by the<br/>22 EPA, yes.<br/>23 BY MS. SENTER:<br/>24 Q So although in the past there's been<br/>25 differentiation between urban and rural, you're</p>   | Page 34 | <p>1 you are, I can take a break and go get it.<br/>2 Q I don't plan to ask you about specific<br/>3 pages and lines, no.<br/>4 A Okay. Fine. We can go for a little<br/>5 bit more before a break.<br/>6 Q Okay. Who were your coauthors on that<br/>7 paper?<br/>8 A You're testing my memory here.<br/>9 Kristin Bevilacqua, Maya Alexandri, and Ronald<br/>10 Gordon.<br/>11 Q And how did each of those individuals<br/>12 come to be one of the coauthors?<br/>13 A Maya Alexandri, despite having a law<br/>14 degree, is a medical student who's spent time<br/>15 working with me doing electives, so she got<br/>16 involved in the paper that way. Kristin<br/>17 Bevilacqua was a former research coordinator and<br/>18 expressed an interest in working with me on the<br/>19 paper.<br/>20 And Dr. Gordon is a colleague of mine<br/>21 from my years at Mount Sinai who we had discussed<br/>22 doing a joint paper where he had done fiber<br/>23 analyses and I had done some more clinical<br/>24 components of the paper.<br/>25 Q That kind of touched on the next area</p>  | Page 36 |
| <p>1 not making that differentiation in your use of a<br/>2 background number?<br/>3 A I'm using the more recent number which<br/>4 does not differentiate. In the past, I have<br/>5 described the ATSDR which made some<br/>6 differentiation between rural and urban. And I<br/>7 can tell you that Bloomington and Normal,<br/>8 Illinois, are not urban.<br/>9 Q I've driven through. I'm familiar.<br/>10 In order for an exposure to be<br/>11 considered significant in your estimation, do you<br/>12 ascribe any certain amount above background that<br/>13 it needs to be?<br/>14 A I haven't given an absolute number. I<br/>15 said it has to be an order of magnitude or more<br/>16 above background.<br/>17 Q All right. Dr. Moline, I'm going to<br/>18 ask you some questions about your paper that you<br/>19 recently authored, Mesothelioma Associated with<br/>20 the use of Cosmetic Talc. Okay?<br/>21 We've been going for close to an hour.<br/>22 We're going to switch topics. So if you'd like<br/>23 to take a break, that's fine.<br/>24 A Are you going to ask me specific pages<br/>25 and lines? Because I don't have it with me. If</p> | Page 35 | <p>1 that I wanted to ask you about, which was the<br/>2 role of each of the coauthors in putting together<br/>3 the paper. If you could tell me what Kristin<br/>4 Bevilacqua --<br/>5 A Correct.<br/>6 Q What was Kristin's role in --<br/>7 A She assisted in formatting, helping<br/>8 with the references. She and I worked together<br/>9 on the -- some of the introduction and<br/>10 conclusion, particularly with respect to<br/>11 references. I wrote up the cases. She helped<br/>12 put the tables together -- or Table 1 together, I<br/>13 believe. She did the more administrative stuff<br/>14 for the paper.<br/>15 Q Other than the formatting and<br/>16 references, the work on the intro and conclusion,<br/>17 putting together the table, is there anything<br/>18 else that Kristin did?<br/>19 A It's challenging to discuss this in a<br/>20 way because it was a collaborative process as we<br/>21 worked on the various sections. But, obviously,<br/>22 she didn't do the testing or the testing protocol<br/>23 or the descriptions. We all worked on editing it<br/>24 to make sure that the language made sense, and so<br/>25 there was more sections than that. And it was</p> | Page 37 |

|  |         |   |         |
|--|---------|---|---------|
| <p>1 a -- it was very much a collaborative process.<br/>2 Q I appreciate that. And to the extent<br/>3 that you can't parse it out, I understand. I'm<br/>4 just asking for what you can.<br/>5 A Yeah. I mean, we were partners in<br/>6 this, and she and I worked on the -- she's not a<br/>7 clinician, so I worked on the more clinical<br/>8 elements of it. But we worked on the other<br/>9 aspects together.<br/>10 Q How about Maya? What was her role in<br/>11 helping put together your paper?<br/>12 A Maya's role was to work on assisting<br/>13 with some of the initial documents and trying to<br/>14 make the -- some of the information from<br/>15 Dr. Gordon fit in more with the clinical aspects<br/>16 of the paper, and she spent more time working on<br/>17 that section on making it into something that<br/>18 would be more relevant to the journal's<br/>19 readership.<br/>20 So that was more her role also to do<br/>21 editing or a reading through to make sure it was<br/>22 all logical. She assisted me when we were coming<br/>23 up with the other -- figuring out how to come up<br/>24 with the other tables.<br/>25 Let me rephrase that. It's not like</p>  | Page 38 | <p>1 numbers because she had not done the<br/>2 measurements, but it was more making it into a<br/>3 unified theme.<br/>4 Q Do you have the initial data or<br/>5 information that you received from Dr. Gordon in<br/>6 the original form before it was somewhat -- I<br/>7 don't want to say changed because I'm not trying<br/>8 to misrepresent it -- but before it was tailored<br/>9 to fit in with the clinical aspects?<br/>10 A Are you asking if I have the initial<br/>11 part that he wrote up as a draft to include in<br/>12 the paper? Is that what you're asking me?<br/>13 Q Yes. Did you retain that in its<br/>14 original format?<br/>15 A I don't know if I still have it. It<br/>16 was basically work that's been rewritten. I<br/>17 don't know if I actually have that.<br/>18 Q Do you know how you received it?<br/>19 A I don't know if he sent it<br/>20 electronically or if it was sent by hard copy. I<br/>21 don't remember. This was about two-and-a-half<br/>22 years ago that initially it was started.<br/>23 Q Which journal did you eventually<br/>24 submit this article to?<br/>25 A It was submitted only to one journal,</p> | Page 40 |
| <p>1 we came up with the other tables. It was how we<br/>2 could best present the data in the tables.<br/>3 Q And Dr. Gordon, what was his role in<br/>4 the drafting of this article?<br/>5 A So Dr. Gordon did the testing of the<br/>6 tissue that was included. He also provided<br/>7 information regarding the controls and the<br/>8 information related to the controls that he had<br/>9 gathered in his laboratory, the methods how he<br/>10 did the actual testing for asbestos. So any of<br/>11 the fiber testing he would have done as described<br/>12 in the paper.<br/>13 Obviously, we all worked on making<br/>14 sure it was written in a way that seemed to flow.<br/>15 Q You mentioned a moment ago that Maya<br/>16 assisted in making the documents or the<br/>17 information received from Dr. Gordon fit in with<br/>18 the clinical aspects. What did you mean by that?<br/>19 A The way an electron microscopist might<br/>20 write something is not the same way as a<br/>21 clinician for a clinical journal might write<br/>22 something, so -- and also how the data were<br/>23 presented, it was basically to work on making it<br/>24 so that it was a more cohesive paper.<br/>25 Obviously, she did not touch the</p> | Page 39 | <p>1 and that was the one it was published in. Do you<br/>2 need the name of that, or can you read that from<br/>3 the bottom of the journal?<br/>4 Q I can read it. I was just for clarity<br/>5 of the record asking you the --<br/>6 A It's the Journal of Occupational and<br/>7 Environmental Medicine. The way your question<br/>8 was worded is it could have been submitted<br/>9 somewhere else and rejected, but it was not.<br/>10 Q I apologize. I didn't mean to imply<br/>11 that. I was just asking which journal you<br/>12 submitted to. And that was the only journal you<br/>13 submitted to, which you just named here; correct?<br/>14 A Correct.<br/>15 Q And it was published?<br/>16 A Correct.<br/>17 Q After you had submitted, did the -- it<br/>18 was peer reviewed by a panel; correct?<br/>19 A It was peer reviewed and -- yes. I<br/>20 don't know who reviewed it. But, yes, it was<br/>21 peer reviewed.<br/>22 Q Did you receive any comments during<br/>23 the peer review process of any revisions that<br/>24 they would like for you to make?<br/>25 A Yes.</p>   | Page 41 |

|  |         |  |         |
|--|---------|--|---------|
| <p>1 Q Do you recall what the substance of<br/>2 those comments were?</p> <p>3 A Some of it was they wanted us to take<br/>4 out some of the initial -- what we had initially<br/>5 submitted was -- there was some quotation in some<br/>6 of the introduction to the conclusion. They<br/>7 asked that we add a line about whether there was<br/>8 any genetic testing, which we did.</p> <p>9 There was a -- some clarifications I<br/>10 think on the tables. There were some minor<br/>11 changes. It was nothing that was not --<br/>12 obviously, it was nothing that prevented it from<br/>13 being published. It was a very constructive<br/>14 review in terms of making it clearer to the<br/>15 reader.</p> <p>16 Q Understood. I assume that you made<br/>17 those revisions; is that right?</p> <p>18 A When we were able to, yes. I mean,<br/>19 sometimes the reviewer will suggest things that<br/>20 are not possible to do, and you note that it's<br/>21 not possible to do it. But in general, one tries<br/>22 to be responsive to the reviewers' requests.</p> <p>23 Q Do you recall any specific request<br/>24 made by the reviewers on this article that you<br/>25 were unable to make?</p> | Page 42 | <p>1 correct?</p> <p>2 A Correct.</p> <p>3 Q And because you were a retained expert<br/>4 on each of those 33 cases associated with the<br/>5 paper, you do have a way of identifying each of<br/>6 the 33 individuals described within your<br/>7 published paper; right?</p> <p>8 A I personally -- yes. I have a way of<br/>9 identifying who is patient 1 or who is patient<br/>10 33.</p> <p>11 Q And for reasons that you can explain,<br/>12 you will not provide the listing or any<br/>13 information about which specific individual is<br/>14 associated with any given case; correct?</p> <p>15 MS. KAGAN: I'm sorry. Can you reask<br/>16 the first part of the question? For reasons she<br/>17 can or cannot explain?</p> <p>18 MS. SENTER: Can.</p> <p>19 BY MS. SENTER:</p> <p>20 Q For reasons that Dr. Moline can state<br/>21 in response to my question, Dr. Moline will not<br/>22 identify the specific individuals that are the<br/>23 subject of your paper; correct?</p> <p>24 A I will not name names in this<br/>25 deposition. That is correct.</p>   | Page 44 |
| <p>1 A No.</p> <p>2 Q As we go forward, I am 99 percent sure<br/>3 that I know your answers to these questions. I<br/>4 just have to ask them for the record. You have a<br/>5 key for the 33 cases that are included in your<br/>6 paper that associates those 33 cases with<br/>7 specific plaintiffs in talc litigation; is that<br/>8 right?</p> <p>9 MS. KAGAN: Foundation, vague, and<br/>10 argument as to "you have a fee."</p> <p>11 THE WITNESS: Are you asking me if I<br/>12 have a way of associating who is who with what's<br/>13 described in the paper?</p> <p>14 BY MS. SENTER:</p> <p>15 Q Yes.</p> <p>16 A Yes. I mean, I don't know if I would<br/>17 call it a key, but yes.</p> <p>18 Q So the paper talks about 33 different<br/>19 individuals, and those were all -- those<br/>20 individuals were all plaintiffs in litigation;<br/>21 correct?</p> <p>22 A Yes.</p> <p>23 Q And for each of those 33 individuals,<br/>24 you have been hired or retained to provide an<br/>25 opinion in association with their litigation;</p>  | Page 43 | <p>1 Q And what is the reason that you have<br/>2 that you will not give the identities of the<br/>3 individuals who were used in this paper?</p> <p>4 A I'm following -- the paper was<br/>5 submitted for IRB approval, Institutional Review<br/>6 Board approval. I was -- it's to protect the<br/>7 privacy of the individuals who we included in the<br/>8 paper with their data in a way that it's not<br/>9 identified in some fashion so that people can't<br/>10 go knocking on their doors or sending them nasty<br/>11 tweets.</p> <p>12 Q When you submitted for IRB approval,<br/>13 was the approval granted conditionally upon the<br/>14 individuals remaining anonymous?</p> <p>15 A We described that -- how we would be<br/>16 describing the individuals, and we said that no<br/>17 names would be included in the paper. So to that<br/>18 extent, yes.</p> <p>19 Q Would it have been possible to submit<br/>20 the scope of this project for IRB approval<br/>21 without the anonymity that you specified in<br/>22 your --</p> <p>23 A I don't know. I've never tried that.<br/>24 It's never been my practice in any of the 70 or<br/>25 80 papers that I've published to ever include</p> | Page 45 |

|   |         |   |         |
|---|---------|---|---------|
| <p>1 someone's name. I would never -- I don't know if<br/>2 IRB would approve it. I've never even tried or<br/>3 have heard of that.<br/>4 And I honestly don't think I've seen a<br/>5 paper, reading thousands of papers, that<br/>6 specifically had someone's name in a scientific<br/>7 journal article.<br/>8 Q To be clear, I'm not asking whether or<br/>9 not you could write a paper specifically<br/>10 identifying each individual. I'm simply asking<br/>11 whether or not maintaining the anonymity of<br/>12 individuals who were involved in litigation<br/>13 outside the context of the paper was required.<br/>14 A That was how we submitted it with the<br/>15 understanding that we would be doing it, and<br/>16 that's how it was approved.<br/>17 Q Now, the 33 cases that are included in<br/>18 your paper, you had already reviewed those cases<br/>19 in the context of litigation; correct?<br/>20 A Yes.<br/>21 MS. KAGAN: Asked and answered.<br/>22 BY MS. SENTER:<br/>23 Q And Dr. Gordon submitted his tissue<br/>24 digestion results in six cases; is that right?<br/>25 A Correct.</p>  | Page 46 | <p>1 had his tissue digestion, there also could have<br/>2 been tissue digestion done by another retained<br/>3 expert. Is that fair?<br/>4 MS. KAGAN: Vague.<br/>5 THE WITNESS: I have no way of knowing<br/>6 that. I don't know. There could have been.<br/>7 BY MS. SENTER:<br/>8 Q And you didn't go back to those<br/>9 specific cases, the six specific cases, to look<br/>10 and see if there were additional tissue<br/>11 digestions done by other experts; is that right?<br/>12 A I did not specifically do that as I<br/>13 was writing a paper with Dr. Gordon's results. I<br/>14 was writing a paper with Dr. Gordon's results, so<br/>15 I was going forward using those data points and<br/>16 those tissue digestions that matched with the<br/>17 cases I had also reviewed.<br/>18 Q So if another analyst or another<br/>19 expert in one of those six cases had found<br/>20 something different than Dr. Gordon, that's not<br/>21 reflected in your article. Is that fair?<br/>22 A That was not the focus, but it would<br/>23 not have been reflected. That's correct.<br/>24 Q So the other 27 cases, same thing? If<br/>25 there was tissue digestion done either by a</p>   | Page 48 |
| <p>1 Q And those six cases were ones that you<br/>2 had also been retained as an expert in<br/>3 litigation?<br/>4 A Correct.<br/>5 Q Now, there's a note in the article<br/>6 about the six cases with the tissue digestion.<br/>7 There may have been additional digestion done by<br/>8 another analyst; is that right?<br/>9 A There may have been other digestions<br/>10 done by others. And I honestly don't recall<br/>11 because, as we were writing the paper, I realized<br/>12 that it becomes repetitive in a sense to give<br/>13 multiple case histories that are going to be<br/>14 very, very similar.<br/>15 So there was a note in there to say<br/>16 that it wasn't -- these were six cases that one<br/>17 person had done that I had also reviewed. There<br/>18 might have been other tissue testing done by<br/>19 others in some of the other 27 cases that were<br/>20 not included. It wasn't to say that these were<br/>21 the only cases that had tissue testing.<br/>22 But, initially, when we started doing<br/>23 the paper, he had these six that we had in<br/>24 common, and that's what we went forward with.<br/>25 Q And within those six that Dr. Gordon</p> | Page 47 | <p>1 plaintiff expert or a defense expert, those<br/>2 results are not reflected in the paper; right?<br/>3 That's why you included that disclaimer?<br/>4 A Right. We didn't go into tissue<br/>5 digestion for the other 27. That's correct.<br/>6 Q And then my understanding is the 33 --<br/>7 the number of 33 that you selected was kind of an<br/>8 homage or a historical nod; correct? That's why<br/>9 you picked the number 33?<br/>10 A Correct. In 1960, the connection<br/>11 between mesothelioma and asbestos was based on<br/>12 33. And if you studied my CV well enough to know<br/>13 what my college major was, you know that things<br/>14 like this are important to me.<br/>15 Q I just wanted to be clear that it was<br/>16 important to you for that reason and there wasn't<br/>17 any particular statistical significance to<br/>18 choosing 33 cases; is that right?<br/>19 A Well, there's no statistics in this<br/>20 paper, so there's no -- so it was basically done<br/>21 because of the historical reference to this big<br/>22 ah-hah moment in the world of medicine saying<br/>23 asbestos is associated with mesothelioma even<br/>24 though it had been described before.<br/>25 But this was really where everyone</p> | Page 49 |

|   |   |
|---|---|
| <p style="text-align: right;">Page 50</p> <p>1 started making the connection. And I similarly<br/>2 hoped that people in the medical community would<br/>3 understand that this is a potential source of<br/>4 asbestos exposure and have their similar ah-hah<br/>5 moments going forward when they are evaluating<br/>6 patients.</p> <p>7 Q And my understanding is that in<br/>8 selecting those 33 cases, you specifically didn't<br/>9 include any cases where there was a potential<br/>10 alternative exposure; is that right?</p> <p>11 A To the best of my ability based on the<br/>12 information I have, that is correct.</p> <p>13 Q So, for instance, if you were writing<br/>14 that same paper now, you would not include<br/>15 Ms. Zimmerman in the paper; right?</p> <p>16 A Right. Ms. Zimmerman would not be the<br/>17 type of person I would include because she has<br/>18 potential alternative exposure, which is why I<br/>19 have -- obviously, I have evaluated more than 33<br/>20 individuals who had cosmetic talc exposure. Some<br/>21 of them have additional exposures as well.</p> <p>22 But for the purposes of the paper, I<br/>23 was trying to keep it, so to speak, clean and try<br/>24 to identify folks for whom no other identifiable<br/>25 source was apparent.</p> | <p style="text-align: right;">Page 52</p> <p>1 deposition transcripts and the questions they<br/>2 were asked.</p> <p>3 Q And so that would be information that<br/>4 you had available at the time that you would have<br/>5 written your report in any one of those<br/>6 underlying cases; correct?</p> <p>7 MS. KAGAN: Mischaracterizes.</p> <p>8 Foundation.</p> <p>9 THE WITNESS: In any one of the<br/>10 underlying suits? I would have been writing my<br/>11 report based on information provided to me at the<br/>12 time I was provided with the information,<br/>13 correct.</p> <p>14 BY MS. SENTER:</p> <p>15 Q And I guess I asked it inartfully.<br/>16 But the information that is included in your<br/>17 article is the same as the information you had<br/>18 available to you at the time that you authored<br/>19 your report in the underlying litigation;<br/>20 correct?</p> <p>21 MS. KAGAN: Mischaracterizes as to<br/>22 "report." As you know, in California, you aren't<br/>23 under report requirements.</p> <p>24 THE WITNESS: So it would have been<br/>25 based on if a report was done and the data were</p>  |
| <p style="text-align: right;">Page 51</p> <p>1 Q Now, I know that that analysis of<br/>2 whether or not there were additional exposures<br/>3 came primarily from the sworn testimony in the<br/>4 case that -- the underlying case; correct?</p> <p>5 A You said case in the singular. Did<br/>6 you mean --</p> <p>7 Q Sorry.</p> <p>8 A I don't know what you're referring to<br/>9 since there were 33 people described.</p> <p>10 Q Right. So, for instance,<br/>11 hypothetically, since I know we're not discussing<br/>12 the specific names of any individual, but for<br/>13 individual number one that's included in your<br/>14 paper, the analysis as to whether or not there<br/>15 were alternative exposures would come from review<br/>16 of the sworn testimony in the litigation that had<br/>17 been filed by individual number one; correct?</p> <p>18 MS. HAGAN: Mischaracterizes.</p> <p>19 THE WITNESS: Any sworn testimony that<br/>20 was available; any family member, coworker,<br/>21 cohabitant depositions that were available. In<br/>22 some instances, I did actually also interview the<br/>23 folks. That wasn't delineated because it was --<br/>24 didn't change materially the exposures. But it<br/>25 would have come for the most part from their</p>                     | <p style="text-align: right;">Page 53</p> <p>1 compiled or based on notes that were done in<br/>2 preparation for a particular case for litigation.</p> <p>3 BY MS. SENTER:</p> <p>4 Q Did you ever do, in association with<br/>5 drafting your paper, any additional investigation<br/>6 specific to the authorship of the paper?</p> <p>7 A I have no idea what you're asking me.<br/>8 I don't know what you mean specifically related<br/>9 to authorship of the paper.</p> <p>10 Q Did you ever go back to look and see<br/>11 whether there had been alternative exposure<br/>12 testimony that you didn't have at the time you<br/>13 came to your opinions in the underlying<br/>14 litigation?</p> <p>15 MS. KAGAN: Vague. Foundation.</p> <p>16 THE WITNESS: I don't recall that<br/>17 occurring. I do know that any time we had any<br/>18 question about if there would be an alternate<br/>19 exposure, we excluded them. But I don't know at<br/>20 what point that would have arisen.</p> <p>21 BY MS. SENTER:</p> <p>22 Q You don't know at what point what<br/>23 would have arisen?</p> <p>24 A If I had additional information that<br/>25 led to the information that there might be</p> |

|  |         |  |         |
|--|---------|--|---------|
| <p>1 alternate exposures prior to submitting the<br/>2 report, then I would have substituted another<br/>3 individual who had no known alternate exposure.<br/>4 I don't recall that happening. I know<br/>5 that there were -- as we were preparing to submit<br/>6 the paper, there were one or two folks that<br/>7 realized there was a possibility, and we actually<br/>8 took them out and substituted in someone else.<br/>9 Q With those one or two folks that you<br/>10 realized there was a possibility, what suddenly<br/>11 clued you in to that possibility of alternative<br/>12 exposure?<br/>13 A I think it was going back in through<br/>14 just reviewing the reports or the notes or the<br/>15 records and seeing -- just to make sure that<br/>16 there were no potential alternate exposures. I<br/>17 don't recall that there had been any exposures<br/>18 that had been raised in other settings that were<br/>19 real that caused me to remove somebody from the<br/>20 paper.<br/>21 Q For any of the 33 cases that you<br/>22 included in your article, did you review any of<br/>23 the expert -- the defense expert reports in those<br/>24 cases?<br/>25 A In preparation for the manuscript, no.</p> | Page 54 | <p>1 So often I'm confronted with questions<br/>2 about whether I considered something that would<br/>3 not be based on my medical training or<br/>4 information that was available to show that there<br/>5 was a potential exposure, that it was an actual<br/>6 exposure an individual suffered.<br/>7 Q So it's based on your training and the<br/>8 information that you had available to you when<br/>9 you reached your opinion as to whether or not a<br/>10 potential exposure is hypothetical or real?<br/>11 A The information in my paper was based<br/>12 on the information I had at hand. What I was<br/>13 discussing was being asked questions about<br/>14 hypothetical exposures for which I had never been<br/>15 provided with any documented evidence of exposure<br/>16 or potential exposure and asked questions about<br/>17 that.<br/>18 So I'm trying to make a<br/>19 differentiation between what I had in hand and<br/>20 based on my training with somebody trying to<br/>21 hypothesize that a potential exposure came<br/>22 because of a particular scenario.<br/>23 Q I guess this is a little bit difficult<br/>24 because we're trying to fit it all to a specific<br/>25 schedule and not have concrete examples. But in</p> | Page 56 |
| <p>1 In general, I don't read defense expert reports.<br/>2 I'm not provided them. I specifically did not<br/>3 read defense expert reports in preparation of my<br/>4 paper.<br/>5 Q Did you ever go back and ask for the<br/>6 defense expert reports to see whether or not<br/>7 there was additional information that you would<br/>8 consider noteworthy before drafting your<br/>9 manuscript?<br/>10 A I did not.<br/>11 Q You specified a moment ago real<br/>12 exposure. Is that an assessment that you make as<br/>13 to whether or not the exposure is real?<br/>14 A Well, I'm often asked hypothetical<br/>15 exposures that would be if someone lived in a<br/>16 city that had a plant that was five miles away<br/>17 that has -- that has no evidence that an<br/>18 individual has actual exposure but might live in<br/>19 a town that has a plant five miles away that has<br/>20 historically made asbestos products even though<br/>21 they don't know what was actually done in the<br/>22 plant and asked if that was a potential alternate<br/>23 exposure when I had no information that that was<br/>24 actually what I would call a real exposure.<br/>25 That's what I was referring to.</p>             | Page 55 | <p>1 terms of these 33 cases included in your paper,<br/>2 do you recall whether there were any hypothetical<br/>3 potential exposures that you deemed not real and<br/>4 so not a reason to exclude that case from your<br/>5 manuscript?<br/>6 MS. KAGAN: Overbroad.<br/>7 THE WITNESS: I have no recollection<br/>8 of those particular scenarios for any of the<br/>9 cases that I included in the paper. I was<br/>10 speaking more broadly. But I have no specific<br/>11 recollection.<br/>12 BY MS. SENTER:<br/>13 Q Did you ever go back and review any<br/>14 sort of trial testimony from any of the 33 cases<br/>15 to see whether there were additional developments<br/>16 regarding potential exposures?<br/>17 A You're assuming that --<br/>18 MS. KAGAN: Vague. Overbroad.<br/>19 A -- it actually went to trial. So<br/>20 there may not be trial testimony in these<br/>21 33 cases. I did not go back -- with that caveat<br/>22 that I know I have not testified in all of those<br/>23 33 cases or that they went to trial, I have not<br/>24 gone back to read trial testimony.<br/>25 BY MS. SENTER:</p>  | Page 57 |

|   |         |   |         |
|---|---------|---|---------|
| 1    Q    Let's start there. Did any of the<br>2    33 cases go to trial?<br>3    A    I'm not going to discuss that.<br>4    Q    If you're not going to tell me whether<br>5    or not they went to trial, I assume you're not<br>6    going to tell me whether or not you testified at<br>7    trial for any of those 33 cases. Is that fair?<br>8    A    That is fair. One can surmise if I<br>9    was asked to be an expert and a case went to<br>10   trial that I might have been asked to testify.<br>11   But I can't tell you which cases I testified in.<br>12   I don't recall which cases I testified in. I<br>13   don't have the names, so I can't go through it<br>14   and -- as I sit here right now in this empty<br>15   conference room, nor would I tell you that anyway<br>16   because that would be too much information.<br>17   Q    So, hypothetically, since we're not<br>18   discussing a specific case, if at trial it came<br>19   out that there were other alternative exposures<br>20   which were unknown at the time of your report in<br>21   a case, you wouldn't include that information in<br>22   drafting your manuscript?<br>23   A    If there was additional information<br>24   that came out after my manuscript had been<br>25   submitted or drafted, I would not have included | Page 58 | 1    (Proceedings in recess, 11:29 a.m. to<br>2    11:35 a.m.)<br>3    BY MS. SENTER:<br>4    Q    Dr. Moline, I looked through my notes.<br>5    I think I have maybe one or two more questions<br>6    for you. And, again, I think I know the answers<br>7    because you said you didn't review defense<br>8    reports. But on your reliance list of all the<br>9    testing that you reviewed, I don't see any<br>10   product testing done by Alan Segrave. Is that<br>11   correct?<br>12   A    Oh, I looked at the wrong list here.<br>13   I don't know if -- is there a date? I don't see<br>14   any. I don't recall anything specific to<br>15   Segrave. I know that there have been some<br>16   questions about his testing, but I didn't put<br>17   anything specific on my reliance list related to<br>18   him.<br>19   Q    Have you ever reviewed any testing of<br>20   any Chanel product done by Alan Segrave?<br>21   A    Not that I recall.<br>22   Q    To the extent that Mr. Segrave's<br>23   testing differs, the results of his testing<br>24   differ from Dr. Compton's or Dr. Longo's, you<br>25   haven't reviewed that in the formation of your | Page 60 |
| 1    that in my manuscript. That is correct.<br>2    Q    And I'm not talking about after your<br>3    manuscript had been drafted. I'm talking about,<br>4    in a hypothetical scenario that one of the cases<br>5    included went to trial and you testified, if<br>6    there was subsequent testimony that showed an<br>7    alternative exposure, you didn't review that<br>8    testimony so you don't account for that<br>9    alternative exposure in whether or not that<br>10   person should have been included in your<br>11   manuscript; right?<br>12        MS. KAGAN: I'm going to object<br>13   because it's vague, argument, calls for<br>14   speculation, incomplete hypothetical,<br>15   mischaracterizes.<br>16        THE WITNESS: I didn't read any trial<br>17   testimony at any point in relation to this<br>18   article, so I didn't review any of that, and it<br>19   would not have been included in the manuscript.<br>20   BY MS. SENTER:<br>21   Q    I'm going to look over my notes, and<br>22   then I might have one or two other questions.<br>23   This would probably be a good time for a break if<br>24   you'd like to take one, Doctor.<br>25   A    That would be great. Thank you.  | Page 59 | 1    opinions; correct?<br>2    A    I don't recall seeing Dr. -- or<br>3    Mr. Segrave. I don't think he's a doctor. I<br>4    don't think he has a Ph.D. I don't recall<br>5    reviewing Mr. Segrave specifically with respect<br>6    to Chanel. That's correct.<br>7        MS. SENTER: Thank you very much. If<br>8    I have follow-ups, I'll jump in, but I'm going to<br>9    go ahead and let somebody else ask some questions<br>10   now. Thank you for your time, Dr. Moline.<br>11        THE WITNESS: You're welcome.<br>12   EXAMINATION<br>13   BY MS. ROMANO:<br>14   Q    Hey, Dr. Moline. It's Julia Romano.<br>15   A    Hi.<br>16   Q    Hi. Let me run through some questions<br>17   with you. Then I'll hand you over to someone<br>18   else.<br>19        You're not one of Ms. Zimmerman's<br>20   treating doctors; right?<br>21   A    I am not.<br>22   Q    And you've not been involved in any of<br>23   her diagnosis, treatment, or care?<br>24   A    Correct.<br>25   Q    It's my understanding from your   | Page 61 |

|  |  |
|--|--|
| <p style="text-align: right;">Page 62</p> <p>1 previous testimony and from reviewing your notes<br/>2 that you have not personally met with or spoken<br/>3 to Ms. Zimmerman. Is that fair?</p> <p>4 A Correct.</p> <p>5 Q In other words, you have not taken an<br/>6 exposure history from her directly, but, instead,<br/>7 you're relying on her deposition?</p> <p>8 A Her deposition, her sister's<br/>9 deposition, her son's deposition, and her other<br/>10 son's deposition.</p> <p>11 Q Got it. Thank you. Have you ever<br/>12 spoken with anyone in Ms. Zimmerman's family or<br/>13 any of her doctors?</p> <p>14 A No.</p> <p>15 Q Is it still true that all of your<br/>16 testimony in asbestos cases has been on behalf of<br/>17 plaintiffs?</p> <p>18 A Yes.</p> <p>19 Q And is it still your opinion that talc<br/>20 itself without asbestos is not a cause of<br/>21 mesothelioma?</p> <p>22 A I don't have enough information that<br/>23 would make me change that opinion at this time.</p> <p>24 Q And so you would agree if the<br/>25 Johnson's baby powder that Ms. Zimmerman used did</p>  | <p style="text-align: right;">Page 64</p> <p>1 was a potential exposure from laundering her<br/>2 sons' clothes if they were in fact working with<br/>3 asbestos-containing brake or friction products;<br/>4 is that right?</p> <p>5 A Right. She wasn't doing brake<br/>6 changes, and she wasn't assisting her --</p> <p>7 Can someone mute or do something? I'm<br/>8 pausing not for effect. All of a sudden, there's<br/>9 a lot of feedback, and I don't know --</p> <p>10 Q I'm hearing it too.</p> <p>11 A It sounds like someone's having a<br/>12 conversation in the background.</p> <p>13 So with respect to the sons, she did<br/>14 not -- they did not describe that she actually<br/>15 assisted them, so it would have only come from<br/>16 laundering their clothes.</p> <p>17 Q So in your opinion, if her sons were<br/>18 working with asbestos-containing friction<br/>19 materials, then Ms. Zimmerman would have been<br/>20 exposed to asbestos from that work via laundering<br/>21 their clothes?</p> <p>22 MS. KAGAN: Incomplete hypothetical.</p> <p>23 THE WITNESS: If he was exposed to<br/>24 asbestos from the automotive work and -- then she<br/>25 would have had a -- and it was on his clothes and</p> |
| <p style="text-align: right;">Page 63</p> <p>1 not contain asbestos then it did not cause or<br/>2 contribute to her mesothelioma. Fair?</p> <p>3 A Correct.</p> <p>4 Q And, hypothetically, if Ms. Zimmerman<br/>5 was exposed to asbestos from Johnson's baby<br/>6 powder but that exposure was at or below<br/>7 background level, then would you agree it did not<br/>8 cause or contribute to her mesothelioma?</p> <p>9 MS. KAGAN: Vague as to "background<br/>10 level."</p> <p>11 THE WITNESS: Correct.</p> <p>12 BY MS. SENTER:</p> <p>13 Q Now, at the beginning of your<br/>14 deposition, you said, I believe, that<br/>15 Ms. Zimmerman had exposure to asbestos or -- had<br/>16 exposure to asbestos from three sources or<br/>17 potential sources: the various cosmetic talc<br/>18 products she used, a potential exposure from her<br/>19 stepdad's work, and then potential exposure from<br/>20 her sons' work with automotive friction products;<br/>21 is that right?</p> <p>22 A Correct.</p> <p>23 Q And I think with respect to the<br/>24 potential exposure from her sons' automotive<br/>25 friction work, you told us that you believe that</p> | <p style="text-align: right;">Page 65</p> <p>1 she laundered the clothes, that's a potential<br/>2 exposure.</p> <p>3 BY MS. ROMANO:</p> <p>4 Q And if she was not exposed to asbestos<br/>5 from laundering her sons' clothes, would you<br/>6 consider that a substantial contributing factor<br/>7 to the development of her mesothelioma?</p> <p>8 MS. KAGAN: Incomplete hypothetical.</p> <p>9 THE WITNESS: Yes.</p> <p>10 BY MS. ROMANO:</p> <p>11 Q And with respect to her stepdad, you<br/>12 also told us that that was another potential<br/>13 source of exposure to Ms. Zimmerman; is that<br/>14 right?</p> <p>15 A Correct.</p> <p>16 Q And that potential source of asbestos<br/>17 exposure was because her stepfather worked at the<br/>18 Union Asbestos and Rubber Company plant in<br/>19 Bloomington; is that right?</p> <p>20 A Correct.</p> <p>21 Q And I know you talked about wind<br/>22 patterns earlier, but I wasn't quite sure what<br/>23 your opinion was in that regard. Do you believe<br/>24 that Ms. Zimmerman had a potential exposure to<br/>25 asbestos from -- well, strike that.</p>   |

|  |  |
|--|--|
| <p style="text-align: right;">Page 66</p> <p>1 Do you believe or is it your opinion<br/>2 that Ms. Zimmerman had a potential environmental<br/>3 exposure to asbestos from living near the Unarco<br/>4 plant in Bloomington?</p> <p>5 A I mean, based on my understanding of<br/>6 the wind rose, it's unlikely. They lived<br/>7 about -- I think it was about a mile and a half<br/>8 from the plant in the direction against the<br/>9 prevailing winds, so it's unlikely. But it is<br/>10 theoretically possible. And it depends on --</p> <p>11 Q Is it fair -- I'm sorry. Go ahead.</p> <p>12 A I mean, it depends on whether there<br/>13 was effluence from the plant. Just because a<br/>14 plant was there doesn't mean it was contaminating<br/>15 the air.</p> <p>16 Q Would it be fair to say that that is a<br/>17 potential exposure or one that you can't rule in<br/>18 or rule out either way?</p> <p>19 MS. KAGAN: When you say "that," you<br/>20 mean the environmental?</p> <p>21 MS. ROMANO: Yes, sorry, the<br/>22 environmental exposure.</p> <p>23 THE WITNESS: The Unarco plant,<br/>24 there's some misinformation about what -- whether<br/>25 there was -- you know, there was -- Ms. Zimmerman</p>                            | <p style="text-align: right;">Page 68</p> <p>1 MS. KAGAN: Calls for speculation.<br/>2 THE WITNESS: Correct.</p> <p>3 BY MS. ROMANO:</p> <p>4 Q And you said this was a potential<br/>5 exposure. What additional information would you<br/>6 want to see or need to see in order to move it<br/>7 from a potential exposure to a certain exposure<br/>8 or probable exposure?</p> <p>9 A This is a case where we actually had<br/>10 testimony describing that she avoided the house<br/>11 as much as possible. There was no testimony that<br/>12 she ever hugged her stepfather, that she gave --<br/>13 she didn't watch TV with the family, so it wasn't<br/>14 like there was cuddling on the couch or<br/>15 interactions that way.</p> <p>16 She didn't do his laundry. And, in<br/>17 fact, his laundry was kept segregated from the<br/>18 family laundry.</p> <p>19 There was no carpet in the house.<br/>20 There was hardwood floors, so it wasn't like the<br/>21 fibers became embedded in the carpet and then<br/>22 when Ms. Zimmerman's chore was vacuuming,<br/>23 hypothetically, she was exposed that way. It was<br/>24 hardwood floors, and she didn't describe the task<br/>25 of sweeping the floors.</p>                        |
| <p style="text-align: right;">Page 67</p> <p>1 or Ms. Fowler did not describe it snowing in July<br/>2 like people who lived a block from other asbestos<br/>3 plants have done where you would say, oh, yes,<br/>4 that was a definite exposure.</p> <p>5 There's no -- if they -- possible<br/>6 exposure is something that I noted because it was<br/>7 a plant that used asbestos and the stepfather<br/>8 worked there. But with respect to the<br/>9 environmental exposure, I haven't seen any<br/>10 testing that shows that they actually<br/>11 contaminated the air and that it would get into<br/>12 the Zimmerman/whatever Amos's last name was home<br/>13 from the environment.</p> <p>14 BY MS. ROMANO:</p> <p>15 Q With respect to the stepdad, setting<br/>16 aside the environmental exposure, going back to<br/>17 the fact that Ms. Zimmerman lived in the same<br/>18 home as her stepdad, Amos Martin, who worked at<br/>19 the Unarco plant, you said that was a potential<br/>20 source of exposure to Ms. Zimmerman; right?</p> <p>21 A Correct.</p> <p>22 Q And that would be from her stepdad<br/>23 bringing asbestos fibers home on his clothing, on<br/>24 his person, and bringing them into the family<br/>25 home. Fair?</p> | <p style="text-align: right;">Page 69</p> <p>1 It sounded like he walked into the<br/>2 basement and went directly into a shower. There<br/>3 was some pretty vivid exposure from Ms. Fowler as<br/>4 to why he did that and -- before it came up into<br/>5 the main living area for the family.</p> <p>6 So it sounded like he got -- tried to<br/>7 clean up as best he could after he came in from<br/>8 work entering through the basement and then<br/>9 showering and getting out of his work clothes<br/>10 before he interacted with the family.</p> <p>11 Q Have you ever testified in a case<br/>12 regarding an exposure to asbestos from this<br/>13 Unarco Bloomington plant?</p> <p>14 A Not that I remember.</p> <p>15 Q You're certainly familiar with the<br/>16 Union Rubber and Asbestos Company there?</p> <p>17 A As a name, sure. I'm not familiar<br/>18 with the plant facilities in any way, shape, or<br/>19 form, but they're a notorious name.</p> <p>20 Q And they're a notorious name for<br/>21 making asbestos-containing products, including<br/>22 insulation; is that right?</p> <p>23 MS. KAGAN: Foundation.</p> <p>24 THE WITNESS: I mean, Selikoff began<br/>25 studying Unarco workers I believe in New Jersey</p> |

|   |  |
|---|--|
| <p>1 in the 1950s. They made asbestos insulation<br/>2 products, correct.<br/>3 BY MS. ROMANO:<br/>4 Q And you understand that at least some<br/>5 of those insulation products contained amosite<br/>6 asbestos?<br/>7 A Yes.<br/>8 Q Is it also your understanding that<br/>9 some of the insulation products that Unarco made<br/>10 contained crocidolite asbestos?<br/>11 A That's my understanding. I believe<br/>12 that was a much smaller percentage, but yes.<br/>13 Q And if Ms. Zimmerman was exposed to<br/>14 asbestos from her stepdad, would you consider<br/>15 that a substantial contributing factor to the<br/>16 development of her disease?<br/>17 A Yes.<br/>18 Q In the materials we received prior to<br/>19 your deposition there are a number of<br/>20 Unarco-related documents, some union records,<br/>21 some employment records, a historic plant view,<br/>22 as well as a Unarco advertisement.<br/>23 Do you know which materials I'm<br/>24 referencing, Dr. Moline?<br/>25 A Yes.</p>  | <p>Page 70</p> <p>1 A Yes.<br/>2 Q And so you're aware that he found both<br/>3 crocidolite and amosite fibers in Ms. Zimmerman's<br/>4 tissue?<br/>5 MS. KAGAN: Mischaracterizes.<br/>6 THE WITNESS: That's not what --<br/>7 that's not the sum total of what he found, but he<br/>8 did find that. He also found that there was<br/>9 anthophyllite, tremolite, talc, and aluminum<br/>10 silicate, I believe.<br/>11 BY MS. ROMANO:<br/>12 Q Correct. That was what I was looking<br/>13 for. But you do agree or you understand that he<br/>14 did find crocidolite and amosite fibers in her<br/>15 tissue; right?<br/>16 MS. KAGAN: Mischaracterizes.<br/>17 THE WITNESS: In the tumor tissue,<br/>18 correct. That was the predominant he found that<br/>19 was in the tumor tissue, correct.<br/>20 BY MS. ROMANO:<br/>21 Q And so we know, based on Dr. Gordon's<br/>22 findings, that Ms. Zimmerman was exposed at some<br/>23 point in her life to both crocidolite and<br/>24 amosite. Fair?<br/>25 A Yes.</p>  |
| <p>1 Q Now, were those materials that -- I<br/>2 guess, where did those materials come from? Were<br/>3 they provided to you by Plaintiffs's lawyers?<br/>4 Did you have them already from previous work?<br/>5 Did you go out looking for them? How did you<br/>6 come to obtain those?<br/>7 A I have no way of obtaining<br/>8 Mr. Martin's employment records or his Unarco<br/>9 contract. Those are not publicly available, to<br/>10 the best of my knowledge, or I don't know how<br/>11 they were obtained. They were given to me by<br/>12 Plaintiff's counsel.<br/>13 I did ask for -- whether there were<br/>14 any maps or locations related to the plant and<br/>15 the distance from the home that were provided to<br/>16 me. So they were all provided by Plaintiff's<br/>17 counsel. But they're publicly available, like a<br/>18 Google map.<br/>19 Q It looks like you also received<br/>20 Dr. Gordon's fiber burden digestion in this case<br/>21 with respect to Ms. Zimmerman's tissue; is that<br/>22 right?<br/>23 A Yes. I just received that yesterday.<br/>24 Q And have you had a chance to review<br/>25 Dr. Gordon's report?</p> | <p>Page 71</p> <p>1 Q Do you have an opinion as to the<br/>2 likely source of Ms. Zimmerman's exposure to<br/>3 amosite or crocidolite?<br/>4 A I mean, it's possible it came from her<br/>5 interactions with her stepfather or from -- but I<br/>6 have no way of pinpointing it.<br/>7 Q Was there anything else in<br/>8 Ms. Zimmerman's history as you were reading<br/>9 through the various depositions in this case and<br/>10 her medical records, was there any other source<br/>11 of exposure that you saw that could have<br/>12 accounted for the amosite and crocidolite<br/>13 findings in her tissue?<br/>14 A You know, there have been some reports<br/>15 of cummingtonite being found in some talc, which<br/>16 is the noncommercial name for amosite. So apart<br/>17 from that, that is a potential source of what<br/>18 Gordon might have found as amosite. And I<br/>19 believe that was from historical samples of<br/>20 Johnson's baby powder where there was the<br/>21 cummingtonite found.<br/>22 But apart from the talc or the Unarco<br/>23 work that her stepfather did, I did not see any<br/>24 other sources.<br/>25 Q And you're not offering an opinion,</p> |

|  |  |
|--|--|
| <p>1 are you, that amosite asbestos is a contaminant<br/>2 of cosmetic talc?<br/>3 A I'm just stating it was found in the<br/>4 historical sample described as cummingtonite by<br/>5 individuals in the past that have tested the<br/>6 historical samples. I'm not opining. I would<br/>7 leave that for the geologists, material<br/>8 scientists to describe more. I can just state<br/>9 what has been found.<br/>10 Q I know I'm going to test your memory,<br/>11 but do you recall what document or test result<br/>12 you're referring to with respect to the<br/>13 cummingtonite findings?<br/>14 A I think it was in a testing document<br/>15 from Mr. Matt Sanchez, who I believe listed<br/>16 samples of the historical -- the archived<br/>17 Johnson's baby powder, and that was what he<br/>18 found.<br/>19 Q It sounds like a single finding of<br/>20 cummingtonite by Dr. Sanchez; is that right?<br/>21 MS. KAGAN: Mischaracterizes.<br/>22 THE WITNESS: I don't know if it<br/>23 was -- I think it was more than one finding. It<br/>24 was in more than one sample. I don't have that<br/>25 report in front of me, unfortunately, or those</p> | <p>Page 74<br/>1 anthophyllite, and talc particles that Dr. Gordon<br/>2 claimed to have found in Ms. Zimmerman's tissue,<br/>3 it's fair to say that you cannot I guess connect<br/>4 those particles to any specific product that<br/>5 Ms. Zimmerman used. Is that fair?<br/>6 MS. KAGAN: Mischaracterizes.<br/>7 Argument.<br/>8 THE WITNESS: So you can't use the<br/>9 word claim in a pejorative sense for one<br/>10 paragraph and not the other. So if you could<br/>11 just rephrase the question because it's making it<br/>12 sound like it was a definite finding when it was<br/>13 one thing and it's a claim when it's another. So<br/>14 if you could just rephrase the question, I'd<br/>15 appreciate it.<br/>16 BY MS. ROMANO:<br/>17 Q Sure. With respect to Dr. Gordon's<br/>18 findings of anthophyllite, tremolite, and talc,<br/>19 you have no way of connecting those specific<br/>20 particles to any specific product that<br/>21 Ms. Zimmerman may have used. Fair?<br/>22 MS. KAGAN: Mischaracterizes.<br/>23 Argument.<br/>24 THE WITNESS: Are you asking can I<br/>25 connect it to any peculiar manufacturer or seller</p> |
| <p>1 reports, so I -- you're testing my memory here.<br/>2 I don't think it was a single sample.<br/>3 BY MS. ROMANO:<br/>4 Q Okay. Fair enough. Have you seen any<br/>5 documents, testing reports, et cetera, aside from<br/>6 Dr. Sanchez's report that shows cummingtonite in<br/>7 any Johnson &amp; Johnson talc or talc product?<br/>8 A I don't recall seeing it, no.<br/>9 Q And have you seen any documents that<br/>10 you believe show crocidolite asbestos being found<br/>11 in any talc or -- J&amp;J talc or finished product?<br/>12 A I haven't seen -- I don't recall<br/>13 seeing any crocidolite in any J&amp;J finished<br/>14 product.<br/>15 Q And with respect to the cummingtonite<br/>16 findings, again, you would defer to a testing<br/>17 expert or a mineralogist with respect to that<br/>18 finding and that mineral characterization. Is<br/>19 that fair?<br/>20 MS. KAGAN: Compound. Characterizes.<br/>21 THE WITNESS: Yes, I would refer to a<br/>22 geologist or a material scientist or somebody who<br/>23 could characterize the fibers.<br/>24 BY MS. ROMANO:<br/>25 Q And with respect to the tremolite,</p>                 | <p>Page 75<br/>Page 77<br/>1 of the product as opposed to just cosmetic talc?<br/>2 Is that what your question is? I'm sorry. I<br/>3 just want clarification.<br/>4 BY MS. ROMANO:<br/>5 Q Sure. Let me break it down. You<br/>6 would agree that there's no way to know where any<br/>7 particular fiber or particle in an individual<br/>8 tissue came from; right? They don't wear name<br/>9 tags or date stamps. Fair?<br/>10 MS. KAGAN: Overbroad.<br/>11 THE WITNESS: They certainly don't<br/>12 have date stamps, so it is not possible to say it<br/>13 came from a container on January 6th, 1957,<br/>14 versus January 7th, 1959. I do look at the<br/>15 comments of what is found in the tissue and see<br/>16 if it makes sense and if it is consistent with<br/>17 what's been found in other folks for a particular<br/>18 type of exposure.<br/>19 But you can't pinpoint a particular<br/>20 particle from a particular exposure on a<br/>21 particular day.<br/>22 I'm done.<br/>23 BY MS. ROMANO:<br/>24 Q Thank you. Would it be fair to say<br/>25 that you cannot say to a reasonable degree of</p>                                |

|   |   |
|---|---|
| <p>1 medical certainty that any of the particles<br/>2 Dr. Gordon found in Ms. Zimmerman's tissue came<br/>3 from Johnson's baby powder?<br/>4 A I can't say which manufacturer of<br/>5 cosmetic talc. The findings of the fiber types<br/>6 along with the talc and the silicates are all<br/>7 consistent with talc exposure and what's been<br/>8 reported in the literature for folks who are<br/>9 exposed to cosmetic talc, so that would be the<br/>10 extent to which I would be able to testify.<br/>11 Q It's fair that you also received<br/>12 Dr. Roggli's pathology report in this case; is<br/>13 that right?<br/>14 A I don't have it with me. It wasn't in<br/>15 my binder. I think -- let me just check. I<br/>16 don't have it in the binder I brought with me. I<br/>17 think he -- the thing I remember is he had<br/>18 asbestos bodies that he found and it was<br/>19 consistent with cosmetic talc.<br/>20 But, unfortunately, I don't have it.<br/>21 I didn't -- I received it online, and I did not<br/>22 print it out.<br/>23 Q That's fine. I was just going to ask<br/>24 you what significance Dr. Roggli's report had to<br/>25 you or if you had any opinions based on</p> | <p>Page 78</p> <p>1 digestion report, Dr. Roggli's pathology report,<br/>2 and Dr. Longo's report related to the two bottles<br/>3 of Johnson's baby powder that were provided by<br/>4 Ms. Zimmerman, did you review any other<br/>5 case-specific expert reports?<br/>6 MS. KAGAN: Julia, I'm just going to<br/>7 clarify that she has the other expert reports<br/>8 that are on her reference and reliance list.<br/>9 They're not specific to Ms. Zimmerman. Is that<br/>10 what you mean?<br/>11 MS. ROMANO: Right. That's exactly<br/>12 what I mean. I don't mean Longo's report or<br/>13 Dr. Compton's, you know, kind of general report<br/>14 about Vermont talc or things like that. I'm<br/>15 really just asking specifically about reports<br/>16 that are specific to Ms. Zimmerman as opposed to<br/>17 a more general report that might relate to one of<br/>18 the Defendants in the case.<br/>19 MS. KAGAN: Thank you for the<br/>20 clarification.<br/>21 THE WITNESS: That's right. I think I<br/>22 have Longo's declaration that would have been<br/>23 specific in this report, but apart from that,<br/>24 that's correct.<br/>25 BY MS. ROMANO:</p> |
| <p>1 Dr. Roggli's report.<br/>2 A I mean, I think it's all consistent<br/>3 with her exposures. He just -- I don't recall<br/>4 that he ascribed it to a source. He just said he<br/>5 found it. And I recall the asbestos bodies and<br/>6 that the meso was -- my recollection is -- and,<br/>7 again, this is from memory, but that the meso<br/>8 was -- the mesothelioma Ms. Zimmerman had was<br/>9 related to asbestos. He found asbestos bodies.<br/>10 And that's what my takeaway was from<br/>11 it. And it was an amphibole exposure. I don't<br/>12 think he differentiated what type of fiber it<br/>13 was. I don't recall that he broke that down.<br/>14 Q Fair enough. Other than Dr. Gordon's<br/>15 report, Dr. Roggli's report, and Dr. Longo's<br/>16 report related to the two Johnson's baby powder<br/>17 bottles that were provided by Ms. Zimmerman, did<br/>18 you review any other case-specific expert<br/>19 reports?<br/>20 MS. KAGAN: Julia, can you go back?<br/>21 I'm sorry. I missed the first part of your<br/>22 question.<br/>23 MS. ROMANO: Sure.<br/>24 BY MS. ROMANO:<br/>25 Q Other than Dr. Gordon's fiber burden</p>  | <p>Page 79</p> <p>1 Q Thank you. And I think you've told us<br/>2 already that you've not calculated a cumulative<br/>3 asbestos dose for Ms. Zimmerman and have no<br/>4 intention of doing so; is that right?<br/>5 A Correct.<br/>6 Q I'm sure I've asked you questions<br/>7 about latency before, so I'll try to keep it<br/>8 short. In your opinion, what is the shortest<br/>9 latency period for mesothelioma? Is it ten<br/>10 years?<br/>11 MS. KAGAN: Julia, could you clarify?<br/>12 Are you asking from the first exposure or from<br/>13 the last exposure?<br/>14 MS. ROMANO: From -- well, I guess<br/>15 I'll ask that of Dr. Moline.<br/>16 BY MS. ROMANO:<br/>17 Q Dr. Moline, in terms of latency,<br/>18 latency is often characterized as the time from<br/>19 onset of exposure to time of diagnosis. Is that<br/>20 fair?<br/>21 A Right. It's typically described as<br/>22 when the first exposure occurred to when they<br/>23 develop the disease.<br/>24 Q And in your opinion, what is the<br/>25 shortest latency period for mesothelioma? Is it</p>   |

|   |   |
|---|---|
| 1 ten years?<br>2 A In general, that's about what the<br>3 minimum latency is. There are about a handful of<br>4 cases that have a shorter latency that have been<br>5 reported in the literature, but in general, it's<br>6 about 10 or 11 years as the beginning latency,<br>7 and then it obviously increases with time.<br>8 Q Of course. And Ms. Zimmerman was<br>9 diagnosed with mesothelioma in June of 2018, I<br>10 believe?<br>11 A Correct.<br>12 Q Do you agree that any potential<br>13 asbestos exposure Ms. Zimmerman may have had the<br>14 ten years prior to her diagnosis would not<br>15 have -- would likely not have played a role in<br>16 the development of her mesothelioma?<br>17 A No. You know, I think it -- that has<br>18 not been well studied with respect to what --<br>19 when the minimum -- the amount of time from when<br>20 a -- the most recent exposure that would not have<br>21 any effect would be. Certainly once the tumor<br>22 has started developing. Then any additional<br>23 exposure would be noncontributory.<br>24 I don't think it's clear in the<br>25 literature, it hasn't been well studied, with                                      | Page 82<br>1 most recent publication. It's my most recent<br>2 publication dealing with asbestos.<br>3 Q Thank you. Your recent publication<br>4 that you authored with Dr. Gordon regarding<br>5 cosmetic talc and mesothelioma, it's my<br>6 understanding that you -- and I think you already<br>7 told us in this deposition -- that you will not<br>8 be divulging the identity of the plaintiffs or<br>9 the 33 subjects or cases in the paper; right?<br>10 A Correct.<br>11 Q And that's true even though they all<br>12 had public lawsuits related to their<br>13 mesothelioma?<br>14 A Correct.<br>15 Q And you talked a little bit about<br>16 the -- I can't remember if you brought up HIPAA<br>17 today, but I know you brought up the IRB. If you<br>18 obtained the 33 plaintiffs' consent, could you<br>19 then divulge their identities, or would there be<br>20 something about the IRB process that would still<br>21 prohibit you from divulging their identities?<br>22 A Well, if you exclusively obtain their<br>23 consent to divulge their identity -- I mean, that<br>24 was not how we presented our paperwork to the<br>25 IRB. That would be a totally different scenario.   |
| Page 83<br>1 respect to the last time an exposure can be<br>2 important. It may be that more recent exposures<br>3 before the tumor developed are the -- and the<br>4 multi-hit hypothesis for carcinogens could be the<br>5 ones that push someone over the edge.<br>6 I don't know that there's a<br>7 hard-and-fast numerical value that one can truly<br>8 attribute for when the last period is.<br>9 Certainly, when the tumor starts to develop, and<br>10 that we're not fully clear on, then no exposure<br>11 after that would contribute.<br>12 Q And in this case is there any way for<br>13 you to determine when Ms. Zimmerman's tumor<br>14 started to develop?<br>15 A Unfortunately, no. People can -- it<br>16 may start a couple years before. It may start a<br>17 year before. It may start three or four years<br>18 before. But we have no way of knowing.<br>19 Q You were asked some questions about<br>20 your most recent publication that you did with<br>21 Dr. Gordon and others. Just a few brief<br>22 questions because I know we've already talked<br>23 about it at length and we've deposed you on it<br>24 before.<br>25 A Just to clarify, it's actually not my | Page 83<br>1 I honestly have never seen a paper<br>2 where someone's name was included. Sometimes<br>3 people will do that in books that they write.<br>4 But I haven't -- it's just not done. I mean, you<br>5 know, we talked about Dr. Roggli earlier. He<br>6 just published a paper on 300-something cases<br>7 from litigation. He didn't divulge anyone's<br>8 name. I mean, it's just not done.<br>9 Q And I understand that with respect to<br>10 the publications. I was wondering what your<br>11 position was on the idea of if you went and asked<br>12 those 33 plaintiffs for their consent whether<br>13 that would then allow you to divulge their<br>14 identities in a deposition, for example, not<br>15 necessarily as part of a publication or a --<br>16 A I see. So it's a different question.<br>17 Some of those people have passed on, so that's<br>18 not possible, and I would not feel comfortable<br>19 doing that.<br>20 Q Have you communicated to those 33<br>21 plaintiffs or their lawyers that they were the<br>22 subject of the paper that you published?<br>23 A I did not have any communication with<br>24 any lawyers in advance of the publication in<br>25 terms of including them, and that was part of the |

|  |         |   |
|--|---------|---|
| <p>1 HIPAA process or the IRB process and -- which was<br/>2 to keep everything anonymous.<br/>3 I did not have any conversations with<br/>4 any lawyers. In fact, they didn't even realize<br/>5 that this paper was coming out from my end.<br/>6 Q What about after the paper was<br/>7 published?<br/>8 A People commented on the paper. They<br/>9 did not specifically say, hey, you included one<br/>10 of our individuals.<br/>11 I've never had such a conversation,<br/>12 nor would I encourage it. What goes for the<br/>13 goose goes for the gander. I don't discuss it<br/>14 with anyone in terms of the names.<br/>15 Q I see that you have the Fordyce<br/>16 article listed on your reliance list. Do you<br/>17 know which article I'm talking about, Dr. Moline?<br/>18 A Are you talking about the Vermont talc<br/>19 one?<br/>20 Q Yes.<br/>21 A Yes. I have that on my list.<br/>22 Q And do you have any opinions or<br/>23 criticisms of the paper?<br/>24 A You know, it's an overwhelmingly small<br/>25 sample size. I think the -- there has been a lot</p>                                       | Page 86 | <p>1 to the various letters to the editor that have<br/>2 been published following the paper's publication?<br/>3 A Yes.<br/>4 Q Okay. But you do understand that the<br/>5 authors of the study concluded that there is no<br/>6 increased risk of mesothelioma in that cohort; is<br/>7 that right?<br/>8 A That's what the authors concluded. I<br/>9 don't know if I agree with that conclusion based<br/>10 on the numbers of the small sample size. I don't<br/>11 know how they came with those numbers, and I<br/>12 think those are some of the questions -- the<br/>13 criticisms that were raised in some of those<br/>14 letters to the editor.<br/>15 That is Fordyce's conclusion. I don't<br/>16 know how they arrived at that conclusion given<br/>17 the small sample size and the fact that they<br/>18 found a mesothelioma. But that is what they<br/>19 found. That is what they stated, not necessarily<br/>20 what they found. But that's what they stated.<br/>21 Q That was their conclusion?<br/>22 A That was their conclusion. And<br/>23 they're entitled to their opinion and their<br/>24 conclusion, but that may not be what the facts<br/>25 are. But the paper will speak for itself, and</p>          |
| <p>1 of back and forth in the published literature<br/>2 about some of the issues related to their<br/>3 comparison group and how the rates were<br/>4 calculated.<br/>5 I mostly took away from it that they<br/>6 actually found a mesothelioma in a cohort of 400<br/>7 people in addition to a discussion that the talc<br/>8 ban that has been not particularly well described<br/>9 by Lamb would also not consider the person with<br/>10 the mesothelioma.<br/>11 So there's the talc ban with<br/>12 mesothelioma in addition to the Fordyce<br/>13 mesothelioma that they found as part of the<br/>14 cohort.<br/>15 I have read some of the back and forth<br/>16 about the rates. I did not analyze the -- how<br/>17 they were calculating the rates, which did seem a<br/>18 little odd to me, but I had -- I think by the<br/>19 time I read that I'd also read a lot of the<br/>20 criticism, so I -- it wasn't in isolation that I<br/>21 read it.<br/>22 Q I'm sorry. Go ahead.<br/>23 A I was done.<br/>24 Q I didn't want to interrupt you. When<br/>25 you said the "back and forth," are you referring</p> | Page 87 | <p>1 the statistical analyses and whether they used<br/>2 appropriate comparison groups I'm sure will be<br/>3 fodder for many people in the future.<br/>4 Q Is it fair to say that you haven't<br/>5 actually undertaken to go back and look at those<br/>6 calculations yourself or to recalculate them? Is<br/>7 that fair?<br/>8 A I would defer to a statistician or an<br/>9 epidemiologist on that. I have not personally<br/>10 done that. I do recall when I was reading it<br/>11 that the numbers and the conclusions didn't match<br/>12 for me. But I did not take the time to sit down<br/>13 with a statistician to go over the numbers and<br/>14 how they arrived at them. That's a fairly large<br/>15 undertaking that I don't have time for.<br/>16 Q Other than what we have discussed just<br/>17 now, is there anything else about the Fordyce<br/>18 paper that you intend to discuss or opine on at<br/>19 trial?<br/>20 A Not that I can think of. I mean, I<br/>21 think that only that other statisticians have<br/>22 commented on it if I'm asked about it, but I<br/>23 think we talked about that already.<br/>24 Q Okay. When you say "other<br/>25 statisticians," are you referring to the letters</p> |

|  |         |  |         |
|--|---------|--|---------|
| <p>1 to the editor?</p> <p>2 A Right. Dr. Madigan's a statistician.</p> <p>3 He commented on it. Finkelstein's an</p> <p>4 epidemiologist. He commented on it. That kind</p> <p>5 of thing.</p> <p>6 Q It's still true that you're not aware</p> <p>7 of any public peer-reviewed epidemiology study</p> <p>8 that has concluded there is an increased risk of</p> <p>9 mesothelioma as a result of exposure to cosmetic</p> <p>10 talc?</p> <p>11 MS. KAGAN: Are you asking about</p> <p>12 cosmetic talc in the absence of asbestos?</p> <p>13 MS. ROMANO: Just cosmetic talc.</p> <p>14 THE WITNESS: I'm not aware of any</p> <p>15 studies that have been done that are not -- that</p> <p>16 is not like a series on end users of cosmetic</p> <p>17 talc.</p> <p>18 BY MS. ROMANO:</p> <p>19 Q But are you aware of any published</p> <p>20 peer-reviewed epidemiology study that concluded</p> <p>21 there is an increased risk of mesothelioma from</p> <p>22 exposure to cosmetic talc?</p> <p>23 A There have been no studies that have</p> <p>24 been done that have addressed that question, so</p> <p>25 I'm unaware of any studies that have been done</p>   | Page 90 | <p>1 A I think you're talking about a table</p> <p>2 with various testing. But if I'm looking at it,</p> <p>3 it has hundreds of different entries, yes.</p> <p>4 Q And you've also seen at trial the</p> <p>5 large blue boards that sort of break out what</p> <p>6 those documents are. Are you with me?</p> <p>7 A I've seen demonstratives that are --</p> <p>8 that blow up some of the summary tables from some</p> <p>9 of the documents included, correct.</p> <p>10 Q Since your and my last case together,</p> <p>11 which was the Crudge case in the fall of 2019,</p> <p>12 have you added any additional documents to that</p> <p>13 list or binder?</p> <p>14 A To be honest, I believe I have. That</p> <p>15 was -- the Crudge case I think was before the</p> <p>16 article in -- or the testing done by the FDA</p> <p>17 finding asbestos in the Johnson &amp; Johnson powder.</p> <p>18 The dates all blur in my head, but I</p> <p>19 believe that there have been a number of</p> <p>20 different -- certainly on my reliance list on</p> <p>21 page 43 there's a number of documents that came</p> <p>22 out afterwards.</p> <p>23 Q That's fair enough. That's actually</p> <p>24 where I was going.</p> <p>25 Other than the group of documents</p>  | Page 92 |
| <p>1 that have applied statistical tools to that in</p> <p>2 the literature.</p> <p>3 Q Well, with respect to -- I understand</p> <p>4 that with respect to I guess end users of</p> <p>5 cosmetic talc. Is it still true that you're not</p> <p>6 aware of any published peer-reviewed epidemiology</p> <p>7 study that has concluded that there is an</p> <p>8 increased risk of mesothelioma to cosmetic talc</p> <p>9 miners and millers?</p> <p>10 A Not by the authors who wrote the</p> <p>11 papers. I think there's been correspondence in</p> <p>12 the medical literature about that. There are</p> <p>13 plenty of other epi studies that have looked at</p> <p>14 the question of asbestos and mesothelioma that</p> <p>15 have looked at that even at low doses, so -- but</p> <p>16 not specifically related to cosmetic talc.</p> <p>17 Q The Johnson &amp; Johnson internal company</p> <p>18 documents, in previous cases, you've relied on</p> <p>19 what I think we've called a testing binder that</p> <p>20 contained -- I forgot the number, but a large</p> <p>21 number of documents that you rely on for your</p> <p>22 opinion that there is asbestos in Johnson &amp;</p> <p>23 Johnson talc.</p> <p>24 Do you know what binder I'm talking</p> <p>25 about?</p> | Page 91 | <p>1 related to the October 2019 findings and</p> <p>2 Johnson &amp; Johnson's voluntary recall, I'm</p> <p>3 grouping those together in one category, are</p> <p>4 there any other new documents related to -- or</p> <p>5 any new internal company documents that you've</p> <p>6 reviewed aside from -- and we'll set aside the</p> <p>7 recall for a moment.</p> <p>8 A Not unless they were enumerated in the</p> <p>9 Reuters article. And it would have been a</p> <p>10 document I hadn't seen. But I think all of those</p> <p>11 are on my reliance document. It would be on the</p> <p>12 reliance list generally.</p> <p>13 Q Now, with respect to the documents</p> <p>14 that you've listed in the -- I'll call it the</p> <p>15 recall section of your reliance list, were those</p> <p>16 documents provided to you by plaintiff lawyers,</p> <p>17 or did you obtain those? How did you come to get</p> <p>18 all the documents listed in that section?</p> <p>19 A I got a lot of them because it was all</p> <p>20 over the news and it was something I was</p> <p>21 interested in. With respect to the FDA</p> <p>22 documents, I had those. The Reuters documents I</p> <p>23 had. FDA news release I had.</p> <p>24 Comments about the testing, I had seen</p> <p>25 some of those. I think some of them became</p> | Page 93 |

|  |         |  |         |
|--|---------|--|---------|
| <p>1 available online. So I -- it was in the public<br/>2 interest, and it was all over the media, so they<br/>3 were available that way.</p> <p>4 Q Do you plan to provide any testimony<br/>5 or opinions regarding FDA's October 2019<br/>6 announcement about AMA's findings of chrysotile<br/>7 in one bottle of Johnson's baby powder?</p> <p>8 A I would assume I would be asked<br/>9 questions about that and would ask if I'd heard<br/>10 about it and was aware of it, yes. But I don't<br/>11 know what I'm going to be asked.</p> <p>12 Q Fair to say that the AMA findings<br/>13 would be something that you would I guess<br/>14 reference in terms of the finding of asbestos in<br/>15 Johnson &amp; Johnson talc, but when it comes to the<br/>16 methodology used or the reliability of those<br/>17 results, that's something that you would defer to<br/>18 others on?</p> <p>19 A As to findings, I mean, it was -- I<br/>20 would expect that I would opine on that this was<br/>21 from a source, meaning the Chinese source, that<br/>22 Ms. Zimmerman had been using for many years. It<br/>23 was consistent with the finding of Longo finding<br/>24 chrysotile in her actual bottle from 2014. And<br/>25 then the FDA testing through AMA also found it in</p> | Page 94 | <p>1 also in addition looking for chrysotile.<br/>2 So I don't recall seeing him look for<br/>3 chrysotile prior to the Zimmerman report. I<br/>4 don't know if he's done other reports or looked<br/>5 for chrysotile in other cases since the FDA<br/>6 report came out.</p> <p>7 Q And with respect to Dr. Longo's<br/>8 testing, again, with respect to his methodology<br/>9 and his results, whether they're reliable and<br/>10 accurate, is something that you would defer to<br/>11 others because that's not your field. Fair?</p> <p>12 MS. KAGAN: Argument as to "reliable<br/>13 and accurate."</p> <p>14 THE WITNESS: I can't speak to the<br/>15 methodology. I'm going to defer to others to<br/>16 speak about methodology.</p> <p>17 BY MS. ROMANO:</p> <p>18 Q And I think you and I have had this<br/>19 conversation before that with respect to any of<br/>20 the documents you rely on for your opinion that<br/>21 there's asbestos in cosmetic talc and<br/>22 specifically Johnson's baby powder, you're<br/>23 essentially taking those conclusions at face<br/>24 value because testing is not your area of<br/>25 expertise. Is that fair?</p>  | Page 96 |
| <p>1 2019, so I would expect that there would be a<br/>2 question related to that.</p> <p>3 With respect to the actual methodology<br/>4 on how the testing was done, I would defer to<br/>5 others.</p> <p>6 Q And you are aware that AMA tested two<br/>7 bottles of Johnson's baby powder and the other<br/>8 bottle tested negative for asbestos; right?</p> <p>9 A That's my recollection, yes.</p> <p>10 Q I want to talk a little bit about<br/>11 Dr. Longo's findings with respect to what I'll<br/>12 call the Zimmerman bottles. Is it your<br/>13 understanding that with respect to Dr. Longo's<br/>14 testing of the Zimmerman bottles, this was the<br/>15 first time that Dr. Longo has ever claimed to<br/>16 find chrysotile in Johnson's baby powder or a J&amp;J<br/>17 talc product?</p> <p>18 A I think that it was -- I mean, his<br/>19 prior methodology specifically states he wasn't<br/>20 measuring chrysotile, so I don't recall seeing<br/>21 it. I think he's using an additional method in<br/>22 addition to the heavy liquid separation which is<br/>23 going to be looking for the amphiboles that<br/>24 separate out that will not find chrysotile<br/>25 because chrysotile is too light, that now he's</p>   | Page 95 | <p>1 MS. KAGAN: Argument.</p> <p>2 THE WITNESS: I mean, in the sense<br/>3 that the findings that are -- I'm taking them --<br/>4 I'm looking at them in the context of the<br/>5 historical testing that's been done that found<br/>6 chrysotile at the University of Minnesota that's<br/>7 using methods from the Colorado School of Mines<br/>8 to find the testing that's been done before.</p> <p>9 It's been found in the historical<br/>10 testing that the detection limits are such that<br/>11 one would find it and not be classified as a<br/>12 nondetect. So it's looking at the described<br/>13 methodology with respect to its sensitivity but<br/>14 also looking in the historical context of what's<br/>15 been done, what's been found.</p> <p>16 In terms of how the methodology is<br/>17 done, I guess that's not my area, but -- so I<br/>18 hope that answers your question. If not, I'm<br/>19 happy to try again.</p> <p>20 BY MS. ROMANO:</p> <p>21 Q No. I think it does. I think we can<br/>22 agree that with respect to the testing documents<br/>23 that you're relying on, you're essentially<br/>24 relying on the conclusions of whoever authored<br/>25 those documents rather than really taking a</p> | Page 97 |

|  |   |
|--|---|
| 1 critical look at the methodology because that's<br>2 somebody else's field?<br>3 MS. KAGAN: Mischaracterizes.<br>4 Argument as to "critical look."<br>5 THE WITNESS: The only -- I mean,<br>6 there are a couple things that I look at. In<br>7 terms of how they actually go about doing a<br>8 columnar separation using various reagents, I'm<br>9 not paying attention to that because I can't --<br>10 wouldn't be able to opine whether that was using<br>11 a standard methodology or not.<br>12 What I am interested in is their<br>13 limits of detection and what they're able to<br>14 find, and that I do look at to see whether, when<br>15 they're referring to a nondetect, if it's a<br>16 nondetect or a true value of not finding anything<br>17 if that is enumerated within the document.<br>18 So it's sort of a two part. Part of<br>19 it, I am not doing a critical review of how<br>20 someone is doing their laboratory work, but the<br>21 other is what do they say their limits are of<br>22 detection and what are they able to find and are<br>23 they using a sensitive enough method, for<br>24 example, if someone's using SEM versus TEM when<br>25 we know that TEM is more sensitive than SEM and | Page 98<br>1 things along those lines.<br>2 Q Thank you. Sorry. That was not a<br>3 very well-worded question on my -- okay. Let me<br>4 look at my notes.<br>5 Going back to your notes that were<br>6 produced to us, Dr. Moline, on the first page,<br>7 you have notes regarding Ms. Zimmerman's use of<br>8 Johnson's baby powder. Do you have those in<br>9 front of you?<br>10 A Yes.<br>11 Q And it says, "Powder started 1954 -<br>12 J&J." Then there's a parentheses, 54 to 2008.<br>13 Is that the number of bottles that you added up<br>14 for Johnson's baby powder based on<br>15 Ms. Zimmerman's testimony?<br>16 MS. KAGAN: Mischaracterizes.<br>17 THE WITNESS: I have 2018 on my notes.<br>18 BY MS. ROMANO:<br>19 Q Oh, okay. The 1 is not showing up on<br>20 what I can see. Okay. So that's just the date<br>21 range that she used Johnson's baby powder, 1954<br>22 to 2018?<br>23 A Correct.<br>24 Q And did you calculate how many bottles<br>25 of Johnson's baby powder Ms. Zimmerman would have  |
| Page 99<br>1 you're not going to be able to differentiate<br>2 certain things if they're only using an SEM<br>3 versus a TEM or a phase contrast microscope.<br>4 So you don't find something on a phase<br>5 contrast microscope. But does that mean that you<br>6 wouldn't see it if you used a TEM? So that's the<br>7 degree that I would look at it.<br>8 BY MS. ROMANO:<br>9 Q With respect to mineral<br>10 characterization with respect to -- if you're<br>11 looking at a particle under a microscope and<br>12 trying to determine what mineral it is, that's<br>13 something that you also are relying on whoever's<br>14 authoring the document rather than doing that<br>15 yourself; right?<br>16 MS. KAGAN: Are you asking for a<br>17 determination of the chemical composition?<br>18 MS. ROMANO: Right.<br>19 BY MS. ROMANO:<br>20 Q The actual conclusion as to what any<br>21 of the documents are finding, you're relying on<br>22 those conclusions with respect to the<br>23 characterization of the mineral?<br>24 A Correct. I'm not doing mineral<br>25 characterization. I'm not looking at peaks and  | Page 99<br>1 used based on her testimony?<br>2 A Yes. And, also, I mean, it was<br>3 corroborated by her sister and then her kids.<br>4 And it was -- I did a whole sheet where I<br>5 calculated those numbers, and I thought I made it<br>6 clear.<br>7 MS. KAGAN: Julia, I think it's the<br>8 last page in the notes.<br>9 MS. ROMANO: I see that. Thank you.<br>10 BY MS. ROMANO:<br>11 Q So if we go to the last page or the<br>12 exposure page, what is the total -- is it the<br>13 768 bottles? Is that the total number of<br>14 bottles, Dr. Moline?<br>15 A The calculations are based on the time<br>16 frame that she used it and how often she said she<br>17 used it. For example, when she was younger, she<br>18 only used Johnson's baby powder. She used that<br>19 once a day, and I calculated once a day even --<br>20 and it's a conservative value because she said<br>21 sometimes she used it more than once a day. But<br>22 I just did once a day, and that would be 730<br>23 times.<br>24 With respect to the bottles, it was<br>25 based -- and, again, this is conservative because |

|  |   |
|--|---|
| <p>Page 102</p> <p>1 she said she used one to two containers a month<br/>2 and I only calculated as based on one container a<br/>3 month for the 64 years. And then I said one<br/>4 container per 64 years, and there are 12 months<br/>5 in a year, and that's how I got the 768 bottles.<br/>6 MS. ROMANO: Thank you for that.<br/>7 Sorry. I'm scrolling through my notes trying to<br/>8 cut down what I need to ask you. Give me one<br/>9 moment, please.<br/>10 I think now's a good time for a break.<br/>11 We've been going an hour.<br/>12 THE WITNESS: Sure. I can do a<br/>13 stretch break.<br/>14 (Proceedings in recess, 12:40 p.m. to<br/>15 12:46 p.m.)<br/>16 BY MS. ROMANO:<br/>17 Q Dr. Moline, are you ready to continue?<br/>18 A Yes.<br/>19 Q With respect to Dr. Longo's report<br/>20 related to the two Zimmerman bottles, is there<br/>21 anything else other than what we've already<br/>22 discussed that you intend to discuss or opine on<br/>23 at trial with respect to that report?<br/>24 A Not I can think of.<br/>25 Q And generally speaking with respect to</p>  | <p>Page 104</p> <p>1 her medical expenses might be in the future or<br/>2 anything like that?<br/>3 A I have not per se. You know, it's so<br/>4 hard to predict because it depends on her course<br/>5 and what she might require and if there's<br/>6 inpatient versus outpatient versus medication<br/>7 costs and things like that.<br/>8 So I haven't -- I would anticipate<br/>9 that it would total -- you know, again, it<br/>10 depends on what she elects to do at the end of<br/>11 life. It could total easily more than six<br/>12 figures, but it depends on her course and what<br/>13 she decides to do.<br/>14 I mean, it's going to be what she's<br/>15 already incurred and then using that as a<br/>16 starting point to say, yes, we know what she's<br/>17 incurred getting these treatments. She's<br/>18 continuing these treatments. They're going to<br/>19 continue, that kind of thing.<br/>20 Q Have you calculated or added up her<br/>21 past medical expenses? Is that something that<br/>22 you've done in this case?<br/>23 A In a general sense that it's -- from<br/>24 the various hospitals and the records that I saw,<br/>25 it's about -- I think it was billed at around</p> |
| <p>Page 103</p> <p>1 the testimony that you intend to give at trial,<br/>2 you obviously go through your background and<br/>3 qualifications. Then you often discuss sort of<br/>4 the historical context of asbestos and learning<br/>5 that asbestos can cause disease.<br/>6 And then you also I guess do that with<br/>7 respect to talc and the evolution of knowledge<br/>8 with respect to talc and asbestos. Then you talk<br/>9 about obviously Ms. Zimmerman and what you<br/>10 believe caused Ms. Zimmerman's mesothelioma. And<br/>11 then you often talk about I guess the disease<br/>12 progression in terms of what the future holds for<br/>13 Ms. Zimmerman.<br/>14 Is that a fair summary or description<br/>15 of the testimony that you intend to give at trial<br/>16 in this case?<br/>17 A I think -- yes. Obviously, I might be<br/>18 asked other questions, but it will be asking<br/>19 about what her medical course is. And I'm often<br/>20 asked if the medical bills and the costs were<br/>21 reasonable and necessary. But that's basically<br/>22 in general what I've been asked at trial.<br/>23 Q Okay. And with respect to<br/>24 Ms. Zimmerman's future medical treatment, have<br/>25 you come up with an estimate in terms of how much</p> | <p>Page 105</p> <p>1 800 -- or I'm sorry -- \$600,000. \$600,000 has<br/>2 been billed as to date.<br/>3 Q When you say "billed," do you mean<br/>4 actually billed as opposed to what actually might<br/>5 be paid out of that \$600,000-ish? Is that right?<br/>6 A Right, because there's always a bill<br/>7 that's -- there's negotiated rates. But the<br/>8 initial bills have been around \$600,000. I think<br/>9 it's been -- because I think she has Medicare as<br/>10 her primary, it -- the Medicare rates are<br/>11 significantly less than what's billed. So it's<br/>12 less.<br/>13 Q And with respect to Ms. Zimmerman's<br/>14 clinical course, what are the most recent medical<br/>15 records that you've reviewed in the case just in<br/>16 terms of a date and general type of medical<br/>17 record?<br/>18 A I have something from -- I think the<br/>19 last I have was October 2019. Yeah, 2019,<br/>20 October 2019.<br/>21 Q So you haven't seen any records<br/>22 demonstrating what type of treatment, if any,<br/>23 she's undergoing at this point in time. Is that<br/>24 fair?<br/>25 A I don't know exactly what she's</p>  |

|  |  |
|--|--|
| <p>Page 106</p> <p>1 getting now. I know the last I saw she was on a<br/>2 steroid paper for radiation pneumonitis. I don't<br/>3 have the medical records, which is something I<br/>4 could ask to be provided, but they may become<br/>5 available.</p> <p>6 Q And so at least as of today you're not<br/>7 going to testify about Ms. Zimmerman's current<br/>8 status. Is that fair?</p> <p>9 A I can only talk about -- right.</p> <p>10 That's correct. I can't comment on what's<br/>11 transpired since October because I haven't seen<br/>12 the records.</p> <p>13 Q With respect to exposure calculations<br/>14 from cosmetic talc, in the past I believe you've<br/>15 relied on Dr. Gordon's 2014 article. You've<br/>16 relied on the Anderson paper that I guess was<br/>17 a -- I don't know if rebuttal is the right word,<br/>18 but a rebuttal to that Dr. Gordon paper.</p> <p>19 You relied on Dr. Longo's exposure<br/>20 data and then I believe also a 2007 paper by<br/>21 Mattenklott.</p> <p>22 Are there any other documents or<br/>23 reports that you rely on for exposure<br/>24 calculations other than the ones I just listed?</p> <p>25 A I mean, some of the timing would be</p> | <p>Page 108</p> <p>1 BY MR. POLCHINSKI:<br/>2 Q Dr. Moline, I guess I will go next.<br/>3 This is Pete Polchinski. I represent Revlon.<br/>4 I'm going to ask you some questions about Jean<br/>5 Nate. Dr. Moline, you have been involved in the<br/>6 talc litigation for at least several years now.<br/>7 Would that be fair to say?</p> <p>8 A Yes.</p> <p>9 Q With regard to cosmetic talc, and I'm<br/>10 not talking about diapering a baby, I'm talking<br/>11 about a person applying talcum powder, is there,<br/>12 in your experience, a typical application time<br/>13 period, in other words, how long it takes to<br/>14 apply the powder?</p> <p>15 A I think that -- I don't know if any<br/>16 woman or man would consider themselves typical<br/>17 with their application. I think some folks can<br/>18 be very fastidious and slow, and then others may<br/>19 be -- may apply it quickly. So I don't know how<br/>20 to answer.</p> <p>21 I mean, everyone is different. I've<br/>22 seen numbers where people describe putting talc<br/>23 on that have been corroborated by family members<br/>24 that it took five minutes. Others have described<br/>25 it as being a minute or two.</p>  |
| <p>Page 107</p> <p>1 like the timing that was represented as how long<br/>2 it takes for -- to diaper a baby. That was from<br/>3 Dement and also some internal Johnson &amp; Johnson<br/>4 documents about how long it takes.</p> <p>5 I mean, there have been other studies<br/>6 that have been done like Compton and Fitzgerald,<br/>7 but when I've done the calculations in the past,<br/>8 I think that's been a fair way to characterize<br/>9 how I've done that.</p> <p>10 Q Okay. Thank you.</p> <p>11 A You're asking me questions related to<br/>12 Johnson &amp; Johnson; right? Because there are<br/>13 other --</p> <p>14 Q Yes. I'm sorry.</p> <p>15 A Okay.</p> <p>16 Q Yes, specific to Johnson's baby<br/>17 powder.</p> <p>18 A Okay.</p> <p>19 MS. ROMANO: I think those are all my<br/>20 questions at this time, Dr. Moline. I'm going to<br/>21 go ahead and pass you on to someone else and<br/>22 check my notes. I may have one or two at the<br/>23 end, but hopefully I'll be done. I'll pass the<br/>24 witness.</p> <p>25 EXAMINATION</p>   | <p>Page 109</p> <p>1 Q So you found a range?</p> <p>2 A Again, I haven't tried to characterize<br/>3 it because those people aren't doing a stop clock<br/>4 to say how long does it take when I put on<br/>5 cosmetic talc. They're usually butt naked in a<br/>6 bathroom without a timer on when they're doing<br/>7 their application of powder, or they have their<br/>8 undergarments on.</p> <p>9 There have been varying descriptions.<br/>10 I don't know if I would characterize it as a<br/>11 range. It all depends also on how they're<br/>12 applying it, if they're pouring it into their<br/>13 hands and applying it to their body or they're<br/>14 using a powder puff and they find it a meditative<br/>15 process, in which case it would take much longer.<br/>16 So I think everyone applies powder somewhat<br/>17 differently.</p> <p>18 Q So would you say that a five-minute<br/>19 application would be on the high end of what you<br/>20 have seen in the course of this litigation?</p> <p>21 A Again, it depends on how they're<br/>22 applying it. But five -- for the powder puff, I<br/>23 think if they're using a powder puff, I think<br/>24 that's about what people have described. Again,<br/>25 if they're putting -- using a powder puff on</p> |

|  |   |
|--|---|
| 1 their full body and it's something that they do<br>2 as part of their routine to help them set their<br>3 day, that would be about what they -- what's been<br>4 described.<br>5 Q Now, have you also seen in the course<br>6 of this litigation that when asbestos or asbestos<br>7 fragments or cleavage fragments have been found<br>8 in talc, cosmetic talc, that it's been found in<br>9 trace -- what's called trace amounts?<br>10 MS. KAGAN: Objection. Argumentative<br>11 as to cleavage fragment. Vague.<br>12 Mischaracterizes.<br>13 THE WITNESS: I'm not quite sure what<br>14 you mean by trace amounts. They -- when they<br>15 describe the asbestos fibers that have been<br>16 found, they will often describe that they found X<br>17 number when they're doing a sample for grams. It<br>18 could be hundreds of thousands or millions of<br>19 fibers.<br>20 And then when they're doing air<br>21 measurements, it's levels that are orders of<br>22 magnitude above background.<br>23 If you're asking by weight, then it's<br>24 less than one percent by weight typically. But<br>25 that still represents millions and billions of | Page 110<br>1 correct, that would be a comparison, yes.<br>2 But if it's -- I mean, if you're<br>3 asking me is one number more than the other, yes.<br>4 BY MR. POLCHINSKI:<br>5 Q Doctor, in the course of your<br>6 involvement in asbestos litigation, you have<br>7 reviewed the report of Dr. Iwatsubo in the French<br>8 mesothelioma study?<br>9 A Yes.<br>10 Q That was from 1998?<br>11 A I believe so.<br>12 Q Dr. Iwatsubo in that report indicated<br>13 that 0.5 fibers per cc-years, anything less than<br>14 that was not significant in causing mesothelioma?<br>15 MS. KAGAN: Mischaracterizes.<br>16 THE WITNESS: I don't have the paper<br>17 in front of me, and I don't recall the specific<br>18 numbers from that particular paper. I do know<br>19 that there have been additional papers published<br>20 since then that have lower values of .1 fiber per<br>21 cc-year that have been associated with a fourfold<br>22 increase of mesothelioma.<br>23 I don't know if I talked about<br>24 Dr. Iwatsubo in my declaration. I think I did.<br>25 If you give me one second, I can refer to what I |
| Page 111<br>1 fibers.<br>2 So a long-winded answer to in some<br>3 ways of it being described as trace meaning it's<br>4 less than one percent, yes, in a bulk sample.<br>5 BY MR. POLCHINSKI:<br>6 Q And have you seen trace amounts of<br>7 1/1,000th?<br>8 A In terms of a bulk weight --<br>9 Q Yes.<br>10 A -- bulk percentage? Yes.<br>11 Q So if you were to compare that to an<br>12 asbestos-containing product that had 30 percent<br>13 asbestos, that would be 300 parts per 1,000;<br>14 correct?<br>15 MS. KAGAN: Argument.<br>16 Mischaracterizes.<br>17 THE WITNESS: Well, it depends on --<br>18 it's not necessarily -- it depends. If you're<br>19 talking about an asbestos product that's bound up<br>20 with cellulose and other things and 30 percent of<br>21 the product is asbestos, that's one thing.<br>22 If you're talking about a product<br>23 that's friable and is meant to become airborne<br>24 and aerosolize as talcum powders were, if you're<br>25 looking at .001 and 30, if your numbers are   | Page 113<br>1 said in my declaration there, which is --<br>2 BY MR. POLCHINSKI:<br>3 Q Sure.<br>4 A Let me just grab it if that's what<br>5 you're referring to. But I don't have the actual<br>6 paper in the room with me. It said -- that was<br>7 his -- I think that was his lowest -- it's in the<br>8 footnote. I think that he gave a relative -- an<br>9 odds ratio of 4.2 for .5 to .99 fiber per<br>10 cc-years. I don't recall what he had for below<br>11 that.<br>12 But the Rodelsperger and the Lacourt<br>13 had values that were at a lower rate than he did.<br>14 Q And Dr. Lacourt had a 0.1 fiber<br>15 cc-years quadrupling the nonoccupational risk of<br>16 developing mesothelioma?<br>17 MS. KAGAN: I'm sorry. Can you reask<br>18 that question?<br>19 BY MR. POLCHINSKI:<br>20 Q Would you like me to repeat that?<br>21 MS. KAGAN: I didn't hear your<br>22 question. Can you please repeat the question?<br>23 MR. POLCHINSKI: Sure.<br>24 BY MR. POLCHINSKI:<br>25 Q Dr. Lacourt had the value of 0.1 fiber   |

|   |   |
|---|---|
| <p style="text-align: right;">Page 114</p> <p>1 cc-years quadrupling the nonoccupational risk of<br/>2 developing mesothelioma. Do I have that correct?<br/>3 MS. KAGAN: Mischaracterizes.<br/>4 THE WITNESS: Lacourt, as I referenced<br/>5 here, had an odds ratio of almost 24 for values<br/>6 of greater than .1 fiber per cc-years. In others<br/>7 I think at a lower level it was fourfold<br/>8 increase.<br/>9 BY MR. POLCHINSKI:<br/>10 Q Now, is there an exposure level,<br/>11 Doctor, that you rely on in calculating exposure<br/>12 from a person applying cosmetic talc?<br/>13 MS. KAGAN: Vague.<br/>14 THE WITNESS: I'm sorry. Can you --<br/>15 I'm not quite -- I don't follow your question.<br/>16 Could you rephrase it?<br/>17 BY MR. POLCHINSKI:<br/>18 Q Sure. Is there an exposure level in<br/>19 fibers per cc that you have relied upon in<br/>20 determining how much exposure exists when a<br/>21 person is applying cosmetic talc?<br/>22 MS. KAGAN: Asked and answered by<br/>23 Julia Romano five minutes ago.<br/>24 MR. POLCHINSKI: Well, we didn't have<br/>25 a number.</p> | <p style="text-align: right;">Page 116</p> <p>1 A Okay.<br/>2 Q All right? Now, to add to that, what<br/>3 we're talking about here, I'm going to submit to<br/>4 you Dr. Longo did some examinations of Jean Nate<br/>5 powder. He looked at five tins, and in three of<br/>6 those tins he found cleavage fragments.<br/>7 MS. KAGAN: Mischaracterizes.<br/>8 Foundation. Argument.<br/>9 BY MR. POLCHINSKI:<br/>10 Q Are you with me so far?<br/>11 MS. KAGAN: Incomplete hypothetical.<br/>12 Mischaracterizes. If you're referring to a<br/>13 specific document, you should tell her. But<br/>14 you're also not accurately describing the<br/>15 document. The hypothetical is incomplete.<br/>16 MR. POLCHINSKI: I'm not finished yet.<br/>17 THE WITNESS: I don't recall that he<br/>18 only described cleavage fragments.<br/>19 BY MR. POLCHINSKI:<br/>20 Q If we just say three out of five<br/>21 tins -- let's just leave it at that -- three out<br/>22 of five would be 60 percent of what he examined.<br/>23 Would that be accurate?<br/>24 MS. KAGAN: Mischaracterizes. He<br/>25 found asbestos in four out of five. I don't know</p>             |
| <p style="text-align: right;">Page 115</p> <p>1 THE WITNESS: I don't think I've ever<br/>2 given a specific number with respect to that.<br/>3 I've been asked whether I felt there was<br/>4 exposures that were above background. I've done<br/>5 characterizations based on the published data<br/>6 from where background is to where exposures are<br/>7 related to cosmetic talc. But it's a range.<br/>8 Every exposure is going to be different.<br/>9 BY MR. POLCHINSKI:<br/>10 Q Now, Dr. Moline, on page ten of your<br/>11 notes, you had a calculation of the number of<br/>12 applications with respect to the Jean Nate<br/>13 product?<br/>14 A Correct.<br/>15 Q And that was 3,016 applications?<br/>16 A Correct.<br/>17 Q And if we were to use five minutes for<br/>18 each application, that would give us<br/>19 15,080 minutes of exposure lifetime. Can you<br/>20 rely on my math?<br/>21 A Yes.<br/>22 MS. KAGAN: Foundation.<br/>23 BY MR. POLCHINSKI:<br/>24 Q Now, if we were to divide that 15,080<br/>25 by 60 minutes, we would come up with 251 hours?</p>                          | <p style="text-align: right;">Page 117</p> <p>1 why you're saying three out of five.<br/>2 MR. POLCHINSKI: That's what my<br/>3 information said.<br/>4 MS. KAGAN: I don't know if you know<br/>5 the difference between PLM and TEM, but he found<br/>6 asbestos in one of the containers by PLM only and<br/>7 then by TEM in three of them. So you should read<br/>8 his declaration, read the reports, and then ask<br/>9 your questions. Otherwise, you're asking a<br/>10 hypothetical that's not based in fact and it<br/>11 makes no sense.<br/>12 BY MR. POLCHINSKI:<br/>13 Q If we go with my three out of five,<br/>14 60 percent, Doctor, of 251 would be roughly<br/>15 150 hours?<br/>16 MS. KAGAN: That's not accurate.<br/>17 We're not going with your three out of five<br/>18 because it's not based in fact. You're asking a<br/>19 hypothetical based on not the facts in this case.<br/>20 MR. POLCHINSKI: Counsel, would it<br/>21 satisfy you if I did four out of five instead of<br/>22 three out of five?<br/>23 MS. KAGAN: It would be factually<br/>24 accurate to use four out of five as opposed to<br/>25 three out of five, yes.</p> |

|  |  |
|--|--|
| 1 BY MR. POLCHINSKI:<br>2 Q All right. Well, let's do that then.<br>3 Let's take -- 250 hours times 80 percent is<br>4 200 hours.<br>5 MS. KAGAN: Vague and<br>6 incomprehensible.<br>7 BY MR. POLCHINSKI:<br>8 Q All right?<br>9 A Okay.<br>10 Q Now, if a person was exposed let's say<br>11 on a job to 0.1 fibers cc for 2,000 hours, a full<br>12 work year, at the end of that year, the person<br>13 would have had 0.1 fiber cc-years; correct?<br>14 MS. KAGAN: Mischaracterizes.<br>15 Foundation.<br>16 THE WITNESS: So I lost you there. So<br>17 2,000 work hours in the year.<br>18 BY MR. POLCHINSKI:<br>19 Q Right.<br>20 A Ask the question again.<br>21 Q If a person works in that environment,<br>22 0.1 fibers per cc, for a full year, 2,000 hours,<br>23 at the end of that year, that person will have<br>24 0.1 fiber cc-years. Is that basically correct?<br>25 A You're talking occupational standards  | Page 118<br>1 along this.<br>2 But we're also discounting the fact<br>3 that you don't leave that -- a workplace is a<br>4 place you typically don't live in, and it's not<br>5 necessarily applicable. It's been used as<br>6 estimates to try to give some sort of<br>7 quantification, but it's a little more<br>8 complicated than this.<br>9 But anyways, go ahead with whatever<br>10 you're doing. I don't like doing math on the<br>11 fly, as anyone who's read my depositions has<br>12 known.<br>13 BY MR. POLCHINSKI:<br>14 Q Especially over the phone.<br>15 A Well, phone or -- I mean, I'm not<br>16 sitting with a calculator. I like to do things<br>17 methodically. If you look at page ten of my<br>18 notes, I was very methodical, and I actually<br>19 confirmed the numbers.<br>20 So we're not isolating out one product<br>21 versus another since they all contribute, and<br>22 that was in her cumulative exposure. But anyway,<br>23 I'm happy to continue answering your questions.<br>24 Q Just with respect to 200 hours, 0.1<br>25 would result in 0.01 fiber per cc-years. Would   |
| Page 119<br>1 now? Yes.<br>2 Q Yes.<br>3 A If someone has .1 fiber per cc for<br>4 2,000 hours, that's one fiber per cc-year for<br>5 their occupational time-weighted average.<br>6 Q So if a person had 200 hours instead<br>7 of 2,000, that's one-tenth of a work year;<br>8 correct?<br>9 MS. KAGAN: Mischaracterizes and<br>10 foundation as to the 200 hours.<br>11 Incomprehensible. Incomplete hypothetical.<br>12 THE WITNESS: Using your numbers, then<br>13 yes, that would be one-tenth of a work year.<br>14 BY MR. POLCHINSKI:<br>15 Q Now, if a person had 200 hours at 0.1<br>16 fibers per cc, at the end of that period of time,<br>17 the 200 hours, their lifetime exposure from what<br>18 we're talking about would be 0.01 fiber cc-years.<br>19 Would that be accurate?<br>20 MS. KAGAN: Mischaracterizes.<br>21 Foundation. Incomplete hypothetical.<br>22 THE WITNESS: I mean, your math is<br>23 correct, but you can't take the 80 percent value.<br>24 You have to take the fact that she had the full<br>25 250 hours of exposure. I'm losing you somewhere | Page 121<br>1 that be accurate?<br>2 MS. KAGAN: Mischaracterizes.<br>3 Foundation. Incomplete hypothetical.<br>4 THE WITNESS: Using the numbers that<br>5 you have stated, that's what the math would work<br>6 out to, yes.<br>7 BY MR. POLCHINSKI:<br>8 Q And if a person were -- if that were<br>9 their lifetime exposure to a particular product,<br>10 that would be less exposure than both<br>11 Dr. Iwatsubo and Dr. Lacourt calculated as sort<br>12 of a threshold for substantial exposure. Would<br>13 that be fair to say?<br>14 A No. They didn't describe that. They<br>15 didn't have a threshold for substantial exposure.<br>16 Lacourt went lower and actually had values that<br>17 were below those numbers. You can't do it in<br>18 simple isolation because there were additional<br>19 exposures.<br>20 All of these exposures would increase<br>21 the risk from the many years of the application<br>22 of a particular product, so it's not like you can<br>23 just say, well, the exposure was below this<br>24 number, there was no risk when the exposures are<br>25 above background. |

|   |   |
|---|---|
| <p style="text-align: right;">Page 122</p> <p>1 Q But you will admit, Doctor, that each<br/>2 product has to be looked at individually?</p> <p>3 MS. KAGAN: Mischaracterizes. Looked<br/>4 at individually for what?</p> <p>5 MR. POLCHINSKI: Looked at for the --</p> <p>6 MS. KAGAN: Counsel, I don't know what<br/>7 jurisdiction you think you're in. I don't know<br/>8 if you're licensed in California. But Rutherford<br/>9 does not require a dose calculation for each<br/>10 individual exposure and it doubling their risk.</p> <p>11 I think you're thinking of the<br/>12 Borg-Warner case in Texas, and I think you're a<br/>13 bit confused here. So I'm not sure what you're<br/>14 asking.</p> <p>15 MR. POLCHINSKI: I assure you I'm not<br/>16 confused, Counsel, but I am asking questions of<br/>17 the doctor. And I'm drawing objections. I<br/>18 understand that.</p> <p>19 MS. KAGAN: You're asking questions<br/>20 about taking an individual product into<br/>21 consideration for exposure purposes which<br/>22 Dr. Moline has already done for you twice. But<br/>23 now you're asking a different question which is<br/>24 not in compliance with the law in California.</p> <p>25 It is not required by Rutherford or --</p> | <p style="text-align: right;">Page 124</p> <p>1 familiar with the Unarco plant in Bloomington,<br/>2 Illinois?</p> <p>3 A Familiar I think would be -- I don't<br/>4 know what you mean by familiar. Am I aware that<br/>5 there was a Unarco plant in Bloomington,<br/>6 Illinois? Yes.</p> <p>7 Q Have you received any photographs of<br/>8 the Unarco plant, interior photographs of that<br/>9 plant?</p> <p>10 A Not that I specifically recall.</p> <p>11 Q You indicated also that Dr. Selikoff<br/>12 did some research into exposures at the Unarco<br/>13 plant in New Jersey; correct?</p> <p>14 A My recollection is that Selikoff<br/>15 evaluated folks who had worked at the Unarco<br/>16 plant in New Jersey, not the Bloomington plant,<br/>17 in the 1950s. He didn't do exposure assessments<br/>18 that I recall seeing, but I know that he was<br/>19 describing the clinical findings from those<br/>20 folks.</p> <p>21 Q Did you ever see a writing from<br/>22 Dr. Selikoff that indicated that the interior of<br/>23 the Unarco plant that he studied had roughly 50<br/>24 fibers per cc?</p> <p>25 MS. KAGAN: Mischaracterizes.</p>  |
| <p style="text-align: right;">Page 123</p> <p>1 I am not sure what exactly you think you're<br/>2 asking or what jurisdiction you practice in, but<br/>3 it's clearly not California.</p> <p>4 BY MR. POLCHINSKI:</p> <p>5 Q The question really goes to -- my<br/>6 particular product is not -- my client is not<br/>7 responsible for everyone else's exposures. Would<br/>8 that be fair to say?</p> <p>9 MS. KAGAN: Mischaracterizes.</p> <p>10 Argument. I don't know what you mean by<br/>11 responsible. You mean legally responsible?</p> <p>12 Again, joint and several liability exists because<br/>13 your client's product contributes to the disease<br/>14 and you are jointly severable for that<br/>15 contribution.</p> <p>16 MR. POLCHINSKI: No. I'm just talking<br/>17 about causation.</p> <p>18 MS. KAGAN: Right. And she's already<br/>19 testified that all these exposures contribute<br/>20 that are above background. I'm not sure, again,<br/>21 what you're trying to parse out here, but it's<br/>22 not the law in California. You're just wasting<br/>23 time.</p> <p>24 BY MR. POLCHINSKI:</p> <p>25 Q Dr. Moline, you've indicated you're</p>  | <p style="text-align: right;">Page 125</p> <p>1 Foundation.</p> <p>2 THE WITNESS: I don't recall that<br/>3 specific number from the New Jersey plant. I<br/>4 don't recall the publication. I probably read<br/>5 it, but I have no recollection of the specific<br/>6 number.</p> <p>7 And that would have -- and, also, I'm<br/>8 not sure how the two plants compare and also what<br/>9 Mr. Martin was actually doing in Bloomington.</p> <p>10 Ms. Fowler testified that she recalled that he<br/>11 worked with metal. And when I looked at his<br/>12 salary, he was making a rate that was associated<br/>13 with the machinists' or other skilled trades'<br/>14 rates because it was more than \$2 an hour, which<br/>15 was quite interesting.</p> <p>16 And that made sense based on what<br/>17 Ms. Fowler had described, that he worked with<br/>18 metal, which is what machinists tend to do,<br/>19 rather than working with the insulation itself.</p> <p>20 Q In your calculation on page ten of<br/>21 your notes, you indicate 2,607 possible<br/>22 interactions by the Plaintiff with her stepfather<br/>23 regarding the Unarco exposure?</p> <p>24 A Right. That was based on the fact<br/>25 that she lived in the same house with him for ten</p> |

|   |   |
|---|---|
| <p>1 years. And there are five workdays in a week, so<br/>2 that's how I came up with that calculation.<br/>3 Q How many minutes per interaction did<br/>4 you calculate?<br/>5 A I didn't. And based on the testimony<br/>6 from Ms. Zimmerman and Ms. Fowler, Ms. Zimmerman<br/>7 tried to stay away from her stepfather as much as<br/>8 possible and was not in the house. It sounded<br/>9 like there was -- she described it as very<br/>10 minimal interaction.<br/>11 And then she was away at college, and<br/>12 then she would go from class to working. I think<br/>13 her sister described quite poignantly that she<br/>14 would make her an egg or a grilled cheese<br/>15 sandwich because she hadn't had anything to eat<br/>16 by the time she came home at the end of the<br/>17 evening.<br/>18 Her sister would wake up and make her<br/>19 a sandwich because she'd been out of the house<br/>20 all day. So she didn't have a lot of interaction<br/>21 with the stepfather.<br/>22 Q How was it that you calculated the<br/>23 2,607 interactions?<br/>24 A I said that she would interact with<br/>25 him once a day for ten years, five days a week,</p>                        | <p>Page 126</p> <p>1 MS. KAGAN: Argument as to "somehow<br/>2 infiltrated the house."<br/>3 THE WITNESS: I don't know how<br/>4 Mr. Martin's exposure managed to contaminate the<br/>5 house. There was also some description of them<br/>6 riding in a car to go to church. Perhaps it was<br/>7 in the car on the rare occasion she was actually<br/>8 in the car with him. I have no way of knowing.<br/>9 BY MR. POLCHINSKI:<br/>10 Q When Dr. Gordon found amosite and<br/>11 crocidolite in Ms. Zimmerman's tumor, was that<br/>12 the only asbestos types that he found in the<br/>13 tumor?<br/>14 A Within the tumor tissue, those were<br/>15 the only two types that he found, that's correct,<br/>16 in the piece of the tumor he had, yes, not in the<br/>17 lymph nodes.<br/>18 Q Based upon the facts that we have<br/>19 before us with the three different types of<br/>20 exposure that have been discussed here, is it<br/>21 more likely than not in your opinion that the<br/>22 amosite and crocidolite in the tumor tissue came<br/>23 from the Unarco plant?<br/>24 MS. KAGAN: Mischaracterizes.<br/>25 Argument. Asked and answered by counsel for</p> |
| <p>Page 127</p> <p>1 five out of seven days a week, meaning it was<br/>2 261 days in a year because he worked 261 days,<br/>3 that's not assuming he took any vacations, and<br/>4 were at the same house for ten years.<br/>5 Q From your review of this case, the<br/>6 stepfather removed his work clothes in the<br/>7 basement?<br/>8 A That's what Ms. Fowler described.<br/>9 Q So if the Plaintiff, Linda Zimmerman,<br/>10 had occasion to go to the basement, be fair to<br/>11 say that it was likely that there was asbestos in<br/>12 the air in the basement?<br/>13 MS. KAGAN: Mischaracterizes.<br/>14 Foundation. Calls for speculation.<br/>15 THE WITNESS: I have no way of<br/>16 knowing. It depends on if she would be in there.<br/>17 It's possible there could have been. I don't<br/>18 recall her describing going into the basement. I<br/>19 don't recall any testimony to that effect at all.<br/>20 What I gleaned is she tried to stay away from her<br/>21 stepfather as much as possible.<br/>22 BY MR. POLCHINSKI:<br/>23 Q Is it your belief that some of the<br/>24 asbestos from the father's clothes somehow<br/>25 infiltrated the house beyond the basement?</p> | <p>Page 129</p> <p>1 Chanel at the beginning of this deposition and by<br/>2 Ms. Romano with respect to the amosite.<br/>3 THE WITNESS: I have no way of knowing<br/>4 the source of any of these particular fibers. As<br/>5 I said before, the amosite, which is the<br/>6 commercial term for cummingtonite, could have<br/>7 come from cosmetic talc. That's been described<br/>8 before. I have no way of knowing.<br/>9 I do know that there was talc that was<br/>10 found and that there was also<br/>11 tremolite-anthophyllite in the lymph nodes<br/>12 consistent with talc.<br/>13 BY MR. POLCHINSKI:<br/>14 Q You've already indicated that it is<br/>15 your belief that the Unarco plant used amosite<br/>16 asbestos and to a lesser degree crocidolite<br/>17 asbestos?<br/>18 MS. KAGAN: Asked and answered.<br/>19 THE WITNESS: Correct.<br/>20 BY MR. POLCHINSKI:<br/>21 Q I didn't hear the answer.<br/>22 A Correct.<br/>23 MS. KAGAN: The question was asked and<br/>24 answered. I don't know why you're re-covering<br/>25 questions that have already been asked by prior</p>  |

|  |  |
|--|--|
| 1 counsel.<br>2 MR. POLCHINSKI: Dr. Moline, that's<br>3 all I have for you this afternoon. Thank you<br>4 very much.<br>5 THE WITNESS: You're welcome.<br>6 EXAMINATION<br>7 BY MS. ANDERSON-THOMPSON:<br>8 Q Good afternoon, Dr. Moline. This is<br>9 Gabrielle Anderson-Thompson. I just have a<br>10 couple questions for you.<br>11 A Sure.<br>12 Q You don't have any opinions regarding<br>13 a retailer's standard of care; correct?<br>14 A Correct.<br>15 Q And you don't have any expert opinions<br>16 specific to the retailer Ralphs Grocery Company.<br>17 True?<br>18 A Correct.<br>19 Q And you don't have any expert opinions<br>20 specific to the retailer Thrifty Payless Inc.<br>21 True?<br>22 A Correct.<br>23 MS. ANDERSON-THOMPSON: Okay. I don't<br>24 have any other questions. Thank you.<br>25 THE WITNESS: You're welcome.   | Page 130<br>1 disease; correct?<br>2 A Correct.<br>3 Q And then do you recall giving a<br>4 deposition in the Ripley matter?<br>5 A Believe it or not, I don't. I<br>6 remember the name because it allowed me to do<br>7 that at the time because it's corny and I<br>8 appreciate that humor. I recall that I was<br>9 deposed in the Ripley case. I don't remember<br>10 what I said.<br>11 Q I noticed on your reliance list the<br>12 specific testing from Dr. Longo and Dr. Compton<br>13 as to Chanel No. 5. And you had all of those<br>14 tests at the time of the Ripley deposition. You<br>15 were asked about your opinions as to that<br>16 testing, and I just wanted to make sure that you<br>17 hadn't reached any new opinions based on that<br>18 testing since the Ripley deposition.<br>19 Does that make sense?<br>20 A With respect to Dr. Longo's testing of<br>21 the Chanel, I don't recall having any -- I don't<br>22 have any new opinions related to that. I haven't<br>23 seen any additional testing.<br>24 Q And do you have any new opinions about<br>25 Chanel based on Dr. Compton's testing which you |
| Page 131<br>1 MS. KAGAN: Anybody else?<br>2 MS. ROMANO: This is Julia. I have<br>3 maybe three more questions that I found that I<br>4 hadn't asked. But go ahead, Meghan.<br>5 MS. SENTER: It's the same for me. I<br>6 just had a couple follow-ups. I'll ask mine real<br>7 quick.<br>8 RE-EXAMINATION<br>9 BY MS. SENTER:<br>10 Q Dr. Moline, when you were asked some<br>11 questions by Julia earlier, she asked some<br>12 questions specific to J&J, and I want to make<br>13 sure they just kind of apply across the board. I<br>14 think they do.<br>15 MS. KAGAN: Could you reask your<br>16 question? Sorry. I couldn't hear because I was<br>17 coughing.<br>18 BY MS. SENTER:<br>19 Q I just wanted to confirm. Some of the<br>20 questions that were asked by Julia earlier were<br>21 specific to J&J, and I just want to make sure<br>22 that they apply across the board.<br>23 If the Chanel product used by<br>24 Ms. Zimmerman did not contain asbestos, you would<br>25 agree that it did not cause or contribute to her | Page 131<br>1 also had at the time of the Ripley deposition?<br>2 A Not that I'm aware of as I sit here<br>3 right now.<br>4 MS. SENTER: I thought we could<br>5 short-circuit that. The only the other things,<br>6 we can ask this off the record, Leah, I'll ask<br>7 afterwards.<br>8 RE-EXAMINATION<br>9 BY MS. ROMANO:<br>10 Q Dr. Moline, just a few more questions.<br>11 You would agree that Ms. Zimmerman's stepfather's<br>12 work at Unarco is certainly a possible source of<br>13 the amosite and crocidolite found by Dr. Gordon<br>14 in Ms. Zimmerman's tissue. True?<br>15 A Yes.<br>16 Q You also reviewed Ms. Zimmerman's<br>17 medical records, obviously not the most recent,<br>18 but I think up until two thousand -- I think you<br>19 said her medical records up to October of 2019,<br>20 thereabouts?<br>21 A Yeah. There was a pulmonology report<br>22 that I recall from October 8th.<br>23 Q And in your review of Ms. Zimmerman's<br>24 medical records, did you see the notation noting<br>25 that her stepdad's work at an asbestos plant was  |

|   |  |
|---|--|
| <p style="text-align: right;">Page 134</p> <p>1 a possible source of asbestos exposure for<br/>2 Ms. Zimmerman? Did you see those statements?<br/>3 A Yes.<br/>4 MS. KAGAN: Foundation.<br/>5 BY MS. ROMANO:<br/>6 Q Did you see any reference in<br/>7 Ms. Zimmerman's medical records to cosmetic talc<br/>8 or specifically Johnson's baby powder being a<br/>9 possible source of asbestos exposure to<br/>10 Ms. Zimmerman?<br/>11 A No.<br/>12 Q Did you see any reference in<br/>13 Ms. Zimmerman's medical records to cosmetic talc<br/>14 or specifically Johnson's baby powder as being a<br/>15 possible cause of her mesothelioma?<br/>16 A Not within her medical records, no.<br/>17 Q Have we now discussed all the<br/>18 testimony that you anticipate providing at trial<br/>19 in this matter at least in a general sense?<br/>20 A With the exception of whether I would<br/>21 comment on future medical and her additional<br/>22 medical since October, yes.<br/>23 MS. ROMANO: Great.<br/>24 MS. KAGAN: Obviously, I'd tender<br/>25 whatever we disclosed in our 2034 disclosure as</p>    | <p style="text-align: right;">Page 136</p> <p>1 MS. KAGAN: I asked if there have been<br/>2 epidemiologic studies of individuals who have<br/>3 been exposed to asbestos.<br/>4 MS. SENTER: Okay. Sorry.<br/>5 THE WITNESS: Yes.<br/>6 BY MS. KAGAN:<br/>7 Q And, Dr. Moline, do you need a<br/>8 specific epidemiological study for every single<br/>9 type of product that contains asbestos that<br/>10 people would be exposed to in order to offer an<br/>11 opinion that exposure to asbestos causes<br/>12 mesothelioma?<br/>13 A No.<br/>14 Q Have there also been instances<br/>15 documented in the peer-reviewed literature of<br/>16 individuals with mesothelioma associated with<br/>17 who have had associations with use of cosmetic<br/>18 talc or exposure to cosmetic talc?<br/>19 A Yes.<br/>20 Q And those references on your reference<br/>21 and reliance list, you've testified about those<br/>22 in trial before?<br/>23 A I have. And, yes, they are on my<br/>24 list.<br/>25 Q Dr. Moline, why didn't you calculate a</p>   |
| <p style="text-align: right;">Page 135</p> <p>1 well as what's on her reference and reliance<br/>2 list, and the materials we produced prior to this<br/>3 deposition would all be fair game and appropriate<br/>4 for questioning at trial.<br/>5 Anybody else have any questions?<br/>6 EXAMINATION<br/>7 BY MS. KAGAN:<br/>8 Q I have a couple of follow-up<br/>9 questions. First, Dr. Moline, I wanted to touch<br/>10 upon the epidemiology questions that counsel for<br/>11 Johnson &amp; Johnson asked you. She asked you<br/>12 whether or not there have been epidemiologic<br/>13 studies following the use of cosmetic talc<br/>14 products that show an increased risk from use of<br/>15 cosmetic talc. Do you remember those questions?<br/>16 A Yes.<br/>17 Q Now, what is it in cosmetic talc that<br/>18 in your opinion is causing mesothelioma?<br/>19 A Asbestos.<br/>20 Q Have there been epidemiological<br/>21 studies of individuals who have been exposed to<br/>22 asbestos?<br/>23 A Yes.<br/>24 MS. SENTER: I'm sorry. Could I have<br/>25 that question back? You cut out, Leah.</p> | <p style="text-align: right;">Page 137</p> <p>1 specific numeric dose for Ms. Zimmerman's<br/>2 lifetime exposure?<br/>3 A For her what exposure?<br/>4 Q For her lifetime exposure to asbestos.<br/>5 A You know, it's -- they're all<br/>6 estimates. She didn't have actual measurements<br/>7 done when she was doing it. We're not measuring<br/>8 the full scope of when somebody applies powder<br/>9 and then they have to clean it up, and I had no<br/>10 way of being able to include that type of<br/>11 exposure in a dose calculation.<br/>12 I don't know what exactly she was<br/>13 exposed to in the home where -- that she shared<br/>14 with Mr. Martin or what contribution, if any, her<br/>15 children's exposure made. So I just -- I wasn't<br/>16 able to -- I had no number to do it.<br/>17 So it's always an estimate. It's not<br/>18 an actual exposure. So there were too many<br/>19 variables for me to feel confident in the number.<br/>20 So that was the main reason.<br/>21 Q On your last page of your notes when<br/>22 you quantified the number of exposures that<br/>23 Ms. Zimmerman had to the various talcum powder<br/>24 products and potentially from her stepfather from<br/>25 Unarco, was this the most reliable quantification</p> |

|   |   |
|---|---|
| 1 that you could have provided in this case?<br>2 A Yes. And that's an underestimate in<br>3 many places because I don't address cleaning.<br>4 And then when she talked about that she would<br>5 shower sometimes more than once a day and apply<br>6 powder once a day, I would err on the side of one<br>7 rather than one and a half since it wasn't clear<br>8 how often she actually showered more than once a<br>9 day.<br>10 But this was the best I could do<br>11 understanding that it's probably undercounting<br>12 based on how she described it.<br>13 Q Dr. Moline, is there any way you could<br>14 take out one of these exposures -- let's say you<br>15 could just remove Jean Nate from this exposure<br>16 profile from contributing to her total cumulative<br>17 dose based on the number of her exposures?<br>18 MR. POLCHINSKI: Objection. Form.<br>19 THE WITNESS: They're all going to<br>20 contribute. You can't just substitute -- take<br>21 one out and say that it had no relevance or it<br>22 wasn't a contributing factor. That's not<br>23 scientifically sound.<br>24 BY MS. KAGAN:<br>25 Q Dr. Moline, counsel for Johnson & | Page 140<br>1 ensued.)<br>2 MS. KAGAN: We can agree to relieve<br>3 the court reporter of her obligation to maintain<br>4 the original transcript under the Code.<br>5 Plaintiff will take custody of the original<br>6 transcript and make it available to anybody upon<br>7 reasonable request.<br>8 We also stipulate to using certified<br>9 copies for motion practice and trial. If the<br>10 original is lost, I propose we use certified<br>11 copies in general for motion practice and in<br>12 trial.<br>13 Then I also propose that we could use<br>14 an expedited rough if necessary for motion<br>15 practice in light of the expedited trial date.<br>16 MS. SENTER: So stipulated.<br>17 (Proceedings adjourned, 1:42 p.m.)<br>18 (Original transcript sent to Leah Kagan.)<br>19 The following reporter and firm<br>disclosures were presented at this proceeding for<br>20 review by counsel:<br>21 <b>REPORTER DISCLOSURES</b><br>22 The following representations and<br>disclosures are made in compliance with Georgia<br>23 Law, more specifically:<br>Article 10(B) of the Rules and Regulations of the<br>24 Board Of Court Reporting (disclosure forms)<br>OCGA 9-11-28(c) (disqualification of reporter<br>25 for financial interest)<br>OCGA 15-14-37(a) and (b) (prohibitions against   |
| Page 139<br>1 Johnson asked you about your review of the<br>2 medical records and whether or not you saw any<br>3 notations about Ms. Zimmerman's exposure to<br>4 asbestos from her use of cosmetic talc.<br>5 In your experience as a medical doctor<br>6 and in your review of medical records for<br>7 hundreds and hundreds of patients, how often do<br>8 physicians ask patients about their use of<br>9 hygiene products like cosmetic talc?<br>10 MS. ROMANO: Calls for speculation.<br>11 Overbroad. Go ahead.<br>12 THE WITNESS: Rarely, if ever.<br>13 MS. KAGAN: Thank you, Dr. Moline.<br>14 Those are all the questions I have.<br>15 THE COURT REPORTER: Dr. Moline, would<br>16 you like to waive signature?<br>17 THE WITNESS: Yes, please.<br>18 MS. KAGAN: Julia, can we do the usual<br>19 stips? Can you put it on the record before I<br>20 choke to death?<br>21 MS. ROMANO: You're testing my memory.<br>22 Meghan, do you have them in front of you? I<br>23 think it's that we can relieve the court reporter<br>24 of her duties.<br>25 (Whereupon off-the-record discussions   | Page 141<br>1 contracts except on a case-by-case basis).<br>- I am a certified reporter in the State of<br>2 Georgia.<br>- I am a subcontractor for Veritext Legal<br>3 Solutions.<br>- I have been assigned to make a complete and<br>4 accurate record of these proceedings.<br>- I have no relationship of interest in the<br>5 matter on which I am about to report which<br>would disqualify me from making a verbatim<br>6 record or maintaining my obligation of<br>impartiality in compliance with the Code of<br>7 Professional Ethics.<br>- I have no direct contract with any party in<br>8 this action and my compensation is determined<br>solely by the terms of my subcontractor<br>9 agreement.<br>10 <b>FIRM DISCLOSURES</b><br>11 - Veritext Legal Solutions was contacted to<br>provide reporting services by the noticing or<br>12 taking attorney in this matter.<br>- There is no agreement in place that is<br>13 prohibited by OCGA 15-14-37(a) and (b). Any<br>case-specific discounts are automatically<br>14 applied to all parties, at such time as any<br>party receives a discount.<br>15 - Transcripts: The transcript of this proceeding<br>as produced will be a true, correct, and<br>16 complete record of the colloquies, questions,<br>and answers as submitted by the certified court<br>17 reporter.<br>- Exhibits: No changes will be made to the<br>18 exhibits as submitted by the reporter,<br>attorneys, or witnesses.<br>19 - Password-Protected Access: Transcripts and<br>exhibits relating to this proceeding will be<br>20 uploaded to a password-protected repository, to<br>which all ordering parties will have access.<br>21<br>22<br>23<br>24<br>25 |

|   |          |
|---|----------|
| <p>1                   CERTIFICATE<br/>2 STATE OF GEORGIA:<br/>3 COUNTY OF COBB:<br/>4                   I hereby certify that the foregoing<br/>5 transcript was taken down, as stated in the<br/>6 caption, and the colloquies, questions and<br/>7 answers were reduced to typewriting under my<br/>8 direction; that the transcript is a true and<br/>9 correct record of the evidence given upon said<br/>10 proceeding.<br/>11                  I further certify that I am not a<br/>12 relative or employee or attorney of any party,<br/>13 nor am I financially interested in the outcome of<br/>14 this action.<br/>15                  I have no relationship of interest in<br/>16 this matter which would disqualify me from<br/>17 maintaining my obligation of impartiality in<br/>18 compliance with the Code of Professional Ethics.<br/>19                  I have no direct contract with any party<br/>20 in this action and my compensation is based<br/>21 solely on the terms of my subcontractor<br/>22 agreement.<br/>23                  Nothing in the arrangements made for<br/>24 this proceeding impacts my absolute commitment to<br/>25 serve all parties as an impartial officer of the</p> | Page 142 |
| <p>1 court.<br/>2                  This the 2nd day of March, 2020.<br/>3<br/>4<br/>5                  <i>Jennifer D. Hamon</i><br/>6                  JENNIFER D. HAMON, CCR B-2287, RPR<br/>7<br/>8<br/>9<br/>10<br/>11<br/>12<br/>13<br/>14<br/>15<br/>16<br/>17<br/>18<br/>19<br/>20<br/>21<br/>22<br/>23<br/>24<br/>25</p>   | Page 143 |

[& - 8th]

Page 1

|  |  |  |  |
|--|--|--|--|
| &  | <b>15</b> 9:20,22 10:8<br><b>15,080</b> 115:19,24<br><b>15-14-37</b> 5:3<br>140:25 141:13<br><b>150</b> 117:15<br><b>1500</b> 3:10<br><b>16.9</b> 10:2<br><b>1600</b> 2:17<br><b>18</b> 4:19<br><b>1950s</b> 70:1 124:17<br><b>1954</b> 100:11,21<br><b>1957</b> 77:13<br><b>1959</b> 77:14<br><b>1960</b> 49:10<br><b>1977</b> 19:25 20:3,4<br><b>1986</b> 26:12<br><b>1998</b> 112:10<br><b>1:42</b> 1:15 140:17 | <b>2029</b> 3:4<br><b>2034</b> 12:20 134:25<br><b>212.897.9655</b> 3:17<br><b>213.443.4365</b> 2:18<br><b>213.955.1150</b> 3:11<br><b>2287</b> 143:7<br><b>24</b> 24:25 114:5<br><b>24272</b> 143:6<br><b>25</b> 9:3<br><b>250</b> 118:3 119:25<br><b>251</b> 115:25 117:14<br><b>26</b> 1:14 5:1<br><b>261</b> 127:2,2<br><b>27</b> 47:19 48:24<br>49:5<br><b>2nd</b> 143:2 | <b>4674</b> 1:3<br><b>5</b><br><b>5</b> 4:4,18 6:3,15<br>7:22 14:8 113:9<br>132:13<br><b>50</b> 124:23<br><b>504.535.2879</b> 2:12<br><b>515</b> 3:10<br><b>54</b> 100:12<br><b>540</b> 2:4<br><b>562.590.3400</b> 2:6 |
| 0  |  |  | 6  |
| <b>0.00001</b> 34:15<br><b>0.00016</b> 30:19<br><b>0.01</b> 119:18 120:25<br><b>0.1</b> 113:14,25<br>118:11,13,22,24<br>119:15 120:24<br><b>0.5</b> 112:13<br><b>001</b> 111:25  |  | <b>6</b> 4:12,14,16,17,18<br>4:19,21 18:17,19<br><b>60</b> 23:24 115:25<br>116:22 117:14<br><b>600</b> 3:16 10:19<br><b>600,000</b> 105:1,1,5<br>105:8<br><b>61</b> 4:4<br><b>633</b> 2:17<br><b>64</b> 102:3,4<br><b>6th</b> 77:13  |  |
| 1  |  |  | 7  |
| <b>1</b> 4:12,21 6:2,8<br>10:1 37:12 44:9<br>100:19 112:20<br>114:6 119:3<br><b>1,000</b> 111:13<br><b>1/1,000th</b> 111:7<br><b>10</b> 82:6 140:23<br><b>10022</b> 3:17<br><b>107</b> 4:5<br><b>10:06</b> 1:15 5:2<br><b>11</b> 82:6<br><b>11:29</b> 60:1<br><b>11:35</b> 60:2<br><b>12</b> 102:4<br><b>12/19/2019</b> 4:15<br><b>12:40</b> 102:14<br><b>12:46</b> 102:15<br><b>130</b> 4:5<br><b>131</b> 4:6<br><b>133</b> 4:6<br><b>135</b> 4:7<br><b>142</b> 4:8<br><b>14842</b> 17:11 |  | <b>3</b> 4:16 6:2,12<br><b>3,016</b> 115:15<br><b>3.550</b> 1:3<br><b>30</b> 111:12,20,25<br><b>300</b> 3:4 85:6<br>111:13<br><b>3000</b> 2:10<br><b>310.284.3884</b> 3:5<br><b>33</b> 43:5,6,18,23<br>44:4,6,10 46:17<br>49:6,7,9,12,18<br>50:8,19 51:9<br>54:21 57:1,14,21<br>57:23 58:2,7 84:9<br>84:18 85:12,20<br><b>365</b> 2:11<br><b>3780</b> 2:5                    | <b>7.2</b> 10:1,2<br><b>70</b> 45:24<br><b>70130</b> 2:11<br><b>70s</b> 26:7 31:11<br><b>730</b> 101:22<br><b>768</b> 101:13 102:5<br><b>7th</b> 16:16 77:14   |
|  |  |  | 8  |
|  |  |  | <b>80</b> 45:25 118:3<br>119:23<br><b>800</b> 105:1<br><b>80s</b> 26:9<br><b>8th</b> 3:16 133:22   |
|  |  |  |  |

[9-11 - application]

Page 2

| 9   | add 42:7 116:2<br>added 92:12<br>100:13 104:20<br>addition 87:7,12<br>95:22 96:1<br>additional 10:21<br>11:7,9 28:8,10<br>30:24 47:7 48:10<br>50:21 51:2 53:5<br>53:24 55:7 57:15<br>58:23 68:5 82:22<br>92:12 95:21<br>112:19 121:18<br>132:23 134:21<br>additionally 25:4<br>address 138:3<br>addressed 90:24<br>adjourned 140:17<br>administrative<br>37:13<br>admit 122:1<br>admonitions 5:22<br>advance 85:24<br>advertisement<br>70:22<br>aerosolize 111:24<br>afternoon 130:3,8<br>ago 5:14 39:15<br>40:22 55:11<br>114:23<br>agree 62:24 63:7<br>72:13 77:6 82:12<br>88:9 97:22 131:25<br>133:11 140:2<br>agreement 141:9<br>141:12 142:22<br>ah 49:22 50:4<br>ahead 6:5,11,14<br>14:7 18:16 61:9<br>66:11 87:22<br>107:21 120:9 | 131:4 139:11<br>aid 3:1<br>air 26:19 30:15<br>32:10 66:15 67:11<br>110:20 127:12<br>airborne 30:9 31:2<br>31:7,18,22 111:23<br>airport 2:5 17:15<br>al 1:8<br>alan 60:10,20<br>alexandri 36:9,13<br>alive 11:9<br>allow 85:13<br>allowed 132:6<br>alternate 53:18<br>54:1,3,16 55:22<br>alternative 50:10<br>50:18 51:15 53:11<br>54:11 58:19 59:7<br>59:9<br>aluminum 72:9<br>ama 94:12,25 95:6<br>ama's 94:6<br>amos 67:18<br>amos's 67:12<br>amosite 70:5 72:3<br>72:14,24 73:3,12<br>73:16,18 74:1<br>128:10,22 129:2,5<br>129:15 133:13<br>amount 25:23<br>35:12 82:19<br>amounts 110:9,14<br>111:6<br>amphibole 79:11<br>amphiboles 95:23<br>analyses 36:23<br>89:1<br>analysis 51:1,14<br>analyst 47:8 48:18 | analyze 87:16<br>anderson 3:2 4:5<br>106:16 130:7,9,23<br>angeles 1:2 2:18<br>3:5,11<br>announcement 23:3,6 94:6<br>anonymity 45:21<br>46:11<br>anonymous 45:14<br>86:2<br>answer 12:1 28:16<br>31:15 108:20<br>111:2 129:21<br>answered 30:4<br>46:21 114:22<br>128:25 129:18,24<br>answering 120:23<br>answers 43:3 60:6<br>97:18 141:16<br>142:7<br>anthophyllite 72:9<br>76:1,18 129:11<br>anticipate 10:20<br>11:6 104:8 134:18<br>anybody 131:1<br>135:5 140:6<br>anyone's 85:7<br>anyway 58:15<br>120:22<br>anyways 120:9<br>apart 33:15 73:16<br>73:22 80:23<br>apologize 17:16<br>24:11 41:10<br>apparent 50:25<br>appearances 2:1<br>appeared 19:4<br>applicable 120:5<br>application 108:12<br>108:17 109:7,19 |
|---|--|---|---|
| 9-11 17:6<br>9-11-28 140:24<br>90067 3:5<br>90071 2:18 3:11<br>90806 2:5<br>99 43:2 113:9 | a<br>a.m. 1:15 5:2 60:1<br>60:2<br>ability 50:11<br>able 9:21 17:18<br>30:20 31:2 32:5<br>32:11 42:18 78:10<br>98:10,13,22 99:1<br>137:10,16<br>absence 90:12<br>absolute 35:14<br>142:24<br>access 141:19,20<br>account 19:14,22<br>33:23 59:8<br>accounted 73:12<br>accumulated<br>16:14<br>accurate 31:1<br>96:10,13 116:23<br>117:16,24 119:19<br>121:1 141:4<br>accurately 116:14<br>action 141:8<br>142:14,20<br>active 22:14,21<br>23:4<br>activities 23:5<br>activity 27:1<br>actual 14:11 32:12<br>39:10 55:18 56:5<br>94:24 95:3 99:20<br>113:5 137:6,18   |   |   |

[application - aware]

Page 3

|                           |                           |                          |   |
|---------------------------|---------------------------|--------------------------|---|
| 115:18 121:21             | 59:18 86:16,17            | 58:9,10 81:6             | <b>assume</b> 18:7 34:16<br>42:16 58:5 94:8 |
| <b>applications</b>       | 92:16 93:9 106:15         | 83:19 85:11 89:22        | <b>assuming</b> 26:22<br>57:17 127:3        |
| 115:12,15                 | 140:23                    | 94:8,11 103:18,20        | <b>assure</b> 122:15                        |
| <b>applied</b> 91:1       | <b>articles</b> 22:4,6,19 | 103:22 114:22            | <b>atsdr</b> 35:5                           |
| 141:14                    | 23:7,16                   | 115:3 128:25             | <b>attached</b> 4:21 5:6                    |
| <b>applies</b> 109:16     | <b>asbestos</b> 1:4 11:18 | 129:18,23,25             | <b>attention</b> 98:9                       |
| 137:8                     | 12:5,8,10,16,25           | 131:4,10,11,20           | <b>attorney</b> 141:12<br>142:12            |
| <b>apply</b> 108:14,19    | 13:4,10 18:24             | 132:15 135:11,11         | <b>attorneys</b> 141:18                     |
| 131:13,22 138:5           | 25:15,16 26:1,3,23        | 136:1 139:1              | <b>attribute</b> 83:8                       |
| <b>applying</b> 108:11    | 30:20 39:10 49:11         | <b>asking</b> 19:20      | <b>authored</b> 35:19<br>52:18 84:4 97:24   |
| 109:12,13,22              | 49:23 50:4 55:20          | 22:15 32:4 38:4          | <b>authoring</b> 99:14                      |
| 114:12,21                 | 62:16,20 63:1,5,15        | 40:10,12 41:5,11         | <b>authors</b> 32:7 88:5<br>88:8 91:10      |
| <b>appreciate</b> 38:2    | 63:16 64:3,18,20          | 43:11 46:8,10            | <b>authorship</b> 53:6,9                    |
| 76:15 132:8               | 64:24 65:4,16,18          | 53:7 76:24 80:15         | <b>automatically</b>                        |
| <b>appropriate</b> 89:2   | 65:25 66:3 67:2,7         | 81:12 90:11 99:16        | 141:13                                      |
| 135:3                     | 67:23 69:12,16,21         | 103:18 107:11            | <b>automotive</b> 63:20                     |
| <b>approval</b> 45:5,6    | 70:1,6,10,14 74:1         | 110:23 112:3             | 63:24 64:24                                 |
| 45:12,13,20               | 75:10 78:18 79:5          | 117:9,18 122:14          | <b>autozone</b> 1:8                         |
| <b>approve</b> 46:2       | 79:9,9 81:3 82:13         | 122:16,19,23             | <b>available</b> 11:8,10                    |
| <b>approved</b> 46:16     | 84:2 90:12 91:14          | 123:2                    | 25:17 26:7 51:20                            |
| <b>approximately</b>      | 91:22 92:17 94:14         | <b>aspects</b> 38:9,15   | 51:21 52:4,18                               |
| 15:3,22                   | 95:8 96:21 103:4          | 39:18 40:9               | 56:4,8 71:9,17                              |
| <b>archived</b> 74:16     | 103:5,8 110:6,6,15        | <b>assessment</b> 55:12  | 94:1,3 106:5                                |
| <b>area</b> 36:25 69:5    | 111:12,13,19,21           | <b>assessments</b>       | 140:6                                       |
| 96:24 97:17               | 112:6 116:25              | 124:17                   | <b>avenue</b> 3:16                          |
| <b>argument</b> 17:19     | 117:6 127:11,24           | <b>assigned</b> 141:3    | <b>average</b> 17:21                        |
| 29:19 30:23 32:3          | 128:12 129:16,17          | <b>assisted</b> 24:25    | 19:12 20:10,15,16                           |
| 43:10 59:13 76:7          | 131:24 133:25             | 37:7 38:22 39:16         | 119:5                                       |
| 76:23 96:12 97:1          | 134:1,9 135:19,22         | 64:15                    | <b>averaged</b> 19:25                       |
| 98:4 111:15 116:8         | 136:3,9,11 137:4          | <b>assisting</b> 38:12   | 20:5  |
| 123:10 128:1,25           | 139:4                     | 64:6                     | <b>avoided</b> 68:10                        |
| <b>argumentative</b>      | <b>ascribe</b> 35:12      | <b>associated</b> 35:19  | <b>aware</b> 7:4 72:2                       |
| 110:10                    | <b>ascribed</b> 79:4      | 44:4,14 49:23            | 90:6,14,19 91:6                             |
| <b>arisen</b> 53:20,23    | <b>aside</b> 14:8 28:9    | 112:21 125:12            | 94:10 95:6 124:4                            |
| <b>arrangements</b>       | 67:16 75:5 93:6,6         | 136:16                   | 133:2                                       |
| 142:23                    | <b>asked</b> 11:14,16,23  | <b>associates</b> 43:6   |   |
| <b>arrived</b> 88:16      | 12:3,23 13:1              | <b>associating</b> 43:12 |   |
| 89:14                     | 16:22 18:23 28:3          | <b>association</b> 43:25 |   |
| <b>article</b> 39:4 40:24 | 28:5 30:3 42:7            | 53:4                     |   |
| 42:24 46:7 47:5           | 46:21 52:2,15             | <b>associations</b>      |   |
| 48:21 52:17 54:22         | 55:14,22 56:13,16         | 136:17                   |   |

[b - calculation]

Page 4

|          |   |   |  |
|----------|---|---|--|
| <b>b</b> | <b>basement</b> 69:2,8<br>127:7,10,12,18,25<br><b>basically</b> 14:23<br>17:21 39:23 40:16<br>49:20 103:21<br>118:24<br><b>basis</b> 141:1<br><b>bathroom</b> 109:6<br><b>bc720153</b> 1:3<br><b>bcrslaw.com</b> 3:12<br><b>beach</b> 2:5<br><b>began</b> 69:24<br><b>beginning</b> 1:15 9:3<br>63:13 82:6 129:1<br><b>behalf</b> 62:16<br><b>belief</b> 127:23<br>129:15<br><b>believe</b> 13:9,16<br>14:4 23:15 24:7<br>26:7 31:12 37:13<br>63:14,25 65:23<br>66:1 69:25 70:11<br>72:10 73:19 74:15<br>75:10 82:10 92:14<br>92:19 103:10<br>106:14,20 112:11<br>132:5<br><b>bellow</b> 3:8<br><b>bendix</b> 24:12,13<br>24:17,19,22<br><b>berkes</b> 3:9<br><b>best</b> 39:2 50:11<br>69:7 71:10 138:10<br><b>bevilacqua</b> 36:9<br>36:17 37:4<br><b>beyond</b> 8:20 23:5<br>127:25<br><b>big</b> 49:21<br><b>biggest</b> 18:2 20:23<br>21:5 | <b>bill</b> 10:6 105:6<br><b>billed</b> 104:25<br>105:2,3,4,11<br><b>billions</b> 30:12 32:9<br>110:25<br><b>bills</b> 103:20 105:8<br><b>binder</b> 78:15,16<br>91:19,24 92:13<br><b>binders</b> 9:12<br><b>bit</b> 5:15 12:1 18:17<br>27:10 36:5 56:23<br>84:15 95:10<br>122:13<br><b>blip</b> 20:15<br><b>block</b> 67:2<br><b>bloomington</b> 35:7<br>65:19 66:4 69:13<br>124:1,5,16 125:9<br><b>blow</b> 92:8<br><b>blowing</b> 21:3,5,8,9<br>21:11,18,19<br><b>blue</b> 92:5<br><b>blur</b> 92:18<br><b>board</b> 34:17,19<br>45:6 131:13,22<br>140:24<br><b>boards</b> 92:5<br><b>bodies</b> 78:18 79:5<br>79:9<br><b>body</b> 24:16 109:13<br>110:1<br><b>bolster</b> 23:16<br><b>books</b> 85:3<br><b>borg</b> 122:12<br><b>bottle</b> 94:7,24 95:8<br><b>bottles</b> 79:17 80:2<br>95:7,12,14 100:13<br>100:24 101:13,14<br>101:24 102:5,20<br><b>bottom</b> 41:3 | <b>bound</b> 111:19<br><b>boys</b> 26:10<br><b>brake</b> 24:21 25:10<br>26:5,17 64:3,5<br><b>brakes</b> 24:23,24<br>24:25 25:5,15,17<br>25:19 26:3,8,14,15<br>26:20,22<br><b>brand</b> 24:19,19<br><b>break</b> 9:21 35:23<br>36:1,5 59:23 77:5<br>92:5 102:10,13<br><b>brief</b> 10:12 83:21<br><b>bring</b> 9:6<br><b>bringing</b> 67:23,24<br><b>broadly</b> 57:10<br><b>broke</b> 79:13<br><b>brought</b> 78:16<br>84:16,17<br><b>btlaw.com</b> 3:6<br><b>bulk</b> 29:13,14,20<br>30:7,15 31:6,15,23<br>31:24 32:9 33:6<br>111:4,8,10<br><b>burden</b> 71:20<br>79:25<br><b>butt</b> 109:5 |
| <b>c</b> |   |   |  |
| <b>c</b> | <b>ca</b> 2:5,18 3:5,11<br><b>calculate</b> 100:24<br>126:4 136:25<br><b>calculated</b> 81:2<br>87:4 101:5,19<br>102:2 104:20<br>121:11 126:22<br><b>calculating</b> 87:17<br>114:11<br><b>calculation</b> 15:20<br>27:15 115:11<br>122:9 125:20  |   |  |

[calculation - clothes]

Page 5

|                            |                           |                           |                            |
|----------------------------|---------------------------|---------------------------|----------------------------|
| 126:2 137:11               | 46:17,18,24 47:1,6        | certify 142:4,11          | circuit 133:5              |
| <b>calculations</b> 14:20  | 47:16,19,21 48:9,9        | <b>cetera</b> 75:5        | city 55:16                 |
| 14:21,23 15:9              | 48:17,19,24 49:18         | <b>challenging</b> 11:25  | claim 76:9,13              |
| 25:8 27:12,21              | 50:8,9 52:6 54:21         | 37:19                     | claimed 76:2               |
| 34:12 89:6 101:15          | 54:24 57:1,9,14,21        | <b>chance</b> 71:24       | 95:15                      |
| 106:13,24 107:7            | 57:23 58:2,7,11,12        | <b>chanel</b> 2:8 8:14    | <b>clarification</b> 77:3  |
| <b>calculator</b> 120:16   | 59:4 62:16 82:4           | 14:16 15:10,11            | 80:20                      |
| <b>california</b> 1:1      | 84:9 85:6 91:18           | 28:25 29:8 60:20          | <b>clarifications</b> 42:9 |
| 52:22 122:8,24             | 96:5                      | 61:6 129:1 131:23         | <b>clarify</b> 80:7 81:11  |
| 123:3,22                   | <b>category</b> 93:3      | 132:13,21,25              | 83:25                      |
| <b>call</b> 7:7,9 14:21,22 | <b>causation</b> 123:17   | <b>change</b> 51:24       | <b>clarity</b> 41:4        |
| 43:17 55:24 93:14          | <b>cause</b> 12:16 20:14  | 62:23                     | <b>clark</b> 3:7           |
| 95:12                      | 20:15 62:20 63:1          | <b>changed</b> 40:7       | <b>class</b> 126:12        |
| <b>called</b> 16:8 91:19   | 63:8 103:5 131:25         | <b>changes</b> 42:11      | <b>classified</b> 97:11    |
| 110:9                      | 134:15                    | 64:6 141:17               | <b>clean</b> 50:23 69:7    |
| <b>calls</b> 59:13 68:1    | <b>caused</b> 54:19       | <b>characterization</b>   | 137:9                      |
| 127:14 139:10              | 103:10                    | 75:18 99:10,23,25         | <b>cleaned</b> 24:21,23    |
| <b>canal</b> 2:10,11       | <b>causes</b> 136:11      | <b>characterizations</b>  | 26:18                      |
| <b>caption</b> 142:6       | <b>causing</b> 112:14     | 115:5                     | <b>cleaning</b> 138:3      |
| <b>car</b> 25:5 128:6,7,8  | 135:18                    | <b>characterize</b> 75:23 | <b>clear</b> 12:25 19:7    |
| <b>carcinogens</b> 83:4    | <b>caveat</b> 57:21       | 107:8 109:2,10            | 28:7 46:8 49:15            |
| <b>care</b> 61:23 130:13   | <b>cc</b> 29:15,24 34:15  | <b>characterized</b>      | 82:24 83:10 101:6          |
| <b>carpet</b> 68:19,21     | 112:13,21 113:10          | 81:18                     | 138:7                      |
| <b>case</b> 1:3 7:13,25    | 113:15 114:1,6,19         | <b>characterizes</b>      | <b>clearer</b> 42:14       |
| 8:18,20,24 9:19            | 118:11,13,22,24           | 75:20                     | <b>clearly</b> 123:3       |
| 10:16 13:1 18:22           | 119:3,4,16,18             | <b>check</b> 78:15        | <b>cleavage</b> 110:7,11   |
| 20:14 23:8 27:17           | 120:25 124:24             | 107:22                    | 116:6,18                   |
| 28:4,6,20 44:14            | <b>ccr</b> 143:7          | <b>cheese</b> 126:14      | <b>client</b> 123:6        |
| 47:13 51:4,4,5             | <b>cellulose</b> 111:20   | <b>chemical</b> 99:17     | <b>client's</b> 123:13     |
| 53:2 57:4 58:9,18          | <b>center</b> 17:4 18:3   | <b>children</b> 27:2      | <b>climatologic</b> 16:15  |
| 58:21 68:9 69:11           | <b>certain</b> 20:7 35:12 | <b>children's</b> 27:4    | <b>climatology</b> 17:17   |
| 71:20 73:9 78:12           | 68:7 99:2                 | 137:15                    | <b>clinical</b> 36:23 38:7 |
| 79:18 80:5,18              | <b>certainly</b> 17:2     | <b>chinese</b> 94:21      | 38:15 39:18,21             |
| 83:12 92:10,11,15          | 26:9 69:15 77:11          | <b>choke</b> 139:20       | 40:9 105:14                |
| 103:16 104:22              | 82:21 83:9 92:20          | <b>choosing</b> 49:18     | 124:19                     |
| 105:15 109:15              | 133:12                    | <b>chore</b> 68:22        | <b>clinician</b> 38:7      |
| 117:19 122:12              | <b>certainty</b> 78:1     | <b>chrysotile</b> 94:6,24 | 39:21                      |
| 127:5 132:9 138:1          | <b>certificate</b> 4:8    | 95:16,20,24,25            | <b>clock</b> 109:3         |
| 141:1,1,13                 | 9:15 142:1                | 96:1,3,5 97:6             | <b>close</b> 35:21         |
| <b>cases</b> 1:4 28:1      | <b>certified</b> 1:13     | <b>church</b> 128:6       | <b>clothes</b> 27:4 64:2   |
| 37:11 43:5,6 44:4          | 140:8,10 141:1,16         |                           | 64:16,21,25 65:1,5         |

[clothes - contribution]

Page 6

|  |   |  |  |
|--|---|--|--|
| 69:9 127:6,24<br><b>clothing</b> 67:23<br><b>clued</b> 54:11<br><b>clutch</b> 25:1<br><b>cnetury</b> 3:4<br><b>coauthors</b> 36:6,12<br>37:2<br><b>cobb</b> 142:3<br><b>code</b> 140:4 141:6<br>142:18<br><b>cohabitant</b> 51:21<br><b>cohesive</b> 39:24<br><b>cohort</b> 87:6,14<br>88:6<br><b>collaborative</b><br>37:20 38:1<br><b>colleague</b> 36:20<br><b>collect</b> 18:12<br><b>collected</b> 18:10,15<br><b>college</b> 22:13,14<br>23:4,6,12 49:13<br>126:11<br><b>colloquies</b> 141:16<br>142:6<br><b>colorado</b> 97:7<br><b>colors</b> 17:22<br><b>columnar</b> 98:8<br><b>come</b> 28:10 36:12<br>38:23 51:15,25<br>64:15 71:2,6<br>93:17 103:25<br>115:25 129:7<br><b>comes</b> 15:6 21:1<br>94:15<br><b>comfortable</b> 85:18<br><b>coming</b> 21:2 38:22<br>86:5<br><b>comment</b> 31:13<br>33:14,18 34:8<br>106:10 134:21 | <b>commented</b> 86:8<br>89:22 90:3,4<br><b>comments</b> 41:22<br>42:2 77:15 93:24<br><b>commercial</b> 129:6<br><b>commitment</b><br>142:24<br><b>common</b> 47:24<br><b>communicated</b><br>85:20<br><b>communication</b><br>85:23<br><b>community</b> 50:2<br><b>company</b> 3:1<br>65:18 69:16 91:17<br>93:5 130:16<br><b>compare</b> 111:11<br>125:8<br><b>comparison</b> 15:9<br>87:3 89:2 112:1<br><b>compensation</b><br>141:8 142:20<br><b>compiled</b> 53:1<br><b>complete</b> 8:19<br>141:3,16<br><b>compliance</b><br>122:24 140:22<br>141:6 142:18<br><b>complicated</b> 120:8<br><b>components</b> 36:24<br><b>composition</b> 99:17<br><b>compound</b> 75:20<br><b>compressed</b> 26:19<br><b>compton</b> 9:13<br>28:23 107:6<br>132:12<br><b>compton's</b> 60:24<br>80:13 132:25<br><b>concluded</b> 88:5,8<br>90:8,20 91:7 | <b>conclusion</b> 15:21<br>37:10,16 42:6<br>88:9,15,16,21,22<br>88:24 99:20<br><b>conclusions</b> 89:11<br>96:23 97:24 99:22<br><b>concrete</b> 56:25<br><b>conditionally</b><br>45:13<br><b>conference</b> 58:15<br><b>confident</b> 137:19<br><b>confirm</b> 29:12<br>131:19<br><b>confirmed</b> 120:19<br><b>confronted</b> 56:1<br><b>confused</b> 122:13<br>122:16<br><b>connect</b> 76:3,25<br><b>connecting</b> 76:19<br><b>connection</b> 49:10<br>50:1<br><b>consent</b> 84:18,23<br>85:12<br><b>conservative</b><br>101:20,25<br><b>consider</b> 27:6 55:8<br>65:6 70:14 87:9<br>108:16<br><b>consideration</b><br>122:21<br><b>considered</b> 14:16<br>35:11 56:2<br><b>considering</b> 33:22<br><b>consistent</b> 77:16<br>78:7,19 79:2<br>94:23 129:12<br><b>constructive</b> 42:13<br><b>consumer</b> 2:14<br><b>contacted</b> 11:13<br>141:11 | <b>contain</b> 63:1<br>131:24<br><b>contained</b> 70:5,10<br>91:20<br><b>container</b> 15:6<br>77:13 102:2,4<br><b>containers</b> 15:3,12<br>27:13 29:3 102:1<br>117:6<br><b>containing</b> 26:23<br>64:3,18 69:21<br>111:12<br><b>contains</b> 136:9<br><b>contaminant</b> 74:1<br><b>contaminate</b> 128:4<br><b>contaminated</b><br>67:11<br><b>contaminating</b><br>66:14<br><b>content</b> 22:8<br><b>context</b> 46:13,19<br>97:4,14 103:4<br><b>continue</b> 102:17<br>104:19 120:23<br><b>continued</b> 2:25<br><b>continuing</b> 104:18<br><b>contract</b> 71:9<br>141:7 142:19<br><b>contracts</b> 141:1<br><b>contrast</b> 99:3,5<br><b>contribute</b> 11:19<br>63:2,8 83:11<br>120:21 123:19<br>131:25 138:20<br><b>contributes</b><br>123:13<br><b>contributing</b> 65:6<br>70:15 138:16,22<br><b>contribution</b><br>123:15 137:14 |
|--|---|--|--|

[controls - demonstratives]

Page 7

|   |   |  |                                   |
|---|---|--|-----------------------------------|
| <b>controls</b> 39:7,8  | 119:23 124:13   | <b>court</b> 1:1,13 5:5  | <b>date</b> 6:25 60:13            |
| <b>conversation</b><br>10:11 64:12 86:11<br>96:19   | 128:15 129:19,22<br>130:13,14,18,22<br>132:1,2 141:15<br>142:9                        | 139:15,23 140:3<br>140:24 141:16<br>143:1                        | 77:9,12 100:20<br>105:2,16 140:15 |
| <b>conversations</b><br>86:3  | <b>correspondence</b><br>91:11  | <b>cover</b> 5:15  | <b>dates</b> 26:6 92:18           |
| <b>conversion</b> 30:6  | <b>corroborate</b> 23:21  | <b>covering</b> 129:24   | <b>day</b> 77:21 101:19           |
| <b>convert</b> 29:14<br>30:14   | <b>corroborated</b> 23:9<br>101:3 108:23  | <b>coworker</b> 51:20  | 101:19,21,22<br>110:3 126:20,25   |
| <b>converted</b> 29:23  | <b>cosmetic</b> 13:22   | <b>crane</b> 3:9   | 138:5,6,9 143:2                   |
| <b>cool</b> 22:25   | 35:20 50:20 63:17   | <b>create</b> 18:6   | <b>days</b> 126:25 127:1          |
| <b>coordinated</b> 1:3  | 74:2 77:1 78:5,9  | <b>critical</b> 98:1,4,19  | 127:2,2                           |
| <b>coordinator</b> 36:17  | 78:19 84:5 90:9   | <b>criticism</b> 87:20   | <b>dba</b> 3:1                    |
| <b>copies</b> 140:9,11  | 90:12,13,16,22  | <b>criticisms</b> 86:23  | <b>dealing</b> 84:2               |
| <b>copy</b> 9:6,11,15<br>14:3 40:20   | 91:5,8,16 96:21   | 88:13  | <b>death</b> 9:14 139:20          |
| <b>corny</b> 132:7  | 106:14 108:9  | <b>crocidolite</b> 70:10   | <b>decades</b> 19:9,12            |
| <b>correct</b> 7:5 12:7<br>12:17 13:9 14:17<br>15:7,17 16:1<br>19:13 21:2 24:6,9<br>26:21 28:1,14,18<br>29:1,4 32:16,19<br>33:25 37:5 41:13<br>41:14,16,18 43:21<br>44:1,2,14,23,25<br>46:19,25 47:4<br>48:23 49:5,8,10<br>50:12 51:4,17<br>52:6,13,20 59:1<br>60:11 61:1,6,24<br>62:4 63:3,11,22<br>65:15,20 67:21<br>68:2 70:2 72:12<br>72:18,19 80:24<br>81:5 82:11 84:10<br>84:14 92:9 99:24<br>100:23 106:10<br>111:14 112:1<br>114:2 115:14,16<br>118:13,24 119:8 | 109:5 110:8<br>114:12,21 115:7<br>129:7 134:7,13<br>135:13,15,17<br>136:17,18 139:4,9 | 72:3,14,23 73:3,12<br>75:10,13 128:11<br>128:22 129:16<br>133:13 | <b>decides</b> 104:13             |
| <b>couch</b> 68:14  | <b>costs</b> 103:20 104:7   | <b>crudge</b> 92:11,15   | <b>declaration</b> 7:15           |
| <b>coughing</b> 131:17  | <b>couch</b> 68:14  | <b>cuddling</b> 68:14  | 9:13,16 80:22                     |
| <b>counsel</b> 2:1 5:5<br>6:16 8:22 10:23<br>16:19 71:12,17   | <b>cumulative</b> 81:2  | <b>cummingtonite</b><br>73:15,21 74:4,13                         | 112:24 113:1                      |
| 17:20 122:6,16  | 120:22 138:16   | 74:20 75:6,15  | <b>deemed</b> 57:3                |
| 128:25 130:1  | <b>current</b> 10:18  | 129:6  | <b>defendant</b> 2:8 3:7          |
| 135:10 138:25   | 106:7   | <b>defendants</b> 1:8  | 2:14 3:1,13 4:12                  |
| 140:20  | <b>curriculum</b> 4:16  | 80:18  | 80:18                             |
| <b>count</b> 26:24  | <b>custody</b> 140:5  | <b>defense</b> 49:1 54:23  |                                   |
| <b>county</b> 1:2 142:3   | <b>cut</b> 102:8 135:25   | 55:1,3,6 60:7  |                                   |
| <b>couple</b> 83:16 98:6<br>130:10 131:6  | <b>cv</b> 6:11 49:12  | <b>defer</b> 32:21 33:9  |                                   |
| 135:8   | <b>d</b>  | 75:16 89:8 94:17   |                                   |
| <b>course</b> 82:8  | <b>d</b> 1:13 3:14 143:7  | 95:4 96:10,15  |                                   |
| 103:19 104:4,12   | <b>daniels</b> 3:7  | <b>definite</b> 67:4 76:12                                       |                                   |
| 105:14 109:20   | <b>data</b> 18:14 19:24   | <b>definitely</b> 7:9  |                                   |
| 110:5 112:5   | 20:3,4,19 21:13,19  | <b>definition</b> 29:21  |                                   |
|   | 39:2,22 40:4 45:8   | <b>degree</b> 36:14  |                                   |
|   | 48:15 52:25   | 77:25 99:7 129:16  |                                   |
|   | 106:20 115:5  | <b>delineated</b> 51:23  |                                   |
|   |   | <b>delivered</b> 24:24   |                                   |
|   |   | <b>dement</b> 107:3  |                                   |
|   |   | <b>demonstrating</b><br>105:22                                   |                                   |
|   |   | <b>demonstratives</b><br>92:7                                    |                                   |

[depends - documents]

Page 8

|   |   |  |   |
|---|---|--|---|
| <b>depends</b> 66:10,12<br>104:4,10,12<br>109:11,21 111:17<br>111:18 127:16<br><b>deposed</b> 83:23<br>132:9<br><b>deposition</b> 1:10<br>4:12 5:6 6:7 7:19<br>10:9,21 13:13,16<br>14:15 15:7 23:9<br>23:10,15 24:8<br>27:14 33:21 44:25<br>52:1 62:7,8,9,9,10<br>63:14 70:19 84:7<br>85:14 129:1 132:4<br>132:14,18 133:1<br>135:3<br><b>depositions</b> 4:14<br>7:24 10:3 13:9<br>14:11 15:3 51:21<br>73:9 120:11<br><b>describe</b> 64:14<br>67:1 68:24 74:8<br>108:22 110:15,16<br>121:14<br><b>described</b> 20:1<br>31:5,10 32:6<br>33:16,19 35:5<br>39:11 43:13 44:6<br>45:15 49:24 51:9<br>74:4 81:21 87:8<br>97:12 108:24<br>109:24 110:4<br>111:3 116:18<br>125:17 126:9,13<br>127:8 129:7<br>138:12<br><b>describing</b> 17:21<br>45:16 68:10<br>116:14 124:19<br>127:18 | <b>description</b> 13:15<br>15:6 34:21 103:14<br>128:5<br><b>descriptions</b> 37:23<br>109:9<br><b>designation</b> 12:21<br><b>despite</b> 36:13<br><b>detection</b> 97:10<br>98:13,22<br><b>determination</b><br>99:17<br><b>determine</b> 29:15<br>83:13 99:12<br><b>determined</b> 15:2<br>141:8<br><b>determining</b><br>114:20<br><b>develop</b> 17:25<br>81:23 83:9,14<br><b>developed</b> 83:3<br><b>developing</b> 82:22<br>113:16 114:2<br><b>development</b> 65:7<br>70:16 82:16<br><b>developments</b><br>57:15<br><b>diagnosed</b> 82:9<br><b>diagnosis</b> 61:23<br>81:19 82:14<br><b>diaper</b> 107:2<br><b>diapering</b> 108:10<br><b>differ</b> 60:24<br><b>difference</b> 117:5<br><b>different</b> 13:23<br>17:22 43:18 48:20<br>84:25 85:16 92:3<br>92:20 108:21<br>115:8 122:23<br>128:19<br><b>differentiate</b> 34:5<br>35:4 99:1 | <b>differentiated</b><br>79:12<br><b>differentiation</b><br>34:10,25 35:1,6<br>56:19<br><b>differently</b> 109:17<br><b>differs</b> 60:23<br><b>difficult</b> 56:23<br><b>digestion</b> 10:25<br>46:24 47:6,7 48:1<br>48:2,25 49:5<br>71:20 80:1<br><b>digestions</b> 47:9<br>48:11,16<br><b>direct</b> 141:7<br>142:19<br><b>direction</b> 17:22<br>19:5 21:8,18,24<br>66:8 142:8<br><b>directional</b> 16:13<br><b>directly</b> 62:6 69:2<br><b>disclaimer</b> 49:3<br><b>disclosed</b> 12:20<br>134:25<br><b>disclosure</b> 5:4<br>134:25 140:24<br><b>disclosures</b> 140:19<br>140:21,22 141:10<br><b>discount</b> 141:14<br><b>discounting</b> 120:2<br><b>discounts</b> 141:13<br><b>discuss</b> 6:6 37:19<br>58:3 86:13 89:18<br>102:22 103:3<br><b>discussed</b> 24:18<br>27:12 36:21 89:16<br>102:22 128:20<br>134:17<br><b>discussing</b> 6:14<br>51:11 56:13 58:18 | <b>discussion</b> 87:7<br><b>discussions</b> 139:25<br><b>disease</b> 11:18 12:6<br>12:8,10,17,25<br>70:16 81:23 103:5<br>103:11 123:13<br>132:1<br><b>dispense</b> 5:22<br><b>disqualification</b><br>140:24<br><b>disqualify</b> 141:5<br>142:16<br><b>distance</b> 18:25<br>71:15<br><b>divide</b> 115:24<br><b>divulge</b> 84:19,23<br>85:7,13<br><b>divulging</b> 84:8,21<br><b>doctor</b> 9:4 59:24<br>61:3 112:5 114:11<br>117:14 122:1,17<br>139:5<br><b>doctors</b> 61:20<br>62:13<br><b>document</b> 16:8,8<br>16:12,17,24 18:18<br>18:21 19:8 20:7<br>20:22 74:11,14<br>93:10,11 98:17<br>99:14 116:13,15<br><b>documented</b> 56:15<br>136:15<br><b>documents</b> 4:13<br>6:1 8:4,24 9:15<br>11:16 12:4 16:6<br>23:19 38:13 39:16<br>70:20 75:5,9<br>91:18,21 92:6,9,12<br>92:21,25 93:4,5,13<br>93:16,18,22,22<br>96:20 97:22,25 |
|---|---|--|---|

[documents - exhibit]

Page 9

|  |  |   |  |
|--|--|---|--|
| 99:21 106:22<br>107:4<br><b>doing</b> 10:21 11:6<br>28:8,11,17 33:19<br>36:15,22 46:15<br>47:22 64:5 81:4<br>85:19 98:7,19,20<br>99:14,24 109:3,6<br>110:17,20 120:10<br>120:10 125:9<br>137:7<br><b>doors</b> 45:10<br><b>dose</b> 27:16,17,19<br>27:25 28:11,17<br>81:3 122:9 137:1<br>137:11 138:17<br><b>doses</b> 91:15<br><b>doubling</b> 122:10<br><b>dr</b> 4:12 5:12 6:23<br>8:7,12,13,25 9:13<br>9:13 10:25 11:4<br>12:20 28:23,23<br>32:15 35:17 36:20<br>38:15 39:3,5,17<br>40:5 44:20,21<br>46:23 47:25 48:13<br>48:14,20 60:4,24<br>60:24 61:2,10,14<br>70:24 71:20,25<br>72:21 74:20 75:6<br>76:1,17 78:2,12,24<br>79:1,14,15,15,25<br>80:1,2,13 81:15,17<br>83:21 84:4 85:5<br>86:17 90:2 95:11<br>95:13,15 96:7<br>100:6 101:14<br>102:17,19 106:15<br>106:18,19 107:20<br>108:2,5 112:7,12<br>112:24 113:14,25 | 115:10 116:4<br>121:11,11 122:22<br>123:25 124:11,22<br>128:10 130:2,8<br>131:10 132:12,12<br>132:20,25 133:10<br>133:13 135:9<br>136:7,25 138:13<br>138:25 139:13,15<br><b>draft</b> 40:11<br><b>drafted</b> 58:25 59:3<br><b>drafting</b> 39:4 53:5<br>55:8 58:22<br><b>drawing</b> 122:17<br><b>driven</b> 35:9<br><b>due</b> 10:12 20:24<br><b>duly</b> 5:8<br><b>duties</b> 139:24<br><br><b>e</b><br><b>earlier</b> 24:1 65:22<br>85:5 131:11,20<br><b>early</b> 7:16<br><b>easily</b> 104:11<br><b>east</b> 3:4<br><b>eat</b> 126:15<br><b>edge</b> 83:5<br><b>editing</b> 37:23<br>38:21<br><b>editor</b> 88:1,14<br>90:1<br><b>effect</b> 64:8 82:21<br>127:19<br><b>effluence</b> 66:13<br><b>egg</b> 126:14<br><b>either</b> 48:25 66:18<br><b>electives</b> 36:15<br><b>electron</b> 39:19<br><b>electronically</b><br>22:12 40:20<br><b>elects</b> 104:10 | <b>elements</b> 38:8<br><b>eliminate</b> 29:11<br><b>else's</b> 98:2 123:7<br><b>email</b> 7:7<br><b>embedded</b> 68:21<br><b>employed</b> 32:20<br>32:23 33:11<br><b>employee</b> 142:12<br><b>employment</b> 70:21<br>71:8<br><b>empty</b> 58:14<br><b>encourage</b> 86:12<br><b>ensued</b> 140:1<br><b>entering</b> 69:8<br><b>entitled</b> 88:23<br><b>entries</b> 92:3<br><b>entry</b> 15:11<br><b>enumerate</b> 19:23<br><b>enumerated</b> 8:15<br>8:25 93:8 98:17<br><b>environment</b><br>67:13 118:21<br><b>environmental</b><br>41:7 66:2,20,22<br>67:9,16<br><b>epa</b> 31:12 34:22<br><b>epa's</b> 34:4<br><b>epi</b> 91:13<br><b>epidemiologic</b><br>135:12 136:2<br><b>epidemiological</b><br>135:20 136:8<br><b>epidemiologist</b><br>89:9 90:4<br><b>epidemiology</b> 90:7<br>90:20 91:6 135:10<br><b>err</b> 138:6<br><b>especially</b> 120:14<br><b>essentially</b> 21:18<br>96:23 97:23 | <b>estimate</b> 27:17,20<br>28:12,18 103:25<br>137:17<br><b>estimates</b> 27:16,25<br>120:6 137:6<br><b>estimation</b> 35:11<br><b>et</b> 1:8 75:5<br><b>ethics</b> 141:7<br>142:18<br><b>evaluated</b> 50:19<br>124:15<br><b>evaluating</b> 50:5<br><b>evening</b> 126:17<br><b>event</b> 25:5<br><b>events</b> 23:23<br><b>eventually</b> 40:23<br><b>evidence</b> 11:2<br>55:17 56:15 142:9<br><b>evolution</b> 103:7<br><b>exact</b> 6:25<br><b>exactly</b> 80:11<br>105:25 123:1<br>137:12<br><b>examination</b> 4:2,4<br>4:4,5,5,6,6,7 5:10<br>61:12 107:25<br>130:6 131:8 133:8<br>135:6<br><b>examinations</b><br>116:4<br><b>examined</b> 5:8<br>116:22<br><b>example</b> 85:14<br>98:24 101:17<br><b>examples</b> 56:25<br><b>exception</b> 134:20<br><b>exclude</b> 57:4<br><b>excluded</b> 53:19<br><b>exclusively</b> 84:22<br><b>exhibit</b> 4:10,12,14<br>4:16,17,18,19 6:2 |
|--|--|---|--|

[exhibit - financially]

Page 10

|   |  |   |   |
|---|--|---|---|
| 6:2,2,2,3,8,11,12<br>6:13,15 7:22 14:8<br>18:17,19<br><b>exhibits</b> 4:11,21<br>6:5 141:17,18,19<br><b>existed</b> 16:21<br><b>exists</b> 114:20<br>123:12<br><b>expect</b> 20:18 94:20<br>95:1<br><b>expedited</b> 140:14<br>140:15<br><b>expenses</b> 104:1,21<br><b>experience</b> 108:12<br>139:5<br><b>expert</b> 4:12 44:3<br>47:2 48:3,19 49:1<br>49:1 54:23,23<br>55:1,3,6 58:9<br>75:17 79:18 80:5<br>80:7 130:15,19<br><b>expertise</b> 96:25<br><b>experts</b> 32:21,21<br>32:25 33:9,13<br>48:11<br><b>explain</b> 44:11,17<br><b>exposed</b> 63:5<br>64:20,23 65:4<br>68:23 70:13 72:22<br>78:9 118:10<br>135:21 136:3,10<br>137:13<br><b>exposure</b> 13:4,10<br>13:19,22,24,25<br>25:10 26:24 27:2<br>27:2,5,8 29:17,23<br>30:22 31:18 32:2<br>35:10 50:4,10,18<br>50:20 53:11,19<br>54:3,12 55:12,13<br>55:18,23,24 56:5,6 | 56:10,15,16,21<br>59:7,9 62:6 63:6<br>63:15,16,18,19,24<br>64:1 65:2,13,17,24<br>66:3,17,22 67:4,6<br>67:9,16,20 68:5,7<br>68:7,8 69:3,12<br>73:2,11 77:18,20<br>78:7 79:11 81:12<br>81:13,19,22 82:13<br>82:20,23 83:1,10<br>90:9,22 101:12<br>106:13,19,23<br>114:10,11,18,20<br>115:8,19 119:17<br>119:25 120:22<br>121:9,10,12,15,23<br>122:10,21 124:17<br>125:23 128:4,20<br>134:1,9 136:11,18<br>137:2,3,4,11,15,18<br>138:15 139:3<br><b>exposures</b> 11:18<br>24:2,3 25:10<br>27:13 50:21 51:2<br>51:15,24 54:1,16<br>54:17 55:15 56:14<br>57:3,16 58:19<br>79:3 83:2 115:4,6<br>121:19,20,24<br>123:7,19 124:12<br>137:22 138:14,17<br><b>expressed</b> 36:18<br><b>extends</b> 20:23<br><b>extent</b> 11:2 23:12<br>38:2 45:18 60:22<br>78:10<br><b>extrapolated</b> 27:14 | <b>f</b><br><b>face</b> 96:23<br><b>facilities</b> 69:18<br><b>facoem</b> 1:11 4:3<br>5:7<br><b>facp</b> 1:11 4:3 5:7<br><b>fact</b> 10:13 12:8,24<br>23:19 26:23 64:2<br>67:17 68:17 86:4<br>88:17 117:10,18<br>119:24 120:2<br>125:24<br><b>factor</b> 65:6 70:15<br>138:22<br><b>facts</b> 88:24 117:19<br>128:18<br><b>factually</b> 117:23<br><b>fair</b> 5:21 9:9 15:5<br>15:12 21:20 28:12<br>34:16 48:3,21<br>58:7,8 62:3 63:2<br>66:11,16 67:25<br>72:24 75:4,19<br>76:3,5,21 77:9,24<br>78:11 79:14 81:20<br>89:4,7 92:23<br>94:12 96:11,25<br>103:14 105:24<br>106:8 107:8 108:7<br>121:13 123:8<br>127:10 135:3<br><b>fairly</b> 89:14<br><b>fall</b> 7:1 92:11<br><b>familiar</b> 5:23 35:9<br>69:15,17 124:1,3,4<br><b>family</b> 13:14 16:23<br>51:20 62:12 67:24<br>68:13,18 69:5,10<br>108:23<br><b>far</b> 116:10 | <b>fashion</b> 18:8 45:9<br><b>fast</b> 83:7<br><b>fastidious</b> 108:18<br><b>father's</b> 127:24<br><b>fda</b> 31:12 92:16<br>93:21,23 94:25<br>96:5<br><b>fda's</b> 94:5<br><b>february</b> 1:14 5:1<br><b>fee</b> 43:10<br><b>feedback</b> 64:9<br><b>feel</b> 85:18 137:19<br><b>felt</b> 11:17 12:24<br>115:3<br><b>fewest</b> 15:11<br><b>fiber</b> 29:15,23<br>36:22 39:11 71:20<br>77:7 78:5 79:12<br>79:25 112:20<br>113:9,14,25 114:6<br>118:13,24 119:3,4<br>119:18 120:25<br><b>fibers</b> 30:12 31:7<br>32:10 34:15 67:23<br>68:21 72:3,14<br>75:23 110:15,19<br>111:1 112:13<br>114:19 118:11,22<br>119:16 124:24<br>129:4<br><b>field</b> 96:11 98:2<br><b>fields</b> 32:22,25<br><b>fifth</b> 2:17<br><b>figueroa</b> 3:10<br><b>figures</b> 104:12<br><b>figuring</b> 38:23<br><b>filed</b> 51:17<br><b>final</b> 10:25<br><b>financial</b> 140:25<br><b>financially</b> 142:13 |
|---|--|---|---|

[find - go]

Page 11

| <b>g</b>   |
|--|
| <b>gabrielle</b> 3:2 130:9   |
| <b>game</b> 135:3  |
| <b>gander</b> 86:13  |
| <b>garnered</b> 18:8   |
| <b>gas</b> 14:1 24:4<br>26:11  |
| <b>gaskets</b> 25:1  |
| <b>gathered</b> 39:9   |
| <b>gathompson</b> 3:6  |
| <b>general</b> 8:10 34:6<br>42:21 55:1 80:13<br>80:17 82:2,5<br>103:22 104:23<br>105:16 134:19<br>140:11 |
| <b>generally</b> 93:12<br>102:25   |
| <b>genetic</b> 42:8  |
| <b>geographic</b> 33:24  |
| <b>geologist</b> 75:22   |
| <b>geologists</b> 74:7   |
| <b>georgia</b> 140:22<br>141:2 142:2   |
| <b>getting</b> 69:9<br>104:17 106:1  |
| <b>give</b> 26:6 31:14<br>32:11 34:5 45:2<br>47:12 102:8 103:1<br>103:15 112:25<br>115:18 120:6          |
| <b>given</b> 7:18 31:23<br>35:14 44:14 71:11<br>88:16 115:2 142:9  |
| <b>gives</b> 30:7  |
| <b>giving</b> 132:3  |
| <b>gleaned</b> 127:20  |
| <b>go</b> 6:4,11,14 14:7<br>18:16 36:1,4 43:2<br>45:10 48:8 49:4<br>53:10 55:5 57:13                     |

[go - identified]

Page 12

|   |  |   |  |
|---|--|---|--|
| 57:21 58:2,13<br>61:9 66:11 71:5<br>79:20 87:22 89:5<br>89:13 98:7 101:11<br>103:2 107:21<br>108:2 117:13<br>120:9 126:12<br>127:10 128:6<br>131:4 139:11<br><b>goes</b> 20:24 86:12<br>86:13 123:5<br><b>going</b> 5:14,18,20<br>6:6,13 8:2 15:8<br>23:18 29:21 35:17<br>35:21,22,24 47:13<br>48:15 50:5 54:13<br>58:3,4,6 59:12,21<br>61:8 67:16 74:10<br>78:23 80:6 92:24<br>94:11 95:23 96:15<br>99:1 100:5 102:11<br>104:14,18 106:7<br>107:20 108:4<br>115:8 116:3<br>117:17 127:18<br>138:19<br><b>good</b> 5:12 59:23<br>102:10 130:8<br><b>google</b> 71:18<br><b>goose</b> 86:13<br><b>gordon</b> 36:10,20<br>38:15 39:3,5,17<br>40:5 46:23 47:25<br>48:20 73:18 76:1<br>78:2 83:21 84:4<br>106:18 128:10<br>133:13<br><b>gordon's</b> 8:13<br>48:13,14 71:20,25<br>72:21 76:17 79:14<br>79:25 106:15 | <b>grab</b> 113:4<br><b>gram</b> 29:22<br><b>grams</b> 110:17<br><b>granted</b> 45:13<br><b>great</b> 59:25 134:23<br><b>greater</b> 17:14<br>114:6<br><b>greenstone</b> 2:4<br><b>grilled</b> 126:14<br><b>grocery</b> 3:1<br>130:16<br><b>group</b> 87:3 92:25<br><b>grouping</b> 93:3<br><b>groups</b> 89:2<br><b>guess</b> 14:22 22:23<br>52:15 56:23 71:2<br>76:3 81:14 91:4<br>94:13 97:17 103:6<br>103:11 106:16<br>108:2 | <b>hardwood</b> 68:20<br>68:24<br><b>hawkins</b> 3:15<br><b>head</b> 92:18<br><b>hear</b> 113:21<br>129:21 131:16<br><b>heard</b> 46:3 94:9<br><b>hearing</b> 64:10<br><b>heavy</b> 95:22<br><b>help</b> 18:21 110:2<br><b>helped</b> 26:15<br>37:11<br><b>helpful</b> 23:22<br><b>helping</b> 37:7 38:11<br><b>hereto</b> 5:6<br><b>hey</b> 61:14 86:9<br><b>hi</b> 61:15,16<br><b>high</b> 21:15 25:22<br>109:19<br><b>highlighting</b> 14:10<br><b>hipaa</b> 84:16 86:1<br><b>hired</b> 43:24<br><b>historic</b> 70:21<br><b>historical</b> 49:8,21<br>73:19 74:4,6,16<br>97:5,9,14 103:4<br><b>historically</b> 55:20<br><b>histories</b> 47:13<br><b>history</b> 62:6 73:8<br><b>hit</b> 83:4<br><b>hold</b> 7:2 16:12<br><b>holds</b> 103:12<br><b>homage</b> 49:8<br><b>home</b> 16:23 19:1,5<br>20:9 22:22 23:11<br>25:5 67:12,18,23<br>67:25 71:15<br>126:16 137:13<br><b>honest</b> 92:14<br><b>honestly</b> 7:9 46:4<br>47:10 85:1 | <b>honors</b> 23:3<br><b>hope</b> 97:18<br><b>hoped</b> 50:2<br><b>hopefully</b> 107:23<br><b>hospitals</b> 104:24<br><b>hour</b> 10:1,1,10,19<br>35:21 102:11<br>125:14<br><b>hours</b> 9:18,22 10:8<br>23:1 115:25<br>117:15 118:3,4,11<br>118:17,22 119:4,6<br>119:10,15,17,25<br>120:24<br><b>house</b> 68:10,19<br>125:25 126:8,19<br>127:4,25 128:2,5<br><b>hpylaw.com</b> 3:18<br><b>huge</b> 20:17<br><b>hugged</b> 68:12<br><b>humor</b> 132:8<br><b>hundreds</b> 92:3<br>110:18 139:7,7<br><b>hygiene</b> 139:9<br><b>hypothesis</b> 83:4<br><b>hypothesize</b> 56:21<br><b>hypothetical</b><br>55:14 56:10,14<br>57:2 59:4,14<br>64:22 65:8 116:11<br>116:15 117:10,19<br>119:11,21 121:3<br><b>hypothetically</b><br>51:11 58:17 63:4<br>68:23 |
|   |  |   | <b>i</b><br><b>idea</b> 53:7 85:11<br><b>identifiable</b> 50:24<br><b>identified</b> 6:1 8:4<br>13:7 18:18 45:9  |

[identifies - johnson]

Page 13

|   |   |  |  |
|---|---|--|--|
| <b>identifies</b> 8:24<br><b>identify</b> 11:17<br>12:4 13:3,20<br>44:22 50:24<br><b>identifying</b> 44:5,9<br>46:10<br><b>identities</b> 45:2<br>84:19,21 85:14<br><b>identity</b> 84:8,23<br><b>illinois</b> 16:15<br>17:15 22:24 35:8<br>124:2,6<br><b>impacts</b> 142:24<br><b>impartial</b> 142:25<br><b>impartiality</b> 141:6<br>142:17<br><b>imply</b> 41:10<br><b>important</b> 49:14<br>49:16 83:2<br><b>inartfully</b> 52:15<br><b>include</b> 40:11<br>45:25 50:9,14,17<br>58:21 137:10<br><b>included</b> 10:8,14<br>15:14 19:24 20:4<br>20:9 24:12 39:6<br>43:5 45:7,17<br>46:17 47:20 49:3<br>51:13 52:16 54:22<br>57:1,9 58:25 59:5<br>59:10,19 85:2<br>86:9 92:9<br><b>including</b> 8:11<br>28:22 69:21 85:25<br><b>incomplete</b> 59:14<br>64:22 65:8 116:11<br>116:15 119:11,21<br>121:3<br><b>incomprehensible</b><br>118:6 119:11 | <b>incorporated</b> 13:5<br><b>increase</b> 112:22<br>114:8 121:20<br><b>increased</b> 88:6<br>90:8,21 91:8<br>135:14<br><b>increases</b> 82:7<br><b>increments</b> 10:7<br><b>incurred</b> 104:15<br>104:17<br><b>indented</b> 24:13<br><b>index</b> 4:1,2,10,23<br><b>indicate</b> 125:21<br><b>indicated</b> 112:12<br>123:25 124:11,22<br>129:14<br><b>indicative</b> 31:17<br>31:21<br><b>individual</b> 31:7<br>33:24 44:13 46:10<br>51:12,13,17 54:3<br>55:18 56:6 77:7<br>122:10,20<br><b>individually</b> 122:2<br>122:4<br><b>individuals</b> 36:11<br>43:19,20,23 44:6<br>44:22 45:3,7,14,16<br>46:12 50:20 74:5<br>86:10 135:21<br>136:2,16<br><b>infiltrated</b> 127:25<br>128:2<br><b>inform</b> 23:7,13<br><b>information</b> 15:1<br>18:9,14 30:7,25<br>38:14 39:7,8,17<br>40:5 44:13 50:12<br>52:3,11,12,16,17<br>53:24,25 55:7,23<br>56:4,8,11,12 58:16 | 58:21,23 62:22<br>68:5 117:3<br><b>informed</b> 22:16<br><b>initial</b> 38:13 40:4<br>40:10 42:4 105:8<br><b>initially</b> 40:22<br>42:4 47:22<br><b>inpatient</b> 104:6<br><b>input</b> 18:5<br><b>instance</b> 19:19<br>20:21 50:13 51:10<br><b>instances</b> 51:22<br>136:14<br><b>institutional</b> 45:5<br><b>insulation</b> 69:22<br>70:1,5,9 125:19<br><b>intend</b> 11:21 89:18<br>102:22 103:1,15<br><b>intention</b> 81:4<br><b>interact</b> 126:24<br><b>interacted</b> 69:10<br><b>interaction</b> 126:3<br>126:10,20<br><b>interactions</b> 15:23<br>68:15 73:5 125:22<br>126:23<br><b>interest</b> 36:18 94:2<br>140:25 141:4<br>142:15<br><b>interested</b> 93:21<br>98:12 142:13<br><b>interesting</b> 125:15<br><b>interior</b> 124:8,22<br><b>internal</b> 91:17<br>93:5 107:3<br><b>interrupt</b> 87:24<br><b>interview</b> 51:22<br><b>intro</b> 37:16<br><b>introduction</b> 37:9<br>42:6 | <b>investigation</b> 53:5<br><b>invoices</b> 10:15<br><b>involved</b> 36:16<br>46:12 61:22 108:5<br><b>involvement</b> 112:6<br><b>irb</b> 45:5,12,20<br>46:2 84:17,20,25<br>86:1<br><b>ish</b> 7:2 105:5<br><b>isolating</b> 120:20<br><b>isolation</b> 87:20<br>121:18<br><b>issued</b> 10:15<br><b>issues</b> 87:2<br><b>iwatubo</b> 112:7,12<br>112:24 121:11  |
| <b>j</b>  |   |  | <b>j&amp;j</b> 4:12 75:11,13<br>95:16 100:12<br>131:12,21<br><b>jacqueline</b> 1:10<br>4:3,13 5:7<br><b>january</b> 31:13<br>77:13,14<br><b>jccp</b> 1:3<br><b>jean</b> 8:11 9:14<br>108:4 115:12<br>116:4 138:15<br><b>jennifer</b> 1:13<br>143:7<br><b>jersey</b> 69:25<br>124:13,16 125:3<br><b>job</b> 118:11<br><b>johnson</b> 2:14,14<br>2:14,14 75:7,7<br>91:17,17,22,23<br>92:17,17 93:2<br>94:15,15 107:3,3<br>107:12,12 135:11<br>135:11 138:25<br>139:1 |
|   |   |  |  |

[johnson's - levels]

Page 14

|  |   |  |   |
|--|---|--|---|
| <b>johnson's</b> 62:25<br>63:5 73:20 74:17<br>78:3 79:16 80:3<br>93:2 94:7 95:7,16<br>96:22 100:8,14,21<br>100:25 101:18<br>107:16 134:8,14<br><b>joint</b> 36:22 123:12<br><b>jointly</b> 123:14<br><b>journal</b> 39:21<br>40:23,25 41:3,6,11<br>41:12 46:7<br><b>journal's</b> 38:18<br><b>jromano</b> 2:19<br><b>julia</b> 2:15 61:14<br>79:20 80:6 81:11<br>101:7 114:23<br>131:2,11,20<br>139:18<br><b>july</b> 67:1<br><b>jump</b> 61:8<br><b>june</b> 82:9<br><b>jurisdiction</b> 122:7<br>123:2 | 75:20 76:6,22<br>77:10 79:20 80:6<br>80:19 81:11 90:11<br>96:12 97:1 98:3<br>99:16 100:16<br>101:7 110:10<br>111:15 112:15<br>113:17,21 114:3<br>114:13,22 115:22<br>116:7,11,24 117:4<br>117:16,23 118:5<br>118:14 119:9,20<br>121:2 122:3,6,19<br>123:9,18 124:25<br>127:13 128:1,24<br>129:18,23 131:1<br>131:15 134:4,24<br>135:7 136:1,6<br>138:24 139:13,18<br>140:2,18<br><b>keep</b> 50:23 81:7<br>86:2<br><b>kept</b> 68:17<br><b>key</b> 43:5,17<br><b>kids</b> 101:3<br><b>kilroy</b> 2:5<br><b>kind</b> 5:21 20:23<br>22:25 23:16 27:13<br>29:11 36:25 49:7<br>80:13 90:4 104:19<br>131:13<br><b>king</b> 2:16<br><b>knew</b> 25:18,19<br><b>knocking</b> 45:10<br><b>know</b> 5:19 7:11,14<br>7:21 8:17 9:5,25<br>16:6,21 17:1,7,13<br>18:5,12 23:3,23<br>27:11 30:10 32:5<br>32:7 34:7,8 40:15<br>40:17,18,19 41:20 | 43:3,16 45:23<br>46:1 48:6 49:12<br>49:13 51:1,8,11<br>52:22 53:8,17,19<br>53:22 54:4 55:21<br>57:22 60:6,13,15<br>64:9 65:21 66:25<br>70:23 71:10 72:21<br>73:14 74:10,22<br>77:6 80:13 82:17<br>83:6,22 84:17<br>85:5 86:17,24<br>88:9,11,16 91:24<br>94:11 96:4 98:25<br>104:3,9,16 105:25<br>106:1,17 108:15<br>108:19 109:10<br>112:18,23 116:25<br>117:4,4 122:6,7<br>123:10 124:4,18<br>128:3 129:9,24<br>137:5,12<br><b>knowing</b> 48:5<br>83:18 127:16<br>128:8 129:3,8<br><b>knowledge</b> 71:10<br>103:7<br><b>known</b> 54:3<br>120:12<br><b>kristin</b> 36:9,16<br>37:3,18<br><b>kristin's</b> 37:6<br><b>kslaw.com</b> 2:19 | <b>lamb</b> 87:9<br><b>language</b> 37:24<br><b>laosd</b> 1:4<br><b>large</b> 31:9 89:14<br>91:20 92:5<br><b>largest</b> 21:19<br><b>latency</b> 81:7,9,17<br>81:18,25 82:3,4,6<br><b>laundered</b> 65:1<br><b>laundering</b> 27:4<br>64:1,16,20 65:5<br><b>laundry</b> 68:16,17<br>68:18<br><b>law</b> 36:13 122:24<br>123:22 140:23<br><b>lawsuits</b> 84:12<br><b>lawyers</b> 10:4 71:3<br>85:21,24 86:4<br>93:16<br><b>lead</b> 30:12<br><b>leading</b> 32:9<br><b>leah</b> 2:3 6:20<br>133:6 135:25<br>140:18<br><b>learning</b> 103:4<br><b>leave</b> 74:7 116:21<br>120:3<br><b>led</b> 53:25<br><b>left</b> 25:4<br><b>legal</b> 141:2,11<br><b>legally</b> 123:11<br><b>length</b> 83:23<br><b>lesser</b> 129:16<br><b>letter</b> 7:6,10<br><b>letters</b> 88:1,14<br>89:25<br><b>level</b> 63:7,10 114:7<br>114:10,18<br><b>levels</b> 21:23 33:23<br>34:4 110:21 |
| <b>k</b>   |   | <b>l</b>   |   |
| <b>kagan</b> 2:3 4:7 6:16<br>6:21 8:2,22 10:12<br>10:13,23 11:22<br>12:18 13:3,11<br>15:18,25 17:19<br>19:16 20:11,25<br>21:21 27:19 28:13<br>29:2,18 30:3,23<br>32:3,24 33:12<br>34:1,18 43:9<br>44:15 46:21 48:4<br>52:7,21 53:15<br>57:6,18 59:12<br>63:9 64:22 65:8<br>66:19 68:1 69:23<br>72:5,16 74:21   |   | <b>la</b> 2:11<br><b>laboratory</b> 39:9<br>98:20<br><b>lacourt</b> 113:12,14<br>113:25 114:4<br>121:11,16   |   |

[lexington - matter]

Page 15

|                           |                           |                            |                           |
|---------------------------|---------------------------|----------------------------|---------------------------|
| <b>lexington</b> 3:16     | 84:15 87:18 95:10         | 97:4,12,14 99:11           | <b>manufacturer</b>       |
| <b>liability</b> 123:12   | 120:7                     | 99:25 111:25               | 76:25 78:4                |
| <b>licensed</b> 122:8     | <b>live</b> 55:18 120:4   | <b>looks</b> 14:14,14,19   | <b>manufacturers</b>      |
| <b>life</b> 72:23 104:11  | <b>lived</b> 55:15 66:6   | 15:11 17:14 71:19          | 13:23 26:6                |
| <b>lifetime</b> 115:19    | 67:2,17 125:25            | <b>los</b> 1:2 2:18 3:5,11 | <b>manuscript</b> 54:25   |
| 119:17 121:9              | <b>living</b> 33:25 66:3  | <b>losing</b> 119:25       | 55:9 57:5 58:22           |
| 137:2,4                   | 69:5                      | <b>lost</b> 118:16 140:10  | 58:24 59:1,3,11,19        |
| <b>light</b> 95:25 140:15 | <b>lkagan</b> 2:6         | <b>lot</b> 22:21 23:11     | <b>map</b> 18:1,1 71:18   |
| <b>limited</b> 31:23      | <b>llp</b> 3:3,15         | 64:9 86:25 87:19           | <b>mapped</b> 17:5        |
| <b>limits</b> 97:10 98:13 | <b>local</b> 22:3         | 93:19 126:20               | <b>maps</b> 71:14         |
| 98:21                     | <b>location</b> 16:22     | <b>low</b> 91:15           | <b>march</b> 143:2        |
| <b>linda</b> 1:5 4:17     | <b>locations</b> 71:14    | <b>lower</b> 112:20        | <b>margin</b> 24:10,15    |
| 22:13 127:9               | <b>logical</b> 38:22      | 113:13 114:7               | <b>mark</b> 6:5,7,9,10    |
| <b>line</b> 11:20 42:7    | <b>long</b> 2:5 8:18      | 121:16                     | 6:11,12,14 18:16          |
| <b>lines</b> 35:25 36:3   | 31:14 107:1,4             | <b>lowest</b> 113:7        | <b>marked</b> 7:22 14:8   |
| 100:1                     | 108:13 109:4              | <b>lymph</b> 128:17        | <b>market</b> 26:4        |
| <b>liquid</b> 95:22       | 111:2                     | 129:11                     | <b>martin</b> 67:18       |
| <b>list</b> 4:17 6:10,12  | <b>longer</b> 109:15      | <b>m</b>                   | 125:9 137:14              |
| 6:19 8:4,9,16,17          | <b>longo</b> 9:13 28:23   | <b>m</b> 2:10              | <b>martin's</b> 9:14 71:8 |
| 8:23 9:6 12:22            | 94:23 95:15 116:4         | <b>machinists</b> 125:13   | 128:4                     |
| 22:12 60:8,12,17          | 132:12                    | 125:18                     | <b>match</b> 89:11        |
| 80:8 86:16,21             | <b>longo's</b> 8:12 60:24 | <b>macy's</b> 3:13         | <b>matched</b> 48:16      |
| 92:13,20 93:12,15         | 79:15 80:2,12,22          | <b>madigan</b> 6:19        | <b>material</b> 32:18     |
| 132:11 135:2              | 95:11,13 96:7             | <b>madigan's</b> 90:2      | 33:10 74:7 75:22          |
| 136:21,24                 | 102:19 106:19             | <b>magnitude</b> 35:15     | <b>materially</b> 51:24   |
| <b>listed</b> 7:23 22:17  | 132:20                    | 110:22                     | <b>materials</b> 7:12,23  |
| 74:15 86:16 93:14         | <b>look</b> 14:7 15:10    | <b>main</b> 25:21,24       | 8:8,14 10:25 11:3         |
| 93:18 106:24              | 18:1 21:10 31:5           | 69:5 137:20                | 12:21 13:21 14:2          |
| <b>listing</b> 44:12      | 31:24 48:9 53:10          | <b>maintain</b> 140:3      | 16:4,7 22:2,18            |
| <b>literature</b> 30:11   | 59:21 77:14 89:5          | <b>maintaining</b> 46:11   | 28:10,20 64:19            |
| 31:11 78:8 82:5           | 96:2 98:1,4,6,14          | 141:6 142:17               | 70:18,23 71:1,2           |
| 82:25 87:1 91:2           | 99:7 100:4 120:17         | <b>major</b> 49:13         | 135:2                     |
| 91:12 136:15              | <b>looked</b> 7:19 17:2   | <b>making</b> 35:1 38:17   | <b>math</b> 115:20        |
| <b>litigation</b> 43:7,20 | 29:10 60:4,12             | 39:13,16,23 40:2           | 119:22 120:10             |
| 43:25 46:12,19            | 91:13,15 96:4             | 42:14 50:1 69:21           | 121:5                     |
| 47:3 51:16 52:19          | 116:5 122:2,3,5           | 76:11 125:12               | <b>matt</b> 74:15         |
| 53:2,14 85:7              | 125:11                    | 141:5                      | <b>mattenklott</b> 31:11  |
| 108:6 109:20              | <b>looking</b> 8:13,14    | <b>malignant</b> 12:13     | 32:8 106:21               |
| 110:6 112:6               | 15:9 17:24 20:21          | <b>man</b> 108:16          | <b>matter</b> 6:24 10:22  |
| <b>little</b> 5:15 27:10  | 28:19 71:5 72:12          | <b>managed</b> 128:4       | 11:14 132:4               |
| 31:8 36:4 56:23           | 92:2 95:23 96:1           |                            | 134:19 141:5,12           |

[matter - mount]

Page 16

|                          |                          |                          |                           |
|--------------------------|--------------------------|--------------------------|---------------------------|
| 142:16                   | 104:1,21 105:14          | <b>methodology</b>       | 74:21 76:6,22             |
| <b>maya</b> 36:9,13      | 105:16 106:3             | 32:20,22 33:2,3,8        | 98:3 100:16               |
| 38:10 39:15              | 133:17,19,24             | 33:11,15 94:16           | 110:12 111:16             |
| <b>maya's</b> 38:12      | 134:7,13,16,21,22        | 95:3,19 96:8,15,16       | 112:15 114:3              |
| <b>md</b> 1:10 4:3 5:7   | 139:2,5,6                | 97:13,16 98:1,11         | 116:7,12,24               |
| <b>mean</b> 8:16 11:23   | <b>medicare</b> 105:9,10 | <b>methods</b> 39:9 97:7 | 118:14 119:9,20           |
| 20:13,17 21:2,13         | <b>medication</b> 104:6  | <b>mg</b> 2:10           | 121:2 122:3 123:9         |
| 22:10 29:2 32:6          | <b>medicine</b> 41:7     | <b>mgmlaw.com</b> 2:12   | 124:25 127:13             |
| 33:2 38:5 39:18          | 49:22                    | <b>microscope</b> 99:3,5 | 128:24                    |
| 41:10 42:18 43:16        | <b>meditative</b> 109:14 | 99:11                    | <b>misinformation</b>     |
| 51:6 53:8 66:5,12        | <b>meghan</b> 1:12 2:9   | <b>microscopist</b>      | 66:24                     |
| 66:14,20 69:24           | 5:13 131:4 139:22        | 32:15,17 39:19           | <b>misrepresent</b> 40:8  |
| 73:4 79:2 80:10          | <b>member</b> 51:20      | <b>microscopy</b> 33:10  | <b>missed</b> 79:21       |
| 80:12,12 84:23           | <b>members</b> 13:14     | <b>mid</b> 7:15 26:9     | <b>moline</b> 1:10 4:3,13 |
| 85:4,8 89:20             | 108:23                   | <b>mile</b> 66:7         | 5:7,12 6:23 8:7,25        |
| 94:19 95:18 97:2         | <b>memory</b> 36:8       | <b>miles</b> 55:16,19    | 11:4 32:15 35:17          |
| 98:5 99:5 101:2          | 74:10 75:1 79:7          | <b>millers</b> 91:9      | 44:20,21 60:4             |
| 104:14 105:3             | 139:21                   | <b>millions</b> 30:12    | 61:10,14 70:24            |
| 106:25 107:5             | <b>mention</b> 8:15      | 32:9 110:18,25           | 81:15,17 86:17            |
| 108:21 110:14            | <b>mentioned</b> 24:1    | <b>mine</b> 36:20 131:6  | 100:6 101:14              |
| 112:2 119:22             | 32:7 39:15               | <b>mineral</b> 75:18     | 102:17 107:20             |
| 120:15 123:10,11         | <b>meso</b> 79:6,7       | 99:9,12,23,24            | 108:2,5 115:10            |
| 124:4                    | <b>mesothelioma</b>      | <b>mineralogist</b>      | 122:22 123:25             |
| <b>meaning</b> 94:21     | 12:13 35:19 49:11        | 75:17                    | 130:2,8 131:10            |
| 111:3 127:1              | 49:23 62:21 63:2         | <b>miners</b> 91:9       | 133:10 135:9              |
| <b>means</b> 25:2,3      | 63:8 65:7 79:8           | <b>mines</b> 97:7        | 136:7,25 138:13           |
| <b>meant</b> 111:23      | 81:9,25 82:9,16          | <b>minimal</b> 126:10    | 138:25 139:13,15          |
| <b>measurement</b>       | 84:5,13 87:6,10,12       | <b>minimum</b> 82:3,19   | <b>moline's</b> 12:20     |
| 30:14                    | 87:13 88:6,18            | <b>minnesota</b> 97:6    | <b>moment</b> 24:1        |
| <b>measurements</b>      | 90:9,21 91:8,14          | <b>minor</b> 42:10       | 39:15 49:22 55:11         |
| 40:2 110:21 137:6        | 103:10 112:8,14          | <b>minute</b> 10:7       | 93:7 102:9                |
| <b>measuring</b> 31:1    | 112:22 113:16            | 108:25 109:18            | <b>moments</b> 5:14       |
| 95:20 137:7              | 114:2 134:15             | <b>minutes</b> 108:24    | 50:5                      |
| <b>mechanic</b> 24:4,25  | 135:18 136:12,16         | 114:23 115:17,19         | <b>month</b> 25:1 102:1   |
| <b>mechanics</b> 26:16   | <b>met</b> 5:13 62:2     | 115:25 126:3             | 102:3                     |
| <b>media</b> 94:2        | <b>metal</b> 125:11,18   | <b>mischaracterizes</b>  | <b>months</b> 25:2 102:4  |
| <b>medical</b> 7:24 10:1 | <b>method</b> 95:21      | 12:18 13:11 15:25        | <b>morning</b> 5:12       |
| 11:9 25:3 31:10          | 98:23                    | 20:11,25 21:21           | <b>motion</b> 140:9,11    |
| 36:14 50:2 56:3          | <b>methodical</b> 120:18 | 28:13 29:18 30:3         | 140:14                    |
| 73:10 78:1 91:12         | <b>methodically</b>      | 51:18 52:7,21            | <b>mount</b> 36:21        |
| 103:19,20,24             | 120:17                   | 59:15 72:5,16            |                           |

[move - once]

Page 17

|   |   |  |   |
|---|---|--|---|
| <b>move</b> 26:8 68:6<br><b>msc</b> 1:11 4:3 5:7<br><b>msenter</b> 2:12<br><b>multi</b> 83:4<br><b>multiple</b> 13:8,8<br>22:3,6 47:13<br><b>mute</b> 64:7  | <b>news</b> 93:20,23<br><b>newspaper</b> 22:4<br>22:18 23:7,16<br><b>nod</b> 49:8<br><b>nodes</b> 128:17<br>129:11<br><b>nonasbestos</b> 25:16<br>26:8<br><b>noncommercial</b><br>73:16<br><b>noncontributory</b><br>82:23<br><b>nondetect</b> 97:12<br>98:15,16<br><b>nonlitigation</b> 17:3<br><b>nonoccupational</b><br>113:15 114:1<br><b>normal</b> 35:7<br><b>north</b> 21:16,25<br><b>northwest</b> 21:12<br>21:12<br><b>notation</b> 133:24<br><b>notations</b> 139:3<br><b>note</b> 6:17 10:23<br>15:14 24:10 28:21<br>42:20 47:5,15<br><b>noted</b> 14:15 22:2<br>26:18 67:6<br><b>notes</b> 4:18 6:15<br>7:18,21,23 9:11,23<br>12:21 13:5,7,12<br>14:3,10 23:25<br>24:16,18 53:1<br>54:14 59:21 60:4<br>62:1 100:4,5,7,17<br>101:8 102:7<br>107:22 115:11<br>120:18 125:21<br>137:21<br><b>noteworthy</b> 55:8 | <b>notice</b> 4:12 6:7,18<br><b>noticed</b> 132:11<br><b>noticing</b> 141:11<br><b>noting</b> 133:24<br><b>notorious</b> 69:19<br>69:20<br><b>now's</b> 102:10<br><b>number</b> 6:5 8:8<br>13:23 15:11 27:12<br>27:23 28:21 32:5<br>34:6,14 35:2,3,14<br>49:7,9 51:13,17<br>70:19 91:20,21<br>92:19,21 100:13<br>101:13 110:17<br>112:3 114:25<br>115:2,11 121:24<br>125:3,6 137:16,19<br>137:22 138:17<br><b>numbers</b> 25:22<br>28:18 40:1 88:10<br>88:11 89:11,13<br>101:5 108:22<br>111:25 112:18<br>119:12 120:19<br>121:4,17<br><b>numeric</b> 137:1<br><b>numerical</b> 83:7<br><b>ny</b> 3:17 | <b>obtaining</b> 71:7<br><b>obviously</b> 37:21<br>39:13,25 42:12<br>50:19 82:7 103:2<br>103:9,17 133:17<br>134:24<br><b>occasion</b> 26:16<br>127:10 128:7<br><b>occupational</b> 41:6<br>118:25 119:5<br><b>occurred</b> 23:23<br>81:22<br><b>occurring</b> 53:17<br><b>ocga</b> 5:3 140:24,25<br>141:13<br><b>october</b> 7:15,16,17<br>16:16 93:1 94:5<br>105:19,20 106:11<br>133:19,22 134:22<br><b>odd</b> 87:18<br><b>odds</b> 113:9 114:5<br><b>offer</b> 11:2,21 12:7<br>136:10<br><b>offering</b> 73:25<br><b>office</b> 16:15<br><b>officer</b> 142:25<br><b>oh</b> 16:9 22:20<br>60:12 67:3 100:19<br><b>okay</b> 5:17 6:20<br>8:17 9:17 15:1<br>35:20 36:4,6 75:4<br>88:4 89:24 100:3<br>100:19,20 103:23<br>107:10,15,18<br>116:1 118:9<br>130:23 136:4<br><b>older</b> 26:11<br><b>once</b> 82:21 101:19<br>101:19,21,22<br>126:25 138:5,6,8 |
| <b>near</b> 66:3<br><b>necessarily</b> 20:8<br>85:15 88:19<br>111:18 120:5<br><b>necessary</b> 103:21<br>140:14<br><b>need</b> 28:10 29:13<br>29:22 30:6,8,13,24<br>41:2 68:6 102:8<br>136:7<br><b>needs</b> 35:13<br><b>negative</b> 95:8<br><b>negotiated</b> 105:7<br><b>neither</b> 25:17<br><b>never</b> 45:23,24<br>46:1,2 56:14 85:1<br>86:11<br><b>new</b> 2:11 3:17<br>69:25 93:4,5<br>124:13,16 125:3<br>132:17,22,24 |   | <b>o</b><br><b>object</b> 8:2 59:12<br><b>objection</b> 17:19<br>110:10 138:18<br><b>objections</b> 6:17<br>122:17<br><b>obligation</b> 140:3<br>141:6 142:17<br><b>obtain</b> 71:6 84:22<br>93:17<br><b>obtained</b> 71:11<br>84:18   |   |

[ones - person]

Page 18

|   |   |   |  |
|---|---|---|--|
| <b>ones</b> 22:13 47:1<br>83:5 106:24<br><b>ongoing</b> 13:2<br><b>online</b> 78:21 94:1<br><b>onset</b> 81:19<br><b>opine</b> 89:18 94:20<br>98:10 102:22<br><b>opining</b> 74:6<br><b>opinion</b> 12:9,16<br>22:17 23:13 43:25<br>56:9 62:19,23<br>64:17 65:23 66:1<br>73:1,25 81:8,24<br>88:23 91:22 96:20<br>128:21 135:18<br>136:11<br><b>opinions</b> 8:1 11:21<br>12:20 18:22 23:7<br>53:13 61:1 78:25<br>86:22 94:5 130:12<br>130:15,19 132:15<br>132:17,22,24<br><b>opposed</b> 77:1<br>80:16 105:4<br>117:24<br><b>opposite</b> 19:5<br><b>order</b> 7:25 29:15<br>35:10,15 68:6<br>136:10<br><b>ordering</b> 141:20<br><b>orders</b> 110:21<br><b>orientation</b> 21:8<br><b>original</b> 4:21,21<br>40:6,14 140:4,5,10<br>140:18<br><b>orleans</b> 2:11<br><b>outcome</b> 142:13<br><b>outpatient</b> 104:6<br><b>outset</b> 6:4<br><b>outside</b> 7:22 46:13 | <b>overbroad</b> 11:22<br>57:6,18 77:10<br>139:11<br><b>overwhelmingly</b><br>86:24<br><br><b>p</b><br><b>p.m.</b> 1:15 102:14<br>102:15 140:17<br><b>page</b> 2:25 4:8 9:3<br>9:8 14:13,14,19<br>24:7 27:16,22<br>30:18 92:21 100:6<br>101:8,11,12<br>115:10 120:17<br>125:20 137:21<br><b>pages</b> 8:18,21 13:8<br>35:24 36:3<br><b>paid</b> 105:5<br><b>panatier</b> 2:4<br><b>panel</b> 41:18<br><b>pantagraph</b> 22:7<br>22:18<br><b>paper</b> 35:18 36:7<br>36:16,19,22,24<br>37:3,14 38:11,16<br>39:12,24 40:12<br>43:6,13,18 44:5,7<br>44:23 45:3,4,8,17<br>46:5,9,13,18 47:11<br>47:23 48:13,14<br>49:2,20 50:14,15<br>50:22 51:14 53:5<br>53:6,9 54:6,20<br>55:4 56:11 57:1,9<br>84:9 85:1,6,22<br>86:5,6,8,23 88:25<br>89:18 106:2,16,18<br>106:20 112:16,18<br>113:6<br><b>paper's</b> 88:2 | <b>papers</b> 14:9 45:25<br>46:5 91:11 112:19<br><b>paperwork</b> 84:24<br><b>paragraph</b> 76:10<br><b>parameters</b> 18:5<br><b>parentheses</b><br>100:12<br><b>park</b> 3:4<br><b>parnell</b> 3:15<br><b>parse</b> 9:24 38:3<br>123:21<br><b>part</b> 10:12 25:13<br>40:11 44:16 51:25<br>79:21 85:15,25<br>87:13 98:18,18<br>110:2<br><b>particle</b> 77:7,20<br>99:11<br><b>particles</b> 76:1,4,20<br>78:1<br><b>particular</b> 18:15<br>19:3,20,21,23<br>20:18 32:5 49:17<br>53:2 56:22 57:8<br>77:7,17,19,20,21<br>112:18 121:9,22<br>123:6 129:4<br><b>particularly</b> 37:10<br>87:8<br><b>parties</b> 141:14,20<br>142:25<br><b>partners</b> 38:5<br><b>parts</b> 12:19 111:13<br><b>party</b> 141:7,14<br>142:12,19<br><b>pass</b> 107:21,23<br><b>passed</b> 85:17<br><b>password</b> 141:19<br>141:20<br><b>pathology</b> 78:12<br>80:1 | <b>patient</b> 44:9,9<br><b>patients</b> 50:6<br>139:7,8<br><b>pattern</b> 20:3,8<br><b>patterns</b> 16:14<br>17:3,5,9 19:1<br>21:23 65:22<br><b>pausing</b> 64:8<br><b>paying</b> 98:9<br><b>payless</b> 3:1 130:20<br><b>pc</b> 2:4<br><b>peaks</b> 21:11 99:25<br><b>peculiar</b> 76:25<br><b>peer</b> 41:18,19,21<br>41:23 90:7,20<br>91:6 136:15<br><b>pejorative</b> 76:9<br><b>people</b> 45:9 50:2<br>51:9 67:2 83:15<br>85:3,17 86:8 87:7<br>89:3 108:22 109:3<br>109:24 136:10<br><b>peoria</b> 17:15,15<br><b>percent</b> 30:19,25<br>43:2 110:24 111:4<br>111:12,20 116:22<br>117:14 118:3<br>119:23<br><b>percentage</b> 29:21<br>30:11 31:6,8,9,16<br>32:8 70:12 111:10<br><b>period</b> 23:20<br>25:14 26:13 81:9<br>81:25 83:8 108:13<br>119:16<br><b>person</b> 22:23<br>47:17 50:17 59:10<br>67:24 87:9 108:11<br>114:12,21 118:10<br>118:12,21,23<br>119:6,15 121:8 |
|---|---|---|--|

[personally - product]

Page 19

|  |  |   |  |
|--|--|---|--|
| <b>personally</b> 44:8<br>62:2 89:9<br><b>pete</b> 108:3<br><b>peter</b> 3:14<br><b>ph.d.</b> 61:4<br><b>pharmacy</b> 3:1<br><b>phase</b> 99:3,4<br><b>phone</b> 7:7,8 10:4<br>22:23 120:14,15<br><b>photographs</b><br>124:7,8<br><b>physicians</b> 139:8<br><b>picked</b> 49:9<br><b>piece</b> 128:16<br><b>pinpoint</b> 77:19<br><b>pinpointing</b> 73:6<br><b>place</b> 2:10 23:1<br>120:4 141:12<br><b>placed</b> 26:3<br><b>places</b> 138:3<br><b>plaintiff</b> 1:6 2:2<br>49:1 93:16 125:22<br>127:9 140:5<br><b>plaintiff's</b> 4:12<br>16:18 71:12,16<br><b>plaintiffs</b> 43:7,20<br>62:17 84:8,18<br>85:12,21<br><b>plaintiffs's</b> 71:3<br><b>plan</b> 36:2 94:4<br><b>planning</b> 28:8,11<br>28:17<br><b>plant</b> 16:23 18:24<br>19:2,6 55:16,19,22<br>65:18 66:4,8,13,14<br>66:23 67:7,19<br>69:13,18 70:21<br>71:14 124:1,5,8,9<br>124:13,16,16,23<br>125:3 128:23<br>129:15 133:25 | <b>plants</b> 67:3 125:8<br><b>played</b> 82:15<br><b>please</b> 22:8 102:9<br>113:22 139:17<br><b>plenty</b> 91:13<br><b>plm</b> 117:5,6<br><b>plot</b> 4:19 17:18,20<br>18:6,15 20:16<br>21:17<br><b>plots</b> 16:13<br><b>pneumonitis</b> 106:2<br><b>poignantly</b> 126:13<br><b>point</b> 7:1,16 17:2<br>20:5,23 21:19<br>25:16 30:7 53:20<br>53:22 59:17 72:23<br>104:16 105:23<br><b>points</b> 21:14 48:15<br><b>polchinski</b> 3:14<br>4:5 108:1,3 111:5<br>112:4 113:2,19,23<br>113:24 114:9,17<br>114:24 115:9,23<br>116:9,16,19 117:2<br>117:12,20 118:1,7<br>118:18 119:14<br>120:13 121:7<br>122:5,15 123:4,16<br>123:24 127:22<br>128:9 129:13,20<br>130:2 138:18<br><b>portion</b> 12:14<br><b>position</b> 85:11<br><b>possibility</b> 54:7,10<br>54:11<br><b>possible</b> 13:19<br>15:22 42:20,21<br>45:19 66:10 67:5<br>68:11 73:4 77:12<br>85:18 125:21<br>126:8 127:17,21 | 133:12 134:1,9,15<br><b>post</b> 17:5<br><b>potential</b> 13:24,25<br>24:2,3 25:10<br>26:24 27:5,8<br>31:17 50:3,9,18<br>54:16 55:22 56:5<br>56:10,16,21 57:3<br>57:16 63:17,18,19<br>63:24 64:1 65:1<br>65:12,16,24 66:2<br>66:17 67:19 68:4<br>68:7 73:17 82:12<br><b>potentially</b> 137:24<br><b>pouring</b> 109:12<br><b>powder</b> 15:4 25:9<br>62:25 63:6 73:20<br>74:17 78:3 79:16<br>80:3 92:17 94:7<br>95:7,16 96:22<br>100:8,11,14,21,25<br>101:18 107:17<br>108:11,14 109:7<br>109:14,16,22,23<br>109:25 116:5<br>134:8,14 137:8,23<br>138:6<br><b>powders</b> 111:24<br><b>ppolchinski</b> 3:18<br><b>practice</b> 45:24<br>123:2 140:9,11,15<br><b>predict</b> 104:4<br><b>predominant</b><br>72:18<br><b>preparation</b> 8:20<br>9:18 10:9,11 53:2<br>54:25 55:3<br><b>preparing</b> 54:5<br><b>present</b> 5:5 39:2<br><b>presented</b> 39:23<br>84:24 140:19 | <b>pretty</b> 17:8 69:3<br><b>prevailing</b> 16:14<br>16:22 17:2,9 19:4<br>19:8 20:8 21:24<br>66:9<br><b>prevented</b> 42:12<br><b>previous</b> 62:1 71:4<br>91:18<br><b>primarily</b> 51:3<br><b>primary</b> 26:17<br>105:10<br><b>print</b> 78:22<br><b>prior</b> 6:10 10:22<br>11:10 54:1 70:18<br>82:14 95:19 96:3<br>129:25 135:2<br><b>privacy</b> 45:7<br><b>probable</b> 68:8<br><b>probably</b> 22:22<br>59:23 125:4<br>138:11<br><b>problem</b> 6:21<br><b>proceeding</b> 1:3<br>140:19 141:15,19<br>142:10,24<br><b>proceedings</b> 4:1<br>60:1 102:14<br>140:17 141:4<br><b>process</b> 5:23 37:20<br>38:1 41:23 84:20<br>86:1,1 109:15<br><b>produced</b> 22:3<br>100:6 135:2<br>141:15<br><b>product</b> 29:16<br>32:1 60:10,20<br>75:7,11,14 76:4,20<br>77:1 95:17 111:12<br>111:19,21,22<br>115:13 120:20<br>121:9,22 122:2,20 |
|--|--|---|--|

[product - recall]

Page 20

|  |  |   |   |
|--|--|---|---|
| 123:6,13 131:23<br>136:9<br><b>production</b> 4:13<br><b>products</b> 15:4<br>25:9 26:1 27:23<br>28:25 33:7 55:20<br>63:18,20 64:3<br>69:21 70:2,5,9<br>135:14 137:24<br>139:9<br><b>professional</b> 141:7<br>142:18<br><b>profile</b> 138:16<br><b>progression</b><br>103:12<br><b>prohibit</b> 84:21<br><b>prohibited</b> 141:13<br><b>prohibitions</b><br>140:25<br><b>project</b> 45:20<br><b>promise</b> 5:18<br><b>proper</b> 32:23,24<br>33:11,13<br><b>propose</b> 140:10,13<br><b>protect</b> 45:6<br><b>protected</b> 141:19<br>141:20<br><b>protocol</b> 37:22<br><b>provide</b> 6:18<br>12:15 43:24 44:12<br>94:4 141:11<br><b>provided</b> 11:3<br>12:15 16:4,7,18<br>39:6 52:11,12<br>55:2 56:15 71:3<br>71:15,16 79:17<br>80:3 93:16 106:4<br>138:1<br><b>providing</b> 134:18<br><b>public</b> 84:12 90:7<br>94:1 | <b>publication</b> 83:20<br>84:1,2,3 85:15,24<br>88:2 125:4<br><b>publications</b> 85:10<br><b>publicly</b> 71:9,17<br><b>published</b> 30:10<br>41:1,15 42:13<br>44:7 45:25 85:6<br>85:22 86:7 87:1<br>88:2 90:19 91:6<br>112:19 115:5<br><b>puff</b> 109:14,22,23<br>109:25<br><b>pulmonology</b><br>133:21<br><b>purposes</b> 50:22<br>122:21<br><b>pursuant</b> 5:3<br><b>push</b> 83:5<br><b>put</b> 37:12 38:11<br>60:16 109:4<br>139:19<br><b>putting</b> 37:2,17<br>108:22 109:25<br><b>q</b><br><b>quadrupling</b><br>113:15 114:1<br><b>qualifications</b><br>103:3<br><b>qualified</b> 17:25<br><b>quantification</b><br>32:12 120:7<br>137:25<br><b>quantified</b> 137:22<br><b>question</b> 11:24<br>31:22 33:7 41:7<br>44:16,21 53:18<br>76:11,14 77:2<br>79:22 85:16 90:24<br>91:14 95:2 97:18<br>100:3 113:18,22 | 113:22 114:15<br>118:20 122:23<br>123:5 129:23<br>131:16 135:25<br><b>questioning</b> 135:4<br><b>questions</b> 11:24<br>18:23,25 29:12<br>35:18 43:3 52:1<br>56:1,13,16 59:22<br>60:5,16 61:9,16<br>81:6 83:19,22<br>88:12 94:9 103:18<br>107:11,20 108:4<br>117:9 120:23<br>122:16,19 129:25<br>130:10,24 131:3<br>131:11,12,20<br>133:10 135:5,9,10<br>135:15 139:14<br>141:16 142:6<br><b>quick</b> 131:7<br><b>quickly</b> 108:19<br><b>quite</b> 17:8 65:22<br>110:13 114:15<br>125:15 126:13<br><b>quotation</b> 42:5<br><b>quotations</b> 14:17 | <b>ratio</b> 113:9 114:5<br><b>rbelow</b> 3:12<br><b>reached</b> 56:9<br>132:17<br><b>read</b> 17:18,20<br>24:21 41:2,4 55:1<br>55:3 57:24 59:16<br>87:15,19,19,21<br>117:7,8 120:11<br>125:4<br><b>reader</b> 42:15<br><b>readership</b> 38:19<br><b>reading</b> 9:23<br>24:18 38:21 46:5<br>73:8 89:10<br><b>ready</b> 102:17<br><b>reagents</b> 98:8<br><b>real</b> 54:19 55:11<br>55:13,24 56:10<br>57:3 131:6<br><b>realize</b> 86:4<br><b>realized</b> 47:11<br>54:7,10<br><b>really</b> 22:21 23:13<br>24:11 49:25 80:15<br>97:25 123:5<br><b>reask</b> 44:15<br>113:17 131:15<br><b>reason</b> 25:12,21<br>25:24 45:1 49:16<br>57:4 137:20<br><b>reasonable</b> 77:25<br>103:21 140:7<br><b>reasons</b> 44:11,16<br>44:20<br><b>rebecca</b> 3:8<br><b>rebuttal</b> 106:17,18<br><b>recalculate</b> 89:6<br><b>recall</b> 7:9 29:5<br>42:1,23 47:10<br>53:16 54:4,17 |
|--|--|---|---|

[recall - research]

Page 21

|   |  |  |  |
|---|--|--|--|
| 57:2 58:12 60:14<br>60:21 61:2,4<br>74:11 75:8,12<br>79:3,5,13 89:10<br>93:2,7,15 95:20<br>96:2 112:17<br>113:10 116:17<br>124:10,18 125:2,4<br>127:18,19 132:3,8<br>132:21 133:22<br><b>recalled</b> 24:19<br>125:10<br><b>recalling</b> 23:23<br><b>receive</b> 41:22<br><b>received</b> 10:24<br>11:3 39:17 40:5<br>40:18 70:18 71:19<br>71:23 78:11,21<br>124:7<br><b>receives</b> 141:14<br><b>recess</b> 60:1 102:14<br><b>recollection</b> 57:7<br>57:11 79:6 95:9<br>124:14 125:5<br><b>record</b> 6:6,17<br>10:24 41:5 43:4<br>105:17 133:6<br>139:19,25 141:4,6<br>141:16 142:9<br><b>records</b> 7:24 10:2<br>11:9 54:15 70:20<br>70:21 71:8 73:10<br>104:24 105:15,21<br>106:3,12 133:17<br>133:19,24 134:7<br>134:13,16 139:2,6<br><b>reduced</b> 142:7<br><b>redundant</b> 5:19<br><b>refer</b> 75:21 112:25<br><b>reference</b> 4:17 8:3<br>12:22 49:21 80:8 | 94:14 134:6,12<br>135:1 136:20<br><b>referenced</b> 114:4<br><b>references</b> 37:8,11<br>37:16 136:20<br><b>referencing</b> 70:24<br><b>referring</b> 34:3,8,9<br>34:20 51:8 55:25<br>74:12 87:25 89:25<br>98:15 113:5<br>116:12<br><b>refine</b> 12:1<br><b>refinement</b> 7:18<br><b>reflected</b> 20:16<br>48:21,23 49:2<br><b>regard</b> 65:23<br>108:9<br><b>regarding</b> 18:14<br>39:7 57:16 69:12<br>84:4 94:5 100:7<br>125:23 130:12<br><b>region</b> 33:24 34:5<br><b>regulations</b> 140:23<br><b>rejected</b> 41:9<br><b>relate</b> 80:17<br><b>related</b> 8:9 11:18<br>12:5,8,10,16,25<br>17:4 18:25 19:1<br>39:8 53:8 60:17<br>70:20 71:14 79:9<br>79:16 80:2 84:12<br>87:2 91:16 93:1,4<br>95:2 102:20<br>107:11 115:7<br>132:22<br><b>relating</b> 141:19<br><b>relation</b> 15:15<br>59:17<br><b>relationship</b> 141:4<br>142:15 | <b>relative</b> 18:25 19:6<br>113:8 142:12<br><b>release</b> 93:23<br><b>relevance</b> 138:21<br><b>relevant</b> 38:18<br><b>reliability</b> 94:16<br><b>reliable</b> 96:9,12<br>137:25<br><b>reliance</b> 6:12,19<br>8:3,9,16,17,23 9:5<br>12:21 22:18 60:8<br>60:17 80:8 86:16<br>92:20 93:11,12,15<br>132:11 135:1<br>136:21<br><b>relied</b> 16:24 91:18<br>106:15,16,19<br>114:19<br><b>relieve</b> 139:23<br>140:2<br><b>rely</b> 23:18 28:21<br>32:12 91:21 96:20<br>106:23 114:11<br>115:20<br><b>relying</b> 23:14<br>28:22 33:6 62:7<br>97:23,24 99:13,21<br><b>remaining</b> 45:14<br><b>remember</b> 40:21<br>69:14 78:17 84:16<br>132:6,9 135:15<br><b>remove</b> 54:19<br>138:15<br><b>removed</b> 127:6<br><b>repeat</b> 113:20,22<br><b>repetitive</b> 47:12<br><b>rephrase</b> 19:19<br>38:25 76:11,14<br>114:16<br><b>replacer</b> 26:17 | <b>report</b> 6:19 8:13<br>8:16 52:5,11,19,22<br>52:23,25 54:2<br>58:20 71:25 74:25<br>75:6 78:12,24<br>79:1,15,15,16 80:1<br>80:1,2,12,13,17,23<br>96:3,6 102:19,23<br>112:7,12 133:21<br>141:5<br><b>reported</b> 33:17<br>78:8 82:5<br><b>reporter</b> 1:13 5:5<br>139:15,23 140:3<br>140:19,21,24<br>141:1,17,18<br><b>reporting</b> 140:24<br>141:11<br><b>reports</b> 28:22<br>54:14,23 55:1,3,6<br>60:8 73:14 75:1,5<br>79:19 80:5,7,15<br>96:4 106:23 117:8<br><b>repository</b> 141:20<br><b>represent</b> 108:3<br><b>representations</b><br>140:22<br><b>represented</b> 107:1<br><b>represents</b> 110:25<br><b>request</b> 42:23<br>140:7<br><b>requests</b> 4:13<br>42:22<br><b>require</b> 104:5<br>122:9<br><b>required</b> 46:13<br>122:25<br><b>requirements</b><br>52:23<br><b>research</b> 36:17<br>124:12 |
|---|--|--|--|

[respect - says]

Page 22

|   |   |  |   |
|---|---|--|---|
| <b>respect</b> 29:7 37:10<br>61:5 63:23 64:13<br>65:11 67:8,15<br>71:21 74:12 75:15<br>75:17,25 76:17<br>82:18 83:1 85:9<br>91:3,4 93:13,21<br>95:3,11,13 96:7,8<br>96:19 97:13,22<br>99:9,10,22 101:24<br>102:19,23,25<br>103:7,8,23 105:13<br>106:13 115:2,12<br>120:24 129:2<br>132:20 | <b>reviewed</b> 7:25 8:3<br>8:19 10:1,2 16:6<br>22:15 28:20,25<br>41:18,19,20,21<br>46:18 47:17 48:17<br>60:9,19,25 90:7,20<br>91:6 93:6 105:15<br>112:7 133:16<br>136:15 | <b>ripley</b> 132:4,9,14<br>132:18 133:1   | <b>roughly</b> 117:14<br>124:23   |
| <b>response</b> 44:21   | <b>reviewing</b> 7:12   | <b>risk</b> 88:6 90:8,21<br>91:8 113:15 114:1<br>121:21,24 122:10<br>135:14  | <b>routine</b> 110:2  |
| <b>responsible</b> 123:7<br>123:11,11   | <b>reviewers</b> 42:22<br>42:24   | <b>rite</b> 3:1  | <b>rpr</b> 143:7  |
| <b>responsive</b> 42:22   | <b>reviewing</b> 7:12<br>54:14 61:5 62:1  | <b>robinson</b> 3:9  | <b>rubber</b> 65:18<br>69:16  |
| <b>rest</b> 8:15  | <b>revised</b> 4:15   | <b>rodelsgperger</b><br>113:12   | <b>ruude</b> 17:17  |
| <b>result</b> 29:16 30:18<br>30:21,22 32:1<br>74:11 90:9 120:25   | <b>revisions</b> 41:23<br>42:17   | <b>roggeli</b> 10:25 85:5  | <b>rule</b> 1:3 66:17,18  |
| <b>results</b> 9:12 29:14<br>31:24,25 46:24<br>48:13,14 49:2<br>60:23 94:17 96:9  | <b>revlon</b> 3:13 108:3  | <b>roggeli's</b> 78:12,24<br>79:1,15 80:1  | <b>rules</b> 140:23   |
| <b>retailer</b> 130:16,20   | <b>rewritten</b> 40:16  | <b>rohl</b> 31:11 32:7   | <b>run</b> 5:20 61:16   |
| <b>retailer's</b> 130:13  | <b>riding</b> 128:6   | <b>role</b> 37:2,6 38:10<br>38:12,20 39:3<br>82:15   | <b>rural</b> 34:11,25<br>35:6   |
| <b>retain</b> 40:13   | <b>right</b> 5:16 9:4 12:6<br>14:20 15:16,24<br>19:9,15 20:24   | <b>romano</b> 2:15 4:4,6<br>61:13,14 65:3,10<br>66:21 67:14 68:3<br>70:3 72:11,20<br>75:3,24 76:16<br>77:4,23 79:23,24<br>80:11,25 81:14,16<br>90:13,18 96:17<br>97:20 99:8,18,19<br>100:18 101:9,10<br>102:6,16 107:19<br>114:23 129:2<br>131:2 133:9 134:5<br>134:23 139:10,21 | <b>rutherford</b> 122:8<br>122:25   |
| <b>retained</b> 6:24 7:6<br>11:13 43:24 44:3<br>47:2 48:2   | <b>right</b> 5:16 9:4 12:6<br>14:20 15:16,24<br>19:9,15 20:24   | <b>ronald</b> 36:9   | <b>s</b>  |
| <b>reuters</b> 93:9,22  | <b>riding</b> 128:6   | <b>room</b> 9:7,10 58:15<br>113:6  | <b>salary</b> 125:12  |
| <b>review</b> 11:4,8,10<br>11:16 12:3 13:8<br>13:13,20 15:2<br>22:4 28:11 41:23<br>42:14 45:5 51:15<br>54:22 57:13 59:7<br>59:18 60:7 71:24   | <b>right</b> 5:16 9:4 12:6<br>14:20 15:16,24<br>19:9,15 20:24   | <b>rose</b> 4:19 16:8,9<br>18:21 19:3,7 66:6   | <b>sample</b> 29:14,20<br>30:7,15,15,19 31:6<br>31:24,25 74:4,24<br>75:2 86:25 88:10<br>88:17 110:17<br>111:4 |
|   |   | <b>rough</b> 140:14  | <b>sampled</b> 32:1   |
|   |   |  | <b>samples</b> 29:13<br>31:15 32:9 33:6,9<br>73:19 74:6,16  |
|   |   |  | <b>sanchez</b> 74:15,20   |
|   |   |  | <b>sanchez's</b> 75:6   |
|   |   |  | <b>sandpaper</b> 24:24<br>26:20   |
|   |   |  | <b>sandwich</b> 126:15<br>126:19  |
|   |   |  | <b>satisfy</b> 117:21   |
|   |   |  | <b>saw</b> 33:21 73:11<br>104:24 106:1<br>139:2   |
|   |   |  | <b>saying</b> 20:22 33:16<br>49:22 117:1  |
|   |   |  | <b>says</b> 15:21 17:10<br>17:14 21:7,7<br>24:13,17,23 25:5   |

[says - solely]

Page 23

|                           |                            |                           |                            |
|---------------------------|----------------------------|---------------------------|----------------------------|
| 100:11                    | 75:4,9,12 85:1             | 63:12 131:5,9,18          | <b>significant</b> 35:11   |
| <b>scenario</b> 56:22     | 92:4,7 93:10,24            | 133:4 135:24              | 112:14                     |
| 59:4 84:25                | 105:21 106:11              | 136:4 140:16              | <b>significantly</b>       |
| <b>scenarios</b> 57:8     | 108:22 109:20              | <b>separate</b> 95:24     | 105:11                     |
| <b>schedule</b> 56:25     | 110:5 111:6                | <b>separation</b> 95:22   | <b>silicate</b> 72:10      |
| <b>school</b> 22:22 97:7  | 132:23                     | 98:8                      | <b>silicates</b> 78:6      |
| <b>science</b> 33:10      | <b>segrave</b> 60:10,15    | <b>september</b> 7:2,3    | <b>similar</b> 25:8 47:14  |
| <b>scientific</b> 46:6    | 60:20 61:3,5               | <b>series</b> 90:16       | 50:4                       |
| <b>scientifically</b>     | <b>segrave's</b> 60:22     | <b>serve</b> 142:25       | <b>similarly</b> 50:1      |
| 138:23                    | <b>segregated</b> 68:17    | <b>services</b> 141:11    | <b>simon</b> 2:4           |
| <b>scientist</b> 32:18    | <b>selected</b> 49:7       | <b>set</b> 93:6 110:2     | <b>simple</b> 121:18       |
| 75:22                     | <b>selecting</b> 50:8      | <b>setting</b> 67:15      | <b>simply</b> 27:22 28:3   |
| <b>scientists</b> 74:8    | <b>selikoff</b> 69:24      | <b>settings</b> 54:18     | 46:10                      |
| <b>scope</b> 11:15,20     | 124:11,14,22               | <b>seven</b> 127:1        | <b>sinai</b> 36:21         |
| 12:15,18,19 45:20         | <b>seller</b> 76:25        | <b>severable</b> 123:14   | <b>single</b> 74:19 75:2   |
| 137:8                     | <b>sem</b> 98:24,25 99:2   | <b>sgpblaw.com</b> 2:6    | 136:8                      |
| <b>scrolling</b> 102:7    | <b>sending</b> 45:10       | <b>shape</b> 69:18        | <b>singular</b> 51:5       |
| <b>scruffed</b> 24:24     | <b>sense</b> 8:19 30:8     | <b>shared</b> 137:13      | <b>sister</b> 101:3        |
| <b>scuffed</b> 26:19      | 37:24 47:12 76:9           | <b>she'd</b> 126:19       | 126:13,18                  |
| <b>se</b> 26:15 104:3     | 77:16 97:2 104:23          | <b>sheet</b> 101:4        | <b>sister's</b> 7:19 23:10 |
| <b>seal</b> 3:9           | 117:11 125:16              | <b>shift</b> 20:17        | 62:8                       |
| <b>second</b> 6:9 12:14   | 132:19 134:19              | <b>short</b> 81:8 133:5   | <b>sit</b> 58:14 89:12     |
| 112:25                    | <b>sensitive</b> 98:23,25  | <b>shorter</b> 82:4       | 133:2                      |
| <b>section</b> 8:5,23     | <b>sensitivity</b> 97:13   | <b>shortest</b> 81:8,25   | <b>sitting</b> 120:16      |
| 24:14,21 38:17            | <b>sent</b> 22:11,11       | <b>shorthand</b> 25:3     | <b>six</b> 46:24 47:1,6,16 |
| 93:15,18                  | 40:19,20 140:18            | <b>show</b> 21:11,17      | 47:23,25 48:9,19           |
| <b>sections</b> 37:21,25  | <b>senter</b> 1:12 2:9 4:4 | 56:4 75:10 135:14         | 104:11                     |
| <b>see</b> 17:11 18:1     | 4:6 5:11,13 6:20           | <b>showed</b> 19:3 30:18  | <b>size</b> 86:25 88:10    |
| 20:23 48:10 53:10         | 6:22 8:6 9:2 11:5          | 59:6                      | 88:17                      |
| 55:6 57:15 60:9           | 11:12 12:2 13:6            | <b>shower</b> 69:2 138:5  | <b>skewing</b> 20:14,19    |
| 60:13 68:6,6              | 13:18 15:19 16:2           | <b>showered</b> 138:8     | <b>skilled</b> 125:13      |
| 73:23 77:15 85:16         | 18:4,16,20 19:18           | <b>showering</b> 69:9     | <b>slow</b> 108:18         |
| 86:15 98:14 99:6          | 20:20 21:4 22:1            | <b>showing</b> 22:20      | <b>small</b> 30:11 31:8    |
| 100:20 101:9              | 27:24 28:15 29:4           | 23:5 100:19               | 31:16 86:24 88:10          |
| 124:21 133:24             | 29:9 30:1,16               | <b>shows</b> 21:22 67:10  | 88:17                      |
| 134:2,6,12                | 31:19 32:14 33:4           | 75:6                      | <b>smaller</b> 19:15,16    |
| <b>seeing</b> 24:19 54:15 | 33:20 34:13,23             | <b>side</b> 138:6         | 70:12                      |
| 61:2 75:8,13              | 43:14 44:18,19             | <b>signature</b> 139:16   | <b>snowing</b> 67:1        |
| 95:20 96:2 124:18         | 46:22 48:7 52:14           | 143:6                     | <b>solely</b> 141:8        |
| <b>seen</b> 17:8,9 27:15  | 53:3,21 57:12,25           | <b>significance</b> 49:17 | 142:21                     |
| 29:6 46:4 67:9            | 59:20 60:3 61:7            | 78:24                     |                            |

[solutions - subject]

Page 24

|                           |                          |                            |                            |
|---------------------------|--------------------------|----------------------------|----------------------------|
| <b>solutions</b> 141:3,11 | <b>spalding</b> 2:16     | <b>speed</b> 18:10,13      | <b>statisticians</b> 89:21 |
| <b>somebody</b> 29:14     | <b>speak</b> 10:13 50:23 | <b>speeds</b> 17:21 18:8   | 89:25                      |
| 54:19 56:20 61:9          | 88:25 96:14,16           | 19:12                      | <b>statistics</b> 49:19    |
| 75:22 98:2 137:8          | <b>speaking</b> 57:10    | <b>spend</b> 23:11         | <b>status</b> 106:8        |
| <b>someone's</b> 46:1,6   | 102:25                   | <b>spending</b> 22:21      | <b>stay</b> 126:7 127:20   |
| 64:11 85:2 98:24          | <b>special</b> 1:3 14:16 | <b>spent</b> 9:18,22 10:9  | <b>stepdad</b> 65:11       |
| <b>somewhat</b> 7:19      | <b>specific</b> 7:25 8:4 | 10:10 23:1 36:14           | 67:15,18,22 70:14          |
| 40:6 109:16               | 8:11,23,24,24            | 38:16                      | <b>stepdad's</b> 63:19     |
| <b>son's</b> 62:9,10      | 18:13 22:5 27:11         | <b>spike</b> 21:5          | 133:25                     |
| <b>sons</b> 13:25 24:3    | 28:20 29:7,16            | <b>spoken</b> 62:2,12      | <b>stepfather</b> 13:24    |
| 63:20,24 64:2,13          | 33:7 35:24 36:2          | <b>spokes</b> 18:2         | 15:16,23 65:17             |
| 64:17 65:5                | 42:23 43:7 44:13         | <b>stamps</b> 77:9,12      | 67:7 68:12 73:5            |
| <b>sorry</b> 14:14 16:9   | 44:22 48:9,9             | <b>standard</b> 33:17      | 73:23 125:22               |
| 28:16 31:14 33:1          | 51:12 53:6 56:24         | 98:11 130:13               | 126:7,21 127:6,21          |
| 44:15 51:7 66:11          | 57:10 58:18 60:14        | <b>standards</b> 118:25    | 137:24                     |
| 66:21 77:2 79:21          | 60:17 76:4,19,20         | <b>start</b> 58:1 83:16,16 | <b>stepfather's</b> 27:7   |
| 87:22 100:2 102:7         | 79:18 80:5,9,16,23       | 83:17                      | 133:11                     |
| 105:1 107:14              | 107:16 112:17            | <b>started</b> 7:12 26:12  | <b>stephen</b> 24:8        |
| 113:17 114:14             | 115:2 116:13             | 40:22 47:22 50:1           | <b>steroid</b> 106:2       |
| 131:16 135:24             | 125:3,5 130:16,20        | 82:22 83:14                | <b>stips</b> 139:19        |
| 136:4                     | 131:12,21 132:12         | 100:11                     | <b>stipulate</b> 140:8     |
| <b>sort</b> 57:14 92:5    | 136:8 137:1              | <b>starting</b> 5:14       | <b>stipulated</b> 140:16   |
| 98:18 103:3 120:6         | 141:13                   | 26:11 104:16               | <b>stop</b> 109:3          |
| 121:11                    | <b>specifically</b> 7:12 | <b>starts</b> 24:7 83:9    | <b>straight</b> 15:7       |
| <b>sound</b> 17:17 76:12  | 8:20 13:1 20:2           | <b>state</b> 1:1 13:12     | <b>street</b> 2:11,17      |
| 138:23                    | 28:5 29:1 34:9           | 16:15 22:24 44:20          | <b>stretch</b> 102:13      |
| <b>sounded</b> 69:1,6     | 46:6,9 48:12 50:8        | 74:8 141:1 142:2           | <b>strike</b> 65:25        |
| 126:8                     | 53:8 55:2 61:5           | <b>stated</b> 88:19,20     | <b>student</b> 36:14       |
| <b>sounds</b> 31:16       | 80:15 86:9 91:16         | 121:5 142:5                | <b>studied</b> 49:12       |
| 64:11 74:19               | 95:19 96:22              | <b>statement</b> 5:4       | 82:18,25 124:23            |
| <b>source</b> 50:3,25     | 124:10 134:8,14          | 31:13                      | <b>studies</b> 90:15,23    |
| 65:13,16 67:20            | 140:23                   | <b>statements</b> 134:2    | 90:25 91:13 107:5          |
| 73:2,10,17 79:4           | <b>specifics</b> 33:18   | <b>states</b> 95:19        | 135:13,21 136:2            |
| 94:21,21 129:4            | <b>specified</b> 45:21   | <b>stating</b> 74:3        | <b>study</b> 88:5 90:7,20  |
| 133:12 134:1,9            | 55:11                    | <b>station</b> 14:1 17:11  | 91:7 112:8 136:8           |
| <b>sources</b> 13:19      | <b>speculation</b> 20:12 | 17:13 24:4 26:11           | <b>studying</b> 69:25      |
| 63:16,17 73:24            | 59:14 68:1 127:14        | <b>statistical</b> 49:17   | <b>stuff</b> 37:13         |
| <b>south</b> 3:10 20:24   | 139:10                   | 89:1 91:1                  | <b>subcontractor</b>       |
| 21:3,3,6,9,15,20          | <b>speculative</b> 25:20 | <b>statistician</b> 89:8   | 141:2,8 142:21             |
| 21:25                     | 25:25                    | 89:13 90:2                 | <b>subject</b> 44:23       |
|                           |                          |                            | 85:22                      |

[subjects - thank]

Page 25

|   |   |   |   |  |
|---|---|---|---|--|
| <b>subjects</b> 84:9<br><b>submit</b> 6:17 40:24<br>45:19 54:5 116:3<br><b>submitted</b> 5:4<br>7:15 40:25 41:8<br>41:12,13,17 42:5<br>45:5,12 46:14,23<br>58:25 141:16,18<br><b>submitting</b> 54:1<br><b>subsequent</b> 59:6<br><b>substance</b> 42:1<br><b>substantial</b> 65:6<br>70:15 121:12,15<br><b>substitute</b> 138:20<br><b>substituted</b> 54:2,8<br><b>sudden</b> 64:8<br><b>suddenly</b> 54:10<br><b>suffered</b> 56:6<br><b>suggest</b> 42:19<br><b>suite</b> 2:4,10,17 3:4<br>3:10<br><b>suits</b> 52:10<br><b>sum</b> 72:7<br><b>summary</b> 92:8<br>103:14<br><b>sun</b> 22:7<br><b>superior</b> 1:1<br><b>supplement</b> 23:20<br><b>sure</b> 6:25 10:6<br>14:5 16:5 17:1<br>25:25 28:24 30:17<br>34:2 37:24 38:21<br>39:14 43:2 54:15<br>65:22 69:17 76:17<br>77:5 79:23 81:6<br>89:2 102:12<br>110:13 113:3,23<br>114:18 122:13<br>123:1,20 125:8<br>130:11 131:13,21<br>132:16 | <b>surmise</b> 58:8<br><b>sweeping</b> 68:25<br><b>switch</b> 35:22<br><b>sworn</b> 5:8 13:14<br>23:18 51:3,16,19 | <b>talcum</b> 15:4 25:9<br>108:11 111:24<br>137:23<br><b>talk</b> 26:5 95:10<br>103:8,11 106:9<br><b>talked</b> 18:17 65:21<br>83:22 84:15 85:5<br>89:23 112:23<br>138:4<br><b>table</b> 37:12,17<br>92:1<br><b>tables</b> 37:12 38:24<br>39:1,2 42:10 92:8<br><b>tags</b> 77:9<br><b>tailored</b> 40:8<br><b>take</b> 19:14,21,25<br>24:16 33:23 35:23<br>36:1 42:3 59:24<br>89:12 109:4,15<br>118:3 119:23,24<br>138:14,20 140:5<br><b>takeaway</b> 79:10<br><b>taken</b> 1:12 62:5<br>142:5<br><b>takes</b> 107:2,4<br>108:13<br><b>talc</b> 13:22 35:20<br>43:7 50:20 62:19<br>63:17 72:9 73:15<br>73:22 74:2 75:7,7<br>75:11,11 76:1,18<br>77:1 78:5,6,7,9,19<br>80:14 84:5 86:18<br>87:7,11 90:10,12<br>90:13,17,22 91:5,8<br>91:16,23 94:15<br>95:17 96:21 103:7<br>103:8 106:14<br>108:6,9,22 109:5<br>110:8,8 114:12,21<br>115:7 129:7,9,12<br>134:7,13 135:13<br>135:15,17 136:18<br>136:18 139:4,9 | <b>test</b> 74:10,11<br><b>tested</b> 29:6 30:19<br>74:5 95:6,8<br><b>testified</b> 5:9 57:22<br>58:6,11,12 59:5<br>69:11 123:19<br>125:10 136:21<br><b>testify</b> 31:25 58:10<br>78:10 106:7<br><b>testimony</b> 4:14<br>6:10 13:14 23:15<br>23:19 27:14 29:11<br>31:20 34:3 51:3<br>51:16,19 53:12<br>57:14,20,24 59:6,8<br><b>talks</b> 19:8 43:18<br><b>task</b> 68:24<br><b>telephone</b> 2:3,9,16<br>3:3,9,15 5:13<br><b>telephonic</b> 1:10<br><b>tell</b> 9:7,24 30:20<br>35:7 37:3 58:4,6<br>58:11,15 116:13<br><b>tem</b> 98:24,25 99:3<br>99:6 117:5,7<br><b>ten</b> 10:7 14:19<br>81:9 82:1,14<br>115:10 120:17<br>125:20,25 126:25<br>127:4<br><b>tend</b> 125:18<br><b>tender</b> 134:24<br><b>tenth</b> 119:7,13<br><b>term</b> 129:6<br><b>terms</b> 25:23 32:8<br>32:20 33:5 42:14<br>57:1 81:17 85:25<br>86:14 94:14 97:16<br>98:7 103:12,25<br>105:16 111:8<br>141:8 142:21 | <b>testing</b> 8:11,12,12<br>8:14 9:12,12,14<br>28:21,25 29:7<br>30:8 33:5,6 36:8<br>37:22,22 39:5,10<br>39:11 42:8 47:18<br>47:21 60:9,10,16<br>60:19,23,23 67:10<br>74:14 75:1,5,16<br>91:19 92:2,16<br>93:24 94:25 95:4<br>95:14 96:8,24<br>97:5,8,10,22<br>132:12,16,18,20<br>132:23,25 139:21<br><b>tests</b> 29:13 132:14<br><b>texas</b> 122:12<br><b>thank</b> 9:17 28:19<br>59:25 61:7,10<br>62:11 77:24 80:19<br>81:1 84:3 100:2 |
|---|---|---|---|--|

[thank - tv]

Page 26

|  |   |  |  |
|--|---|--|--|
| 101:9 102:6<br>107:10 130:3,24<br>139:13<br><b>thanks</b> 6:20<br><b>theme</b> 40:3<br><b>theoretically</b><br>66:10<br><b>thereabouts</b><br>133:20<br><b>thing</b> 6:9 16:21<br>48:24 76:13 78:17<br>90:5 104:19<br>111:21<br><b>things</b> 7:18 8:25<br>23:2 42:19 49:13<br>80:14 98:6 99:2<br>100:1 104:7<br>111:20 120:16<br>133:5<br><b>think</b> 5:14 7:8,16<br>15:21 17:7 20:22<br>26:8,11 31:21<br>33:21 34:3 42:10<br>46:4 54:13 60:5,6<br>61:3,4 63:23 66:7<br>74:14,23 75:2<br>78:15,17 79:2,12<br>80:21 81:1 82:17<br>82:24 84:6 86:25<br>87:18 88:12 89:20<br>89:21,23 91:11,19<br>92:1,15 93:10,25<br>95:18,21 96:18<br>97:21,21 101:7<br>102:10,24 103:17<br>104:25 105:8,9,18<br>107:8,19 108:15<br>108:17 109:16,23<br>109:23 112:24<br>113:7,8 114:7<br>115:1 122:7,11,12 | 123:1 124:3<br>126:12 131:14<br>133:18,18 139:23<br><b>thinking</b> 122:11<br><b>thompson</b> 3:2 4:5<br>130:7,9,23<br><b>thornburg</b> 3:3<br><b>thorough</b> 30:6<br><b>thought</b> 22:25<br>25:19 101:5 133:4<br><b>thousand</b> 133:18<br><b>thousands</b> 46:5<br>110:18<br><b>three</b> 14:13 24:8<br>63:16 83:17 116:5<br>116:20,21 117:1,7<br>117:13,17,22,25<br>128:19 131:3<br><b>threshold</b> 121:12<br>121:15<br><b>thrifty</b> 3:1 130:20<br><b>time</b> 10:9 19:15,16<br>22:21 23:11,20<br>25:13,16,23 36:14<br>38:16 52:4,12,18<br>53:12,17 58:20<br>59:23 61:10 62:23<br>81:18,19 82:7,19<br>83:1 87:19 89:12<br>89:15 95:15<br>101:15 102:10<br>105:23 107:20<br>108:12 119:5,16<br>123:23 126:16<br>132:7,14 133:1<br>141:14<br><b>timer</b> 109:6<br><b>times</b> 5:19 14:24<br>24:25 27:23<br>101:23 118:3 | <b>timing</b> 106:25<br>107:1<br><b>tins</b> 116:5,6,21<br><b>tissue</b> 39:6 46:23<br>47:6,18,21 48:1,2<br>48:10,16,25 49:4<br>71:21 72:4,15,17<br>72:19 73:13 76:2<br>77:8,15 78:2<br>128:14,22 133:14<br><b>title</b> 1:3<br><b>today</b> 5:15 9:7,10<br>10:5 84:17 106:6<br><b>today's</b> 10:9<br><b>told</b> 63:25 65:12<br>81:1 84:7<br><b>tools</b> 91:1<br><b>top</b> 24:13<br><b>topics</b> 35:22<br><b>total</b> 72:7 101:12<br>101:13 104:9,11<br>138:16<br><b>totally</b> 84:25<br><b>touch</b> 39:25 135:9<br><b>touched</b> 36:25<br><b>town</b> 55:19<br><b>trace</b> 110:9,9,14<br>111:3,6<br><b>trade</b> 17:4<br><b>trades</b> 125:13<br><b>training</b> 56:3,7,20<br><b>transcript</b> 4:21<br>13:17 23:10,10<br>140:4,6,18 141:15<br>142:5,8<br><b>transcripts</b> 52:1<br>141:15,19<br><b>transition</b> 26:13<br><b>translate</b> 31:9<br><b>transpired</b> 13:15<br>106:11 | <b>treat</b> 14:16<br><b>treating</b> 61:20<br><b>treatment</b> 61:23<br>103:24 105:22<br><b>treatments</b> 104:17<br>104:18<br><b>tremolite</b> 72:9<br>75:25 76:18<br>129:11<br><b>trial</b> 10:22 11:11<br>11:21,24 28:9,12<br>57:14,19,20,23,24<br>58:2,5,7,10,18<br>59:5,16 89:19<br>92:4 102:23 103:1<br>103:15,22 134:18<br>135:4 136:22<br>140:9,12,15<br><b>tried</b> 45:23 46:2<br>69:6 109:2 126:7<br>127:20<br><b>tries</b> 42:21<br><b>true</b> 32:2 62:15<br>84:11 90:6 91:5<br>98:16 130:17,21<br>133:14 141:15<br>142:8<br><b>truly</b> 83:7<br><b>try</b> 5:18,20 50:23<br>81:7 97:19 120:6<br><b>trying</b> 8:18 17:16<br>38:13 40:7 50:23<br>56:18,20,24 99:12<br>102:7 123:21<br><b>tumor</b> 72:17,19<br>82:21 83:3,9,13<br>128:11,13,14,16<br>128:22<br><b>turn</b> 14:13 23:25<br><b>tv</b> 68:13 |
|--|---|--|--|

|  |   |  |   |
|--|---|--|---|
| <b>tweets</b> 45:11  | <b>undergarments</b><br>109:8   | <b>users</b> 90:16 91:4  | <b>vivid</b> 69:3   |
| <b>twice</b> 25:1 122:22   | <b>undergoing</b><br>105:23   | <b>usual</b> 5:22 139:18   | <b>volumetric</b> 29:23   |
| <b>two</b> 13:25 14:14<br>24:3 40:21 54:6,9<br>59:22 60:5 79:16<br>80:2 95:6 98:18<br>102:1,20 107:22<br>108:25 125:8<br>128:15 133:18   | <b>underlying</b> 51:4<br>52:6,10,19 53:13  | <b>usually</b> 109:5   | 30:13   |
| <b>type</b> 12:9 15:4<br>26:13 30:13 50:17<br>77:18 79:12<br>105:16,22 136:9<br>137:10   | <b>understand</b> 31:20<br>33:2 38:3 50:3<br>70:4 72:13 85:9<br>88:4 91:3 122:18  | <b>vacations</b> 127:3   | <b>voluntary</b> 93:2   |
| <b>types</b> 78:5 128:12<br>128:15,19  | <b>understanding</b><br>13:2 17:23 19:11<br>20:6 23:17 26:2<br>31:4 46:15 49:6<br>50:7 61:25 66:5<br>70:8,11 84:6<br>95:13 138:11 | <b>vacuuming</b> 68:22   | <b>vs</b> 1:7   |
| <b>typewriting</b> 142:7   | <b>understood</b> 11:5<br>42:16   | <b>vague</b> 19:16 27:19<br>32:24,25 33:12,13<br>34:1,18 43:9 48:4<br>53:15 57:18 59:13<br>63:9 110:11<br>114:13 118:5 | <b>w</b>  |
| <b>typical</b> 108:12,16   | <b>undertaken</b> 89:5  | <b>valid</b> 33:11,12  | <b>waive</b> 139:16   |
| <b>typically</b> 81:21<br>110:24 120:4   | <b>undertaking</b> 89:15  | <b>validity</b> 33:8   | <b>wake</b> 126:18  |
| <b>u</b>   | <b>unfortunately</b><br>74:25 78:20 83:15   | <b>value</b> 29:15 83:7<br>96:24 98:16<br>101:20 113:25<br>119:23  | <b>walked</b> 69:1  |
| <b>unable</b> 42:25  | <b>unified</b> 40:3   | <b>values</b> 112:20<br>113:13 114:5<br>121:16   | <b>want</b> 5:15 6:16<br>14:4 27:10 28:24<br>40:7 68:6 77:3<br>87:24 95:10<br>131:12,21 |
| <b>unarco</b> 8:13 9:15<br>15:15,20 16:6<br>19:6 25:10 27:7<br>66:3,23 67:19<br>69:13,25 70:9,20<br>70:22 71:8 73:22<br>124:1,5,8,12,15,23<br>125:23 128:23<br>129:15 133:12<br>137:25 | <b>union</b> 65:18 69:16<br>70:20   | <b>variables</b> 137:19  | <b>wanted</b> 16:3 29:12<br>37:1 42:3 49:15<br>131:19 132:16<br>135:9                   |
| <b>unaware</b> 90:25   | <b>university</b> 22:24<br>97:6   | <b>various</b> 7:23 27:23<br>32:21 33:6 37:21<br>63:17 73:9 88:1<br>92:2 98:8 104:24<br>137:23                         | <b>warner</b> 122:12  |
| <b>unclear</b> 25:14<br>26:13  | <b>unknown</b> 58:20  | <b>varying</b> 21:23<br>26:6 109:9   | <b>wasting</b> 123:22   |
| <b>undercounting</b><br>138:11   | <b>updated</b> 6:18   | <b>venture</b> 22:22   | <b>watch</b> 68:13  |
| <b>underestimate</b><br>138:2  | <b>uploaded</b> 141:20  | <b>verbatim</b> 141:5  | <b>way</b> 2:5 11:25  |
| <b>underestimation</b><br>31:5   | <b>ups</b> 61:8 131:6   | <b>veritext</b> 141:2,11   | 17:24 24:16 31:1  |
|  | <b>urban</b> 34:11,25<br>35:6,8   | <b>vermont</b> 80:14<br>86:18  | 36:16 37:20 39:14   |
|  | <b>use</b> 11:1 28:12<br>31:25 34:14,17<br>35:1,20 76:8<br>100:7 115:17   | <b>versed</b> 17:17  | 39:19,20 41:7   |
|  | <b>117:24 135:13,14<br/>136:17 139:4,8<br/>140:10,13</b>  | <b>versus</b> 77:14 98:24<br>99:3 104:6,6<br>120:21  | 43:12 44:5,8 45:8<br>48:5 66:18 68:15   |
|  |   | <b>view</b> 70:21  | 68:23 69:18 71:7  |
|  |   | <b>vitae</b> 4:16  | 73:6 76:19 77:6   |
|  |   |  | 83:12,18 94:3   |
|  |   |  | 107:8 127:15  |
|  |   |  | 128:8 129:3,8   |
|  |   |  | 137:10 138:13   |
|  |   |  | <b>ways</b> 111:3   |
|  |   |  | <b>we've</b> 35:21 83:22  |
|  |   |  | 83:23 91:19   |
|  |   |  | 102:11,21   |
|  |   |  | <b>wear</b> 77:8  |
|  |   |  | <b>wedding</b> 23:3,6   |
|  |   |  | <b>wednesday</b> 1:14   |

[week - zimmerman's]

Page 28

|   |   |  |   |
|---|---|--|---|
| <b>week</b> 126:1,25<br>127:1<br><b>weigh</b> 31:7<br><b>weight</b> 29:22<br>30:11,20,25 31:8<br>110:23,24 111:8<br><b>weighted</b> 119:5<br><b>welcome</b> 61:11<br>130:5,25<br><b>went</b> 7:17 13:4<br>33:18 47:24 57:19<br>57:23 58:5,9 59:5<br>69:2 85:11 121:16<br><b>west</b> 2:17 21:12<br><b>whittaker</b> 3:7<br><b>whoever's</b> 99:13<br><b>wind</b> 4:19 16:8,9<br>16:13,14 17:2,4,5<br>17:9,21,22 18:7,10<br>18:13,21 19:1,3,7<br>20:3,8,17 21:1,5<br>21:11,18,22,24,25<br>65:21 66:6<br><b>winded</b> 31:14<br>111:2<br><b>winds</b> 16:22 19:4<br>19:8 66:9<br><b>windsocks</b> 18:12<br><b>wish</b> 10:5<br><b>witness</b> 4:12 11:6<br>11:23 12:23 13:12<br>16:1 17:20 20:13<br>21:1,22 27:21<br>28:14 29:5,20<br>30:5,24 32:4 33:1<br>33:14 34:2,20<br>43:11 48:5 51:19<br>52:9,24 53:16<br>57:7 59:16 61:11<br>63:11 64:23 65:9<br>66:23 68:2 69:24 | 72:6,17 74:22<br>75:21 76:8,24<br>77:11 80:21 90:14<br>96:14 97:2 98:5<br>100:17 102:12<br>107:24 110:13<br>111:17 112:16<br>114:4,14 115:1<br>116:17 118:16<br>119:12,22 121:4<br>125:2 127:15<br>128:3 129:3,19<br>130:5,25 136:5<br>138:19 139:12,17<br><b>witnesses</b> 141:18<br><b>woman</b> 108:16<br><b>wondering</b> 85:10<br><b>word</b> 76:9 106:17<br><b>worded</b> 11:25 41:8<br>100:3<br><b>words</b> 62:5 108:13<br><b>work</b> 10:3,21 11:7<br>11:15,20 12:15,19<br>15:24 17:3,4 24:5<br>26:15 27:7,11<br>28:8 37:16 38:12<br>39:23 40:16 63:19<br>63:20,25 64:20,24<br>69:8,9 71:4 73:23<br>98:20 118:12,17<br>119:7,13 121:5<br>127:6 133:12,25<br><b>workdays</b> 126:1<br><b>worked</b> 14:1 24:4<br>26:14 37:8,21,23<br>38:6,7,8 39:13<br>65:17 67:8,18<br>124:15 125:11,17<br>127:2<br><b>workers</b> 69:25 | <b>working</b> 25:14<br>26:10 36:15,18<br>38:16 64:2,18<br>125:19 126:12<br><b>workplace</b> 120:3<br><b>works</b> 118:21<br><b>world</b> 17:4 49:22<br><b>write</b> 39:20,21<br>46:9 85:3<br><b>writing</b> 9:23 24:12<br>47:11 48:13,14<br>50:13 52:10<br>124:21<br><b>written</b> 5:4 14:9<br>24:20 39:14 52:5<br><b>wrong</b> 60:12<br><b>wrote</b> 37:11 40:11<br>91:10                     | <b>yesterday</b> 71:23<br><b>york</b> 3:17<br><b>young</b> 3:15<br><b>younger</b> 101:17<br><b>z</b><br><b>zimmerman</b> 1:5<br>4:17 8:5,23 11:8<br>11:17 12:5,10<br>13:10,13 24:8<br>25:17,18 26:10,25<br>27:3,17 29:1,7<br>50:15,16 62:3,25<br>63:4,15 64:19<br>65:13,24 66:2,25<br>67:12,17,20 70:13<br>72:22 76:5,21<br>79:8,17 80:4,9,16<br>81:3 82:8,13<br>94:22 95:12,14<br>96:3 100:25<br>102:20 103:9,13<br>126:6,6 127:9<br>131:24 134:2,10<br>137:23<br><b>zimmerman's</b><br>14:15 15:23 24:3<br>27:7 29:2 61:19<br>62:12 68:22 71:21<br>72:3 73:2,8 76:2<br>78:2 83:13 100:7<br>100:15 103:10,24<br>105:13 106:7<br>128:11 133:11,14<br>133:16,23 134:7<br>134:13 137:1<br>139:3 |
|   |   | <b>x</b><br><b>x</b> 110:16<br><b>y</b><br><b>yeah</b> 9:16 38:5<br>105:19 133:21<br><b>year</b> 19:21,21,23<br>19:24 20:18 83:17<br>102:5 112:21<br>118:12,12,17,22<br>118:23 119:4,7,13<br>127:2<br><b>years</b> 14:25 20:5,7<br>23:24 36:21 40:22<br>81:10 82:1,6,14<br>83:16,17 94:22<br>102:3,4 108:6<br>112:13 113:10,15<br>114:1,6 118:13,24<br>119:18 120:25<br>121:21 126:1,25<br>127:4 |   |
|   |   |  |   |

California Code of Civil Procedure

Article 5. Transcript or Recording

Section 2025.520

(a) If the deposition testimony is stenographically recorded, the deposition officer shall send written notice to the deponent and to all parties attending the deposition when the original transcript of the testimony for each session of the deposition is available for reading, correcting, and signing, unless the deponent and the attending parties agree on the record that the reading, correcting, and signing of the transcript of the testimony will be waived or that the reading, correcting, and signing of a transcript of the testimony will take place after the entire deposition has been concluded or at some other specific time.

(b) For 30 days following each notice under subdivision (a), unless the attending parties and the deponent agree on the record or otherwise in writing to a longer or shorter time period, the deponent may change the form or the substance of the answer to a question, and may either approve the transcript of the deposition by signing it, or

refuse to approve the transcript by not signing it.

(c) Alternatively, within this same period, the deponent may change the form or the substance of the answer to any question and may approve or refuse to approve the transcript by means of a letter to the deposition officer signed by the deponent which is mailed by certified or registered mail with return receipt requested. A copy of that letter shall be sent by first-class mail to all parties attending the deposition.

(d) For good cause shown, the court may shorten the 30-day period for making changes, approving, or refusing to approve the transcript.

(e) The deposition officer shall indicate on the original of the transcript, if the deponent has not already done so at the office of the deposition officer, any action taken by the deponent and indicate on the original of the transcript, the deponent's approval of, or failure or refusal to approve, the transcript. The deposition officer shall also notify in writing the parties attending the deposition of any changes which the deponent timely made in person.

(f) If the deponent fails or refuses to approve the transcript within the allotted period, the

deposition shall be given the same effect as though it had been approved, subject to any changes timely made by the deponent.

(g) Notwithstanding subdivision (f), on a reasonable motion to suppress the deposition, accompanied by a meet and confer declaration under Section 2016.040, the court may determine that the reasons given for the failure or refusal to approve the transcript require rejection of the deposition in whole or in part.

(h) The court shall impose a monetary sanction under Chapter 7 (commencing with Section 2023.010) against any party, person, or attorney who unsuccessfully makes or opposes a motion to suppress a deposition under this section, unless the court finds that the one subject to the sanction acted with substantial justification or that other circumstances make the imposition of the sanction unjust.

DISCLAIMER: THE FOREGOING CIVIL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1, 2019. PLEASE REFER TO THE APPLICABLE STATE RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS  
COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at [www.veritext.com](http://www.veritext.com).